

PATENT COOPERATION TREATY

PCT

NOTIFICATION CONCERNING
SUBMISSION OF PRIORITY DOCUMENTS

(PCT Administrative Instructions, Section 411)

From the INTERNATIONAL BUREAU

To:

TAKANO, Toshihiko
10-805, Shin Ogawa-machi 9-chome
Shinjuku-ku
Tokyo 162-0814
JAPON

Date of mailing (day/month/year)

05 May 1998 (05.05.98)

Applicant's or agent's file reference

PCT - 98 - 007

IMPORTANT NOTIFICATION

International application No.

PCT/JP98/01094

International filing date (day/month/year)

16 March 1998 (16.03.98)

Priority date (day/month/year)

21 March 1997 (21.03.97)

Applicant

SHISEIDO COMPANY, LTD. et al

The applicant is hereby notified of the date of receipt by the International Bureau of the priority document(s) relating to the following application(s):

<u>Priority application No.</u>	<u>Priority date:</u>	<u>Priority country:</u>	<u>Date of receipt of priority document:</u>
9/87660	21 Mar 1997 (21.03.97)	JP	01 May 1998 (01.05.98)
9/163275	05 Jun 1997 (05.06.97)	JP	01 May 1998 (01.05.98)
9/185884	26 Jun 1997 (26.06.97)	JP	01 May 1998 (01.05.98)
9/185885	26 Jun 1997 (26.06.97)	JP	01 May 1998 (01.05.98)
9/224240	06 Aug 1997 (06.08.97)	JP	01 May 1998 (01.05.98)
9/225642	07 Aug 1997 (07.08.97)	JP	01 May 1998 (01.05.98)
9/225643	07 Aug 1997 (07.08.97)	JP	01 May 1998 (01.05.98)

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

Sean Taylor

Telephone No.: (41-22) 338.83.38

E P



P C T

国際調査報告

(法8条、法施行規則第40、41条)
[PCT18条、PCT規則43、44]

出願人又は代理人 の書類記号 PCT-98-007	今後の手続きについては、国際調査報告の送付通知様式(PCT/ISA/220)及び下記5を参照すること。		
国際出願番号 PCT/JP98/01094	国際出願日 (日.月.年) 16.03.98	優先日 (日.月.年) 21.03.97	
出願人(氏名又は名称) 株式会社 資生堂			

国際調査機関が作成したこの国際調査報告を法施行規則第41条(PCT18条)の規定に従い出願人に送付する。
この写しは国際事務局にも送付される。

この国際調査報告は、全部で 4 ページである。

☐ この調査報告に引用された先行技術文献の写しも添付されている。

1. ☐ 請求の範囲の一部の調査ができない(第I欄参照)。

2. ☒ 発明の単一性が欠如している(第II欄参照)。

3. ☐ この国際出願は、ヌクレオチド及び/又はアミノ酸配列リストを含んでおり、次の配列リストに基づき国際調査を行った。

☐ この国際出願と共に提出されたもの

☐ 出願人がこの国際出願とは別に提出したもの

☐ しかし、出願時の国際出願の開示の範囲を越える事項を含まない旨を記載した書面が添付されていない

☐ この国際調査機関が書換えたもの

4. 発明の名称は ☒ 出願人が提出したものを承認する。

☐ 次に示すように国際調査機関が作成した。

5. 要約は ☒ 出願人が提出したものを承認する。

☐ 第III欄に示されているように、法施行規則第47条(PCT規則38.2(b))の規定により国際調査機関が作成した。出願人は、この国際調査報告の発送の日から1カ月以内にこの国際調査機関に意見を提出することができる。

6. 要約書とともに公表される図は、
第 _____ 図とする。 ☐ 出願人が示したとおりである。

☒ なし

☐ 出願人は図を示さなかった。

☐ 本図は発明の特徴を一層よく表している。

第Ⅰ欄 請求の範囲の一部の調査ができないときの意見 (第1ページの1の続き)

法第8条第3項 (PCT 17条(2)(a)) の規定により、この国際調査報告は次の理由により請求の範囲の一部について作成しなかった。

1. ☐ 請求の範囲 _____ は、この国際調査機関が調査をすることを要しない対象に係るものである。つまり、
2. ☐ 請求の範囲 _____ は、有意義な国際調査をすることができる程度まで所定の要件を満たしていない国際出願の部分に係るものである。つまり、
3. ☐ 請求の範囲 _____ は、従属請求の範囲であってPCT規則6.4(a)の第2文及び第3文の規定に従って記載されていない。

第Ⅱ欄 発明の単一性が欠如しているときの意見 (第1ページの2の続き)

次に述べるようにこの国際出願に二以上の発明があるときこの国際調査機関は認めた。

(認定した発明)請求項1～4、請求項5及び6、請求項7及び8、請求項9及び10、請求項11及び12、請求項13及び14：認定した六の発明は、すべて「紫外線皮膚免疫機能低下」にかかるものであるが、「紫外線皮膚免疫機能低下」にかかる疾病を治癒する医薬又は化粧品は従前から存在するものと認められ、この医薬用途を新規な課題として共通の主要部として認めることはできない。そして、上記六のそれぞれの発明は、グルタチオン、オウゴン抽出物、シナノキ抽出物、チョウジ抽出物、ゲンノショウコ抽出物及びローズマリー抽出物をそれぞれ有効成分として含有する医薬であるが、それらの成分に共通性があるものとは、本願明細書を参酌しても認められず、また、医薬、化粧品の分野で、それらの成分が、通常同等の効能を奏するものとして一群のものと認識されているものとも認められない。

1. ☒ 出願人が必要な追加調査手数料をすべて期間内に納付したので、この国際調査報告は、すべての調査可能な請求の範囲について作成した。
2. ☐ 追加調査手数料を要求するまでもなく、すべての調査可能な請求の範囲について調査することができたので、追加調査手数料の納付を求めなかった。
3. ☐ 出願人が必要な追加調査手数料を一部のみしか期間内に納付しなかったため、この国際調査報告は、手数料の納付のあった次の請求の範囲のみについて作成した。
4. ☐ 出願人が必要な追加調査手数料を期間内に納付しなかったため、この国際調査報告は、請求の範囲の最初に記載されている発明に係る次の請求の範囲について作成した。

追加調査手数料の異議の申立てに関する注意

- ☐ 追加調査手数料の納付と共に出願人から異議申立てがあった。
- ☐ 追加調査手数料の納付と共に出願人から異議申立てがなかった。

A. 発明の属する分野の分類 (国際特許分類 (IPC))

Int. Cl.⁸ A61K38/06, A61K7/00, A61K7/48, A61K35/78

B. 調査を行った分野

調査を行った最小限資料 (国際特許分類 (IPC))

Int. Cl.⁸ A61K38/06, A61K7/00, A61K7/48

最小限資料以外の資料で調査を行った分野に含まれるもの

国際調査で使用した電子データベース (データベースの名称、調査に使用した用語)

CAPLUS (STN), REGISTRY (STN)

C. 関連すると認められる文献

引用文献の カテゴリー*	引用文献名 及び一部の箇所が関連するときは、その関連する箇所の表示	関連する 請求の範囲の番号
PX ✓	WO, 97/21444, A1 (Balazovsky Mark BORISOVICH) 19. 6月. 1997 (19. 06. 9 7) (ファミリーなし)	1-4
A ✓	JP, 7-48241, A (ロレアル) 21. 2月. 1995 (2 1. 02. 95) 全文、特に第2欄第34行目~35行目 & EP, 623342, A1 & FR, 2704754, A1 & CA, 2122969, A & US, 5516507, A	1-4
X ✓	Chemical Abstracts, Vol. 82 (197 5) 要約番号51359, Kahn GUINTER, Ultra	3, 4

☒ C欄の続きにも文献が列举されている。☐ パテントファミリーに関する別紙を参照。

* 引用文献のカテゴリー

「A」 特に関連のある文献ではなく、一般的技術水準を示すもの
「E」 先行文献ではあるが、国際出願日以後に公表されたもの
「L」 優先権主張に疑義を提起する文献又は他の文献の発行日若しくは他の特別な理由を確立するために引用する文献 (理由を付す)
「O」 口頭による開示、使用、展示等に言及する文献
「P」 国際出願日前で、かつ優先権の主張の基礎となる出願

の日の後に公表された文献
「T」 国際出願日又は優先日後に公表された文献であって出願と矛盾するものではなく、発明の原理又は理論の理解のために引用するもの
「X」 特に関連のある文献であって、当該文献のみで発明の新規性又は進歩性がないと考えられるもの
「Y」 特に関連のある文献であって、当該文献と他の1以上の文献との、当業者にとって自明である組合せによって進歩性がないと考えられるもの
「&」 同一パテントファミリー文献

国際調査を完了した日

22. 06. 98

国際調査報告の発送日

30.06.98

国際調査機関の名称及びあて先

日本国特許庁 (ISA/JP)

郵便番号100-8915

東京都千代田区霞が関三丁目4番3号

特許庁審査官 (権限のある職員)

田村 聖子

4C

9051

電話番号 03-3581-1101 内線 3452

C (続き) . 関連すると認められる文献

引用文献の カテゴリー*	引用文献名 及び一部の箇所が関連するときは、その関連する箇所の表示	関連する 請求の範囲の番号
	violet light protection by several new compounds, Arch. Dermatol., Vol. 109, No. 4 (1974) P. 510-511	
A ✓	JP, 5-238925, A (株式会社ヤクルト本社) 17. 9月. 1993 (17. 09. 93) (ファミリーなし)	5, 6
X ✓	Chemical Abstracts, Vol. 109 (1988) 要約番号204576 (Yakovlev, A. I., Study of mechanisms of the immunostimulating effects of some plant, Vol. 51, No. 5 (1988) P. 68-72)	7, 8
X ✓	Chemical Abstracts, Vol. 122 (1995) 要約番号151064 (Lee GYEONG-IM, Inhibitory effects of oriental herbal medicines on IL-8 induction in lipopolysaccharide-activated rat macrophages, Planta Med., Vol. 61, No. 1 (1995) P. 26-30)	9, 10
X ✓	Chemical Abstracts, Vol. 110 (1983) 要約番号63717	9, 10
X ✓	WO, 96/5849, A1 (Mepat Ltd., Bahamas) 29. 2月. 1996 (29. 02. 96) (ファミリーなし)	11, 12
A ✓	JP, 1-83022, A (ライオン株式会社) 28. 3月. 1989 (28. 03. 89) (ファミリーなし)	13, 14

PCT
WELTORGANISATION FÜR GE
Internationales
INTERNATIONALE ANMELDUNG VERÖFFENTLICHUNG
INTERNATIONALE ZUSAMMENARBEIT AUF DI



WO 9605849A1

<p>(51) Internationale Patentklassifikation ⁶ : A61K 35/78 // (A61K 35/78, 31:70)</p>	<p>A1</p>	<p>(11) Internationale Veröffentlichungsnummer: WO 96/05849 (43) Internationales Veröffentlichungsdatum: 29. Februar 1996 (29.02.96)</p>
<p>(21) Internationales Aktenzeichen: PCT/EP95/03319 (22) Internationales Anmeldedatum: 21. August 1995 (21.08.95) (30) Prioritätsdaten: P 44 29 735.1 22. August 1994 (22.08.94) DE (71) Anmelder (für alle Bestimmungsstaaten ausser US): MEPAT LTD. [BS/BS]; P.O. Box N 7768, Bank-Lane, Nassau (BS). (72) Erfinder; und (75) Erfinder/Anmelder (nur für US): REUCHLIN, George, J. [NL/NL]; Oude Maasdiik, NL-6621 AA Dreumel (NL). (74) Anwalt: HERING, H.; Berendt, Leyh & Hering, Innere Wiener Strasse 20, D-81667 München (DE).</p>		<p>(81) Bestimmungsstaaten: AU, BR, CA, CN, CZ, FI, HU, JP, KP, KR, LR, MG, MX, NO, RO, RU, SK, US, VN, europäisches Patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI Patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO Patent (KE, MW, SD, SZ, UG). Veröffentlicht <i>Mit internationalem Recherchenbericht. Vor Ablauf der für Änderungen der Ansprüche zugelassenen Frist. Veröffentlichung wird wiederholt falls Änderungen eintreffen.</i></p>
<p>(54) Title: MEANS FOR TREATING IMMUNOBIOLOGICAL CELL STRESS WEAKNESSES AND A PROCESS FOR MANUFACTURING THE SAME</p>		
<p>(54) Bezeichnung: MITTEL ZUR BEHANDLUNG IMMUNBIOLOGISCHER ZELLBELASTUNGSSCHWÄCHEN UND VERFAHREN ZU DESSEN HERSTELLUNG</p>		
<p>(57) Abstract</p> <p>According to the invention, a process is proposed for manufacturing a plant-based redox catalyst. The process in question involves the following steps: (i) leaves of geranium (pelargonium odoratissimum), clove plant (eugenia caryophyllata), myrrh (commophora abyssinica, c. molmol, c. schimperi) and/or juniper (juniperus communis) are shredded and a sludge of the shredded leaves in water is made; (ii) the pH value of the suspension thus obtained is adjusted using an alkaline lye to 9-11 and the suspension is stirred for 48 hours at a temperature of 45-50 °C before undergoing coarse filtration; (iii) the pH value of the filtrate is adjusted by dialysis to 6-7 and particles of the resulting precipitate are removed by centrifugation; (iv) the residue thus obtained is subjected to chromatography using silica gel or aluminium hydroxide; (v) molecules with a molecular weight of less than 5000 Dalton and greater than 30000 Dalton are removed by ultracentrifugation; (vi) the filtrate containing the fraction with molecular weights of 5000-30000 Dalton is subjected to dialysis against a 0.9 % NaCl solution and finally to sterile filtration. Also disclosed are a plant-based redox catalyst, a pharmaceutical composition and the use of the proposed plant redox catalyst for the prevention and/or treatment of immunobiological cell stress weaknesses.</p> <p>(57) Zusammenfassung</p> <p>Nach der Erfindung wird ein Verfahren zur Herstellung eines pflanzlichen Redoxkatalysators (ROK) angegeben, welches die folgenden Schritte aufweist: (i) Blätter der Geranie (Pelargonium odoratissimum), der Nelke (Eugenia caryophyllata), der Myrrhe (Commophora abyssinica, C. molmol, C. schimperi) und/oder des Wacholders (Juniperus communis) zu zerkleinern und in Wasser aufzuschlämmen; (ii) die erhaltene Suspension mit Alkalilauge auf einen pH-Wert von 9-11 einzustellen, bei 45-50 °C 48 Stunden zu rühren und anschließend grob zu filtrieren; (iii) das Filtrat mittels Dialyse auf einen pH-Wert von 6-7 einzustellen und dabei ausfallende Partikel abzuzentrifugieren; (iv) den so erhaltenen Überstand an Kieselgel oder Aluminiumhydroxid zu chromatographieren; (v) die Moleküle mit einem Molekulargewicht von kleiner 5000 und größer 30000 Dalton mittels Ultrazentrifugation zu entfernen; und (vi) das die Fraktion mit einem Molekulargewicht von 5000 bis 30000 Dalton enthaltende Filtrat gegen 0,9 %ige NaCl-Lösung zu dialysieren und abschließend steril zu filtrieren. Ferner werden ein pflanzlicher Redoxkatalysator (ROK), eine pharmazeutische Zusammensetzung und die Verwendung des pflanzlichen Redoxkatalysators zur Prophylaxe und/oder Behandlung von immunbiologischen Zellbelastungsschwächen beschrieben.</p>		

LEDIGLICH ZUR INFORMATION

Codes zur Identifizierung von PCT-Vertragsstaaten auf den Kopfbögen der Schriften, die internationale Anmeldungen gemäss dem PCT veröffentlichen.

AT	Österreich	GA	Gabon	MR	Mauretanien
AU	Australien	GB	Vereinigtes Königreich	MW	Malawi
BB	Barbados	GE	Georgien	NE	Niger
BE	Belgien	GN	Guinea	NL	Niederlande
BF	Burkina Faso	GR	Griechenland	NO	Norwegen
BG	Bulgarien	HU	Ungarn	NZ	Neuseeland
BJ	Benin	IE	Irland	PL	Polen
BR	Brasilien	IT	Italien	PT	Portugal
BY	Belarus	JP	Japan	RO	Rumänien
CA	Kanada	KE	Kenya	RU	Russische Föderation
CF	Zentrale Afrikanische Republik	KG	Kirgisistan	SD	Sudan
CG	Kongo	KP	Demokratische Volksrepublik Korea	SE	Schweden
CH	Schweiz	KR	Republik Korea	SI	Slowenien
CI	Côte d'Ivoire	KZ	Kasachstan	SK	Slowakei
CM	Kamerun	LJ	Liechtenstein	SN	Senegal
CN	China	LK	Sri Lanka	TD	Tschad
CS	Tschechoslowakei	LU	Luxemburg	TG	Togo
CZ	Tschechische Republik	LV	Lettland	TJ	Tadschikistan
DE	Deutschland	MC	Monaco	TT	Trinidad und Tobago
DK	Dänemark	MD	Republik Moldau	UA	Ukraine
ES	Spanien	MG	Madagaskar	US	Vereinigte Staaten von Amerika
FI	Finnland	ML	Mali	UZ	Usbekistan
FR	Frankreich	MN	Mongolei	VN	Vietnam

MITTEL ZUR BEHANDLUNG IMMUNBIOLOGISCHER ZELLBELASTUNGSSCHWÄ-
CHEN UND VERFAHREN ZU DESSEN HERSTELLUNG

Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung eines pflanzlichen Redoxkatalysators (Mittels), das mittels dieses Verfahrens gewonnene Mittel sowie die Verwendung dieses Mittels zur Behandlung immunbiologischer Zellbelastungsschwächen wie z.B. AIDS und verschiedene maligne Entartungen.

Nach DE 38 29 200 A1 soll ein Mittel gegen AIDS bereitgestellt werden. Dazu wird die Verwendung von aus Nelkenfruchtfleisch bzw. Nelkenöl isolierbaren Verbindungen 2-Methoxyallylphenol (Eugenöl) und sein Isomere 2-Methoxypropenylphenol (Isoeugenol) offenbart. Dieses Mittel setzt sich also aus Eugenol und Isoeugenol zusammen und die Anwendung ist offensichtlich auf AIDS beschränkt. Diese Substanzkombination kann aber auch mit den synthetisch hergestellten Verbindungen Eugenol und Isoeugenol bereitgestellt werden. Demgegenüber handelt es sich bei ROK um ein komplexes Molekülverbundsystem ausschließlich auf pflanzlicher Basis. Es sind keine Hinweise auf ein Verfahren zur Herstellung eines pflanzlichen Redoxkatalysators hieraus zu entnehmen, der den Grundstoff für eine pharmazeutisch wirksame Zusammensetzung bildet.

Bekannt ist, pflanzliche Präparate verschiedener Herkunft zur Behandlung von Immunschwächen einzusetzen. Abgesehen von Einzelvorschlägen zur Verwendung von bekannten Pflanzenauszügen (-extrakten) oder von Pflanzeninhaltsstoffen, z.B. von Echinacea, wurden auch bereits Extrakte von Ligninarten zur Behandlung von viralen Infektionskrankheiten (DE-A 40 17 091) vorgeschlagen, deren Wirkungsmechanismus auf einem Redoxsystem zu

beruhen scheint (Naturheilpraxis 12, 1988, Seiten 1496-1502)

Es wurde nun gefunden, daß ein vermutlich auf einem Redox Katalysatorsystem beruhender Extrakt aus verschiedenen Pflanzen, nämlich aus Blättern der Geranie (*Pelargonium odoratissimum*), des Wacholder (*Juniperus communis*), der Myrrhe (*Commiphora abyssinica*, *C. molmol*, *C. schimperi*) und/oder der Nelk (*Eugenia caryophyllata*), Wirkungen aufweist, die wegen der vielfältigen Einwirkungen auf immunbiologische Zellbelastungen schwächen (Zellimmunschwächeerscheinungen) eine große therapeutische Bedeutung hat.

Insbesondere sind positive Einwirkungen auf Herzmuskelnekrosen, auf toxisch induzierten Enzymaustritt aus Leberzellen auf gewisse Krebsformen und auch auf Immunzellen (und damit speziell auf die durch HIV verursachte Immunschwächekrankheit AIDS) zu beobachten.

Allgemein formuliert stellen Redox-Katalysatoren Wirkstoff dar, die auf Grund ihrer biochemischen Eigenschaften in der Lage sind, unmittelbar und auf physiologische Weise in die intrazelluläre Stoffwechsel-Regulation einzugreifen. Von diesen Stoffwechsel-Regulatoren am interessantesten sind solche, die die allgemeine Adaptationsleistung der Zelle erhöhen können. Biochemisch gesehen bedeuten Stoffwechseländerungen jedoch Umbauten von Biomolekülen und damit letztlich Elektronenübergänge zwischen Molekülen und Molekülsystemen. Hierbei steigt die Belastbarkeit der Zelle (Anstieg der Belastungstoleranz), ohne daß belastungsbedingte Mikrotraumen (z.B. Veränderungen an Zellorganellen) resultieren. Ein auf diese Weise wirksames Mittel grenzt sich von verwechselbaren Verbindungen wie Hormonen, unspezifischen Reizkörpern, Chemotherapeutika u.s.w. prinzipiell ab.

Eine Aufgabe der vorliegenden Erfindung besteht darin, ein Verfahren zur Herstellung eines pflanzlichen Redoxkatalysators bereitzustellen.

Eine weitere Aufgabe der vorliegenden Erfindung besteht darin, einen nach diesem Verfahren erhältlichen pflanzlichen Redoxkatalysators (ROK) bereitzustellen.

Noch eine weitere Aufgabe der vorliegenden Erfindung besteht darin, eine pharmazeutische Zusammensetzung zur Verfügung zu stellen, die diesen pflanzlichen Redoxkatalysator als Wirkstoff enthält.

Schließlich besteht eine vierte Aufgabe der vorliegenden Erfindung darin, die Verwendung dieses pflanzlichen Redoxkatalysators (Mittels), insbesondere in Kombination mit Zidovudin (AZT), zur Herstellung eines Medikamentes zur Behandlung von immunbiologischen Zellbelastungsschwächen (z.B. AIDS und verschiedene Krebsformen) bereitzustellen.

Bei dem erfindungsgemäßen, pflanzlichen Redoxkatalysator (Mittel) handelt es sich um ein bifunktionelles Molekülsystem, d.h. das erfindungsgemäße Mittel enthält sowohl katabol- wie anabolaktive Systemanteile, die Redoxveränderungen in der Zelle katalysieren. Die besondere Bedeutung des erfindungsgemäßen Mittels besteht nun darin, daß es in der Lage ist, bei Vorhandensein von Streß, traumatischen Veränderungen, Entzündungen, Infektionen sowie malignen Entgleisungen des Gewebes über Redox-Vorgänge normale, physiologische Zustände zu erzeugen, was zu einem raschen Abklingen der Stoffwechselentgleisung führt (Heilungsvorgang).

Hierbei erfolgt gleichzeitig eine Stimulierung des Immunsystems über eine verstärkte Aktivierung der T- und B-Zellen, die sich direkt und durch einen Konzentrationsanstieg von Zytokinen wie Interleukin 2 (IL-2), Interleukin 3 (IL-3), Interleukin 6 (IL-6) und Tumornekrosefaktor alpha (TNF-alpha) nachweisen läßt. Diese Zytokine sind bekannt als induzierbare zelluläre Proteine mit zentraler Bedeutung bei embryonalen Entwicklungsvorgängen, bei Entzündungsabläufen und bei Immun-

regulationsvorgängen.

Für die therapeutische Verwendung des ROK eignen sich i.v. Injektionen ganz besonders, es können jedoch auch eine andere Form der parenteralen (intraperitoneale, s.c. injizierte) oder eine orale Verabreichung erfolgen. Als geeignete Dosis werde je nach Form der Verabreichung 1 - 30, bevorzugterweise 5 - 20, besonders bevorzugterweise 10 - 20, mg ROK/Tag und Patient verwendet. Die zu verabreichende Dosis hängt weiterhin natürlich auch von dem Allgemeinzustand der Patienten ab: bei bereits fortgeschrittenem Zustand der Krankheit wie z.B. AID und desolatem Allgemeinzustand des Patienten muß die Dosis gegebenenfalls (auf z.B. 2 - 5 oder 10 mg) reduziert werden um eine zu hohe Autointoxikation durch Aktivierung des Stoffwechsels zu vermeiden.

Insbesondere wurden diese oben beschriebenen Wirkungen des ROK an in-vitro-Modellen von Leukozyten- und Fibroblastenkulturen gezeigt. Eine antivirale Wirkung des erfindungsgemäßen Mittels ließ sich an mit FV (Friend-Virus) infizierten Kulturen sowohl alleine als auch in Kombination mit Zidovudin (AZT) nachweisen. Damit ist eine therapeutische Anwendung bei z.B. HIV-infizierten Patienten mit hoher Wirkung bei gleichzeitig niedriger Toxizität gegeben.

Ausgangsprodukt für den erfindungsgemäßen Redoxkatalysator (ROK) sind Blätter von der Geranie (*Pelargonium odoratissimum*), der Nelke (*Eugenia caryophyllata*), der Myrrhe (*Commiphora abyssinica*, *C. molle*, *C. schimperi*) und/oder des Wacholder (*Juniperus communis*). Die Blätter werden zerkleinert und in Wasser aufgeschlämmt. Die Suspension wird mit Alkalilauge auf einen pH-Wert von 9 bis 11 eingestellt und dann 4 Stunden lang bei 45 - 50°C, vorteilhafterweise bei ziemlich genau 48°C, gerührt. Dann folgen eine Grobfiltration und eine Dialyse der resultierenden Lösung gegen eine Pufferlösung mit einem pH von 6 - 7. Ausfallende Partikel werden durch Zentrifugation entfernt. Der erhaltene Überstand wird zunächst mit

tels Chromatographie an Kieselgel oder Aluminiumhydroxid gereinigt, dann zweimal ultrafiltriert, so daß Moleküle mit einem Molekulargewicht von weniger als 5000 und mehr als 30.000 Dalton abgetrennt werden. Das Filtrat enthält den erfindungsgemäßen Redoxkatalysator (ROK). Es wird gegen 0,9% NaCl dialysiert, auf die gewünschte Konzentration (z.B. 1 mg/ml) an ROK gebracht und steril filtriert.

Beispiele:

Herstellung des erfindungsgemäßen Mittels

Beispiel 1

1. Zur Verwendung kommen gleiche Gewichtsanteile von frischen oder getrockneten Blättern aller oben genannten Pflanzen (Geranie, Nelke und Wacholder). Die in dieser Mischung enthaltene Wirkstoffkonzentration (Konzentration des ROK) variiert von 0,1 - 2 Gew.-%.
2. 100 g des zerkleinerten Blattgemisches werden in ca. 1000 ml entmineralisiertem Wasser aufgeschlämmt. Es erfolgt mit Alkalilauge, NaOH oder KOH, eine Einstellung auf einen pH im Bereich von 9-11. Das Gemisch wird für 48 Std. unter ständigem Rühren bei einer Temperatur von 48°C gehalten. Anschließend werden die verbliebenen Feststoffe durch Grobfiltration entfernt und verworfen.
3. Die so erhaltene Lösung wird durch Dialyse gegen eine Standard-Phosphat-Pufferlösung (Soerensen) auf pH 6,8 eingestellt. Da bei diesem Schritt eine Reihe von unspezifischen Feststoffen (Pflanzenproteine bzw. -proteide) ausfallen, erfolgt ein erster Reinigungsschritt durch Klarzentrifugation bei 1000-3000 x g.
4. Die weitere Reinigung des klaren Überstandes erfolgt zunächst mittels Chromatographie an Kieselgel oder Aluminiumhydroxid, dann durch zweistufige, fraktionierte Ultrafiltration mit AMICON®-Membranen; in dem ersten Schritt werden gegen eine 5000 Dalton-Membran alle Biomoleküle kleiner als 5000 Dalton abgetrennt und verworfen, Abtrennmedium ist die oben erwähnte Phosphat-Pufferlösung. Der zweite Filtrationsschritt erfolgt

durch eine Membran mit Molekulargewichtsabtrennung größer gleich 30.000 Dalton. Das klare Filtrat enthält das erfindungsgemäße aktive Mittel als Molekülverbundsystem mit einem Molekulargewichtsspektrum von 5000 - 30.000 Dalton.

5. Die so gereinigte Lösung des erfindungsgemäßen Redoxkatalysators wird gegen eine 0,9%ige NaCl-Lösung dialysiert und auf eine Konzentration von 1mg/ml eingestellt. Zur Ermittlung der Wirkstoffkonzentration finden fluorimetrische Standardverfahren Anwendung; das Fluoreszenzanregungsspektrum der Wirksubstanz (des ROK) liegt bei einer Wellenlänge von 450 nm.

6. Es erfolgt Sterilfiltration durch ein Membranfilter mit 0,2 µm Porenweite und abschließendes Ampullieren in 1ml-Ampullen

Beispiel 2

1. Die Schritte 1-3 werden wie bei Beispiel 1 durchgeführt.
2. Es erfolgt die Abtrennung der Moleküle kleiner als 500 Dalton durch die entsprechende Ultrafiltrationsmembran, wie es im ersten Beispiel in Schritt 4 beschrieben worden ist. Bei der so vorgereinigten Lösung erfolgt nun die Abtrennung der Moleküle größer als 30.000 Dalton in einer Ultrazentrifuge für 10-11 Stunden bei 50.000 x g.
3. Wie in Beispiel 1 folgen abschließend die Schritte 5 und 6

Beispiele 3 und 4

Die Schritte 1-6 werden wie bei Beispiel 1 durchgeführt, außer daß in Beispiel 3 nur Geranien-, in Beispiel 4 nur Wacholderblätter verwendet werden.

Eigenschaften des erfindungsgemäßen Mittels (ROK)

Beispiel 5

Zytotoxizität in vitro und in vivo

In Monolayerkulturen von Mus du n n i-Maus-Fibroblasten konnte die zytotoxische Dosis (CD₅₀) ermittelt werden, bei der 50% der Zellen absterben. Sie beträgt 23µg/µl.

Tabelle 1

Wirkstoff-Konz. ($\mu\text{g}/\mu\text{l}$)	320	100	32	10	3,2	1,0	0,32	0
Überlebensrate Zellkultur %	17	43	29	62	73	90	82	100

Grundsätzlich steigt die Überlebensrate der Zellen mit sinkender Konzentration des Wirkstoffes stetig an. Bei der Ermittlung der Überlebensrate treten in der Praxis jedoch methodische Schwierigkeiten dahingehend auf, daß eine statistische Zählung (die Zellen aus einem Tropfen Zellkultur werden auf eine Neubauer-Zählkammer aufgetragen, die 4 Quadranten unter einem Mikroskop ausgezählt und so die Zahl der Zellen pro ml bzw. Liter hochgerechnet) der Zellen unter dem Mikroskop erfolgt, wobei die Variationsbreite der Zellzahlen in den verschiedenen Kulturflaschen in der Praxis relativ hoch sein kann. Dies ist eine Erklärung für die in der Tabelle 1 fehlende Stetigkeit. Allerdings zeigen die Werte in Tabelle 1, daß die Überlebensrate mit der Wirkstoff-Konzentration korreliert, auch wenn sich unter den Werten einzelne "Ausreißer" (z.B. 29% bei 32 $\mu\text{g}/\mu\text{l}$) befinden.

Die letale Dosis LD_{50} , d.h. die Dosis, bei der 50% der Versuchstiere sterben, wurde in SCID-Mäusen ermittelt. Sie beträgt bei intraperitonealer Verabreichung 1024mg/kg Körpergewicht.

Beispiel 6

Immunologische Effekte

Immunologische Wirkungen des erfindungsgemäßen Mittels wurden sowohl in einer definierten Zelllinie (L-929, NCTC clone 929 der ATCC) als auch an Kulturen menschlicher, peripherer Lymphozyten von gesunden Probanden ermittelt.

1. L-929-Zellkultur

Eine signifikante Erhöhung der Lipopolisaccharid (LPS)-induzierten Blastogenese sowie eine leichte Erhöhung der Aktivität der natürlichen Killerzellen (NK) wurde bei einer optimalen Wirkstoffkonzentration von 0,32 mg/ml festgestellt.

Tabelle 2

Dosis (mg/ml)	LPS (cpm)	Zytotoxizität der NK (%)
3,2	4092	9,4
1,6	10895	11,3
0,32	17062	42,7
0,16	14971	39,6
0,08	14368	35,8

cpm: gezählte Zerfälle pro Minute (counts per minute)

LPS: Lipopolysaccharid

NK : natürliche Killerzellen (natural killer cells)

2. Human-Lymphozytenkulturen

Von Probanden werden 5ml venöses Vollblut entnommen, mit Heparin stabilisiert und die buffy-coat-Fraktion mit Ringer-Lösung pH 7,2 in 5ml-Einmalplastik-Zellkulturflaschen (FALCON) für 72 Stunden bei 37°C inkubiert. Pro Kultur erfolgt die Zugabe des erfindungsgemäßen Wirkstoffes (ROK) zu einer Endkonzentration von 0,32 mg/ml. Es wird die Konzentrationszunahme (in pg/ml verschiedener Zytokine (IL-2, IL-3, IL-6 und TNF-alpha, Assay-Mikrotiterplatten DIANOVA) im Vergleich zu Probandenkontrollen ohne Wirkstoffzugabe untersucht. Die Ergebnisse (siehe Tabellen 3 - 6) zeigen eine durch den Wirkstoff bedingte starke Zytokinexpression als spezifische Immunwirkung.

Tabelle 3: Induktion von IL-2 durch ROK

Proband Nr.	IL-2-Konzentration (pg/ml)	
	I	II
1	22,2	50,8
2	4,1	11,9
3	5,5	22,1
4	6,8	12,0
5	4,1	13,2
6	2,0	9,4
7	1,2	1,4
8	10,0	62,5
9	9,9	56,5
10	9,8	67,3
11	4,5	19,9
12	2,1	72,5
13	14,0	69,0
14	9,9	84,5
15	13,1	55,5

I bezeichnet Probandenblut unbehandelt

II bezeichnet Probandenblut behandelt mit Wirksubstanz

Tabelle 4: Induktion von IL-3 durch ROK

Proband Nr.	IL-3-Konzentration (pg/ml)	
	I	II
1	7,1	78,8
2	0,3	4,4
3	4,6	29,9
4	0,2	24,5
5	3,4	63,6
6	0,1	3,7
7	2,7	21,8
8	2,3	3,6
9	7,4	19,8
10	8,0	24,5
11	0,0	0,0
12	0,1	7,8
13	6,2	0,3
14	3,0	7,1
15	0,1	7,3

I bezeichnet Probandenblut unbehandelt

II bezeichnet Probandenblut behandelt mit Wirksubstanz

Tabelle 5: Induktion von IL-6 durch ROK

Proband Nr.	IL-6-Konzentration (pg/ml)	
	I	II
1	37,1	28,0
2	66,6	32,0
3	8,0	7,0
4	17,1	17,1
5	21,7	39,0
6	45,2	61,9
7	3,0	20,6
8	12,2	28,7
9	15,5	60,7
10	14,5	84,5
11	3,7	21,0
12	18,2	47,5
13	0,5	36,5
14	9,0	15,0
15	14,6	79,0

I bezeichnet Probandenblut unbehandelt

II bezeichnet Probandenblut behandelt mit Wirksubstanz

Tabelle 6: Induktion von TNF- α durch ROK

Proband Nr.	TNF- α -Konzentration (pg/ml)	
	I	II
1	3,0	9,6
2	1,5	0,2
3	0,7	0,1
4	3,3	7,4
5	3,3	0,0
6	9,1	0,0
7	0,5	2,1
8	1,8	0,0
9	1,6	0,3
10	3,7	7,3
11	2,5	0,9
12	12,8	15,5
13	2,3	9,0
14	4,3	5,2
15	6,8	9,5

I bezeichnet Probandenblut unbehandelt

II bezeichnet Probandenblut behandelt mit Wirksubstanz

Beispiel 7

In-Vitro-Effekt der Kombination des Redoxkatalysators ROK mit AZT an mit Friend-Virus (FV) infizierten Maus-Fibroblasten-Kulturen

Verwendung findet eine Monolayer-Kultur von M u s d u n n i-Maus-Fibroblastenzellen nach 18stündiger Kulturdauer, bei der zunächst die Infektion mit Friend-Virus vorgenommen wird. Drei Stunden später werden nachfolgend aufgeführte Substanzkombinationen in die Kultur eingebracht:

- | | |
|--------------|---|
| Experiment 1 | AZT allein in Konzentrationen von
1, 0.1, 0.01, 0.001µg/ml Kulturmedium |
| Experiment 2 | ROK allein in Konzentrationen von
320, 100, 32, 10, 3.2, 1.0, 0.32mg/ml Kulturmedium |
| Experiment 3 | ROK in allen Konzentrationen aus Exp. 2 zusammen mit 1µg AZT/ml Kulturmedium |
| Experiment 4 | ROK in allen Konzentrationen aus Exp. 2 zusammen mit 0.1µg AZT/ml Kulturmedium |
| Experiment 5 | ROK in allen Konzentrationen aus Exp. 2 zusammen mit 0.01µg AZT/ml Kulturmedium |
| Experiment 6 | ROK in allen Konzentrationen aus Exp. 2 zusammen mit 0.001µg AZT/ml Kulturmedium |

Zusammenfassend ergeben sich nachfolgend beschriebene Resultate, die auf Grund von verschiedenen Versuchsreihen erhalten wurden (Tabellen 7 bis 10). Dabei traten bei den verschiedenen Versuchsreihen Schwankungen der Meßwerte von bis zu $\pm 15\%$ auf.

1. Werden die Zytotoxizitäten, die beide Mittel/Substanzen (ROK, AZT) jeweils allein auf die Zellkultur ausüben, mit der Zytotoxizität verglichen, die durch gemeinsame Verwendung beider Substanzen (ROK, AZT) an Zellkulturen beobachtet werden kann, läßt sich eine stark antagonistische Wirkung der beiden Substanzen erkennen (AZT allein ist sehr toxisch). Mit anderen Worten, die Kombination von AZT und ROK ergibt eine weit ge-

ringere Toxizität (optimale Konzentrationen beider Substanzen 10µg/µl ROK; 0.01µg/ml AZT) als bei den allein verwendeten Substanzen in jeglicher Konzentration (bzgl. der genaueren Definition von "Antagonismus" und seiner Quantifizierung wird auf Berenbaum, M.C., J. Infect. Dis. 137, 122 (1978) verwiesen, der den sog. Fraktionellen Inhibitions-Konzentrationsindex (FIC) wie folgt definiert:

$$FIC = \frac{CD_{50} \text{ v. Substanz 1 in Komb.}}{CD_{50} \text{ v. Substanz 1 allein}} + \frac{CD_{50} \text{ v. Substanz 2 in Komb.}}{CD_{50} \text{ v. Substanz 2 allein}}$$

mit

FIC < 0,5 : signifikant synergistische Wirkung
0,5 < FIC < 0,9: synergistische Wirkung angedeutet
FIC = 1 : additive Wirkung
1,1 < FIC < 1,9: potentiell antagonistische Wirkung
FIC > 2 : (stark) antagonistische Wirkung

2. AZT allein hat den höchsten FV-Inhibitionseffekt mit einer die Bildung von Foci zu 50% inhibierenden Dosis (ED₅₀) von 0,0079 µg/ml. ROK allein hat einen geringeren FV-Inhibitionseffekt (ED₅₀ = 10,8 µg/µl).

3. In Kombination beider Wirksubstanzen werden optimale FV-Hemm-Effekte erzielt bei 0.01µg/ml AZT zusammen mit 10-30 µg/µl ROK (63-84% Hemmung), die höher sind als bei den Wirksubstanzen allein. Gleichzeitig ist die Zytotoxizität bei diesen Konzentrationen niedriger als bei der Verwendung der Einzelsubstanzen.

Tabelle 7: Zytotoxische Effekte an Mus dunni-Kulturen
durch Kombination von ROK und AZT

Überleben der Kulturen (%)					
ROK-Kon- zentra- tion ($\mu\text{g}/\mu\text{l}$)	AZT-Konzentration ($\mu\text{g}/\text{ml}$)				
	0	1.0	0.1	0.01	0.001
0	100	55	56	80	70
320	17	19	30	55	73
100	43	63	59	94	
32	29	38	67	76	90
10	62	49	75	100	82
3.2	73	65	66	94	85
1.0	90	100	75	100	97
0.32	82	100	84	85	8

Tabelle 8: Friend-Virus-Hemmung in Mus dunni-Zellen
durch Kombination von ROK und AZT

% Hemmung					
ROK-Kon- zentra- tion ($\mu\text{g}/\mu\text{l}$)	AZT-Konzentration ($\mu\text{g}/\text{ml}$)				
	0	1.0	0.1	0.01	0.001
0	0	100	100	56	3
320	100	100	100	100	100
100	100	100	100	100	89
32	70	100	100	84	58
10	35	100	100	63	35
3.2	33	100	100	47	9
1.0	0	100	100	42	11
0.32	3	100	100	40	2

Tabelle 9: Zytotoxische Effekte an Mus dunni-Kulturen durch Kombination von ROK und AZT

Überleben der Kulturen (%)					
ROK-Konzentration (µg/µl)	AZT-Konzentration (µg/ml)				
	0	1.0	0.1	0.01	0.001
0	100	54	57	81	71
320	18	18	31	54	74
100	44	62	58	95	94
32	28	39	68	77	90
10	63	48	76	100	83
3.2	73	65	66	94	85
1.0	90	99	76	100	98
0.32	83	100	83	86	7

Tabelle 10: Friend-Virus-Hemmung in Mus dunni-Zellen durch Kombination von ROK und AZT

% Hemmung					
ROK-Konzentration (µg/µl)	AZT-Konzentration (µg/ml)				
	0	1.0	0.1	0.01	0.001
0	0	100	100	56	3
320	100	100	100	100	100
100	100	100	100	100	88
32	70	100	100	83	59
10	35	100	100	64	36
3.2	33	100	100	48	9
1.0	0	100	100	43	12
0.32	3	100	100	39	2

Die CD_{50} - und ED_{50} -Werte wurden an Hand der Versuchsreihen wie folgt ermittelt (Angaben in $\mu\text{g/ml}$ ROK bzw. $\mu\text{g}/\mu\text{l}$ AZT bei den nachfolgend aufgeführten AZT- bzw. ROK-Konzentrationen):

Tabelle 11: ED_{50} -Werte für ROK in $\mu\text{g}/\mu\text{l}$ bei folgenden AZT-Konzentrationen

		AZT-Konzentration (µg/ml)				
		0	1.0	0.1	0.01	0.001
ED ₅₀	10.8	<0.32	<0.32		7.5	23

Tabelle 12: CD_{50} -Werte für ROK in $\mu\text{g}/\mu\text{l}$ bei folgenden AZT-Konzentrationen

		AZT-Konzentration (µg/ml)				
		0	1.0	0.1	0.01	0.001
CD ₅₀	23	31	110	480	3,5	

Tabelle 13: ED_{50} -Werte für AZT in $\mu\text{g/ml}$ bei folgenden ROK-Konzentrationen

ROK-Konzentration ($\mu\text{g}/\mu\text{l}$)	ED_{50}
0	0,0079
320	<0.001
100	0.000025
32	0,00037
10	0,0032
3,2	0,0085
1,0	0,01
0.32	0,011

Tabelle 14: CD_{50} -Werte für AZT in $\mu\text{g/ml}$ bei folgenden ROK-Konzentrationen

ROK-Konzentration ($\mu\text{g}/\mu\text{l}$)	CD_{50}
0	5
320	0.014
100	5
32	0,5
10	0,9
3,2	10
1,0	70
0.32	70

In der Anmeldung ist unter dem Begriff "Immunbiologische Belastungsschwäche" eine Dysfunktion der Regulierung und Adaptation des Zellstoffwechsels zu verstehen, welcher für den Immunhaushalt verantwortlich ist. Ferner fällt hierunter - wie allgemein bekannt - daß z.B. Virusinfektionen, rheumatische Erkrankungen, Autoimmunerkrankungen, Malignomen, Leukämien, Lymphomen, Carcinomen und AIDS-Syndromen sich die immunologischen Parameter des Immunsystems im Vergleich zu einem Gesunden stark verändern. Diese Veränderung, die in einem Immunscreening durch die Messung der Immunglobuline, der Lymphozyten-Subpopulationen, der Makrophagen-Phagozytose etc. erfaßt wird, kann oftmals sogar als Hinweis auf das Vorliegen einer spezifischen Veränderung qualitativ wie quantitativ durch eine Suppression der Immunzellen oder durch Defekte an der Immunzelle selbst gekennzeichnet sein, was beispielsweise mit "Immunbiologische Belastungsschwäche" zusammengefaßt wird.

Als weitere Beispiele für die Verdeutlichung der Indikationen werden nachstehend Patientenbehandlungen beschrieben.

Beispiel I

Eine 1926 geborene Patientin, Diagnose Januar 1992 metastasierendes Rektum-Carcinom mit Operation. Oktober 1993 Rezidiv in der Sakralhöhle, Exzision des Tumors und Anlegen eines Anus praeter, nachfolgend 2 Zyklen Chemotherapie. Dezember 1993 nach allgemeinem schlechten subjektiven Zustand Erhöhung des CEA-Wertes auf 70 (Normalwert <5), Erhöhung der Alkalischen Phosphatase, Erhöhung von SGOT- und SGPT-Wert. Auftreten einer Lebermetastase, die durch CT-Werte gesichert ist.

Therapie: Seit dem 17.1.1994 erhält die Patientin vierwöchige Zyklen von ROK mit 5 x wöchentlich 2 Ampullen i.m., anschließend zwei Tage Injektionspause. Nach vier Wochen Injektionszyklus zwei Wochen Injektionspause. Kontrolle des CEA-Wertes (Rückgang auf CEA bei 15, Normalisierung der Alkalischen Phosphatase und der Leberwerte). Starke Besserung des subjektiven Wohlbefindens. Nach vier vierwöchigen Injektionszyklen Reduktion der Ampullenfrequenz auf 5 x wöchentlich 1 Ampulle, nach weiteren vier vierwöchigen Zyklen Reduktion auf die bleibende Erhaltungsdosis von 3 x wöchentlich 1 Ampulle. Derzeitiger CEA-Wert bei 7,5.

Beispiel II

Ein 1919 geborener Patient, Diagnose Makroglobulinämie (Mb. Waldenström), Zustand nach drei Zyklen Chemotherapie, Leukozyten (Leu) 1600, Erythrozyten (Ery) 2560, Thrombozyten (Thr) 55000, Blutsenkung (BSG) 55/150, Hämoglobin (Hb) 8,1.

Therapie Oktober 1993: Vierwöchige Zyklen von ROK mit 5 x wöchentlich 2 Ampullen i.m., anschließend zwei Tage Injektionspause. Nach einem vierwöchigen Zyklus zwei Wochen Injektionspause. Reduktion der wöchentlichen Ampullenfrequenz nach zwei vierwöchigen Zyklen auf 3 x wöchentlich 2 Ampullen. Während dieser Zeit keine Fremdtherapie, keine Chemotherapie. Nach je zwei vierwöchigen Zyklen Kontrolle der Blutwerte. Im

Juli 1994 Leu 4190, Ery 3390, Thr 81000, BSG 25/60, Hb 11,1. Guter subjektiver Allgemeinzustand des Patienten, der trotz des relativ stark ausgeprägten anämischen Zustandsbildes sich sportlich betätigt (Radfahren 70 km Tagestour, Bergwandern).

Beispiel III

Eine 1944 geborene Patientin, Diagnose HIV pos. seit 1992, Zustand nach fünfmonatiger Einnahme von AZT subjektiv desolat, keine Lebensqualität. Als Marker werden CD_4 -Helferzellen absolut (CD_4 -abs.) und CD_4 -Helferzellen % (CD_4 -%) verwendet. Ausgangswerte sind CD_4 -abs. bei 20, CD_4 -% bei 5.

Therapie seit Juli 1993: Vierwöchige Zyklen von ROK mit 5 x wöchentlich 2 Ampullen i.m., anschließend 2 Tage Injektionspause. Nach einem vierwöchigen Zyklus eine Woche Injektionspause. Reduktion der wöchentlichen Ampullenfrequenz nach vierwöchigen Zyklen auf 3 x wöchentlich 2 Ampullen, Fortführung dieser Frequenz als Erhaltungsdosis.

Blutwertkontrolle alle 4 Wochen. Kontinuierlicher Anstieg der T_4 -abs. auf 40 nach 12 Wochen (T_4 -% auf 10), nach 24 Wochen Anstieg der T_4 -abs. auf 80 (T_4 -% auf 14). Subjektiv guter Allgemeinzustand der Patientin, Lebensqualität deutlich gestiegen. Geplante Reduktion der Ampullenfrequenz auf 2 x wöchentlich 2 Ampullen bei weiterem Anstieg der CD_4 -Helferzellen.

Beispiel IV

Ein 1961 geborener Patient, Diagnose Multiple Sklerose, gesichert durch Kernspinresonanz- und Liquordiagnostik. Symptome taubes Gefühl in den Beinen, der linke Fuß kann beim Gehen nicht richtig gehoben werden, so daß Unsicherheitsgefühl und Stolperverhalten resultieren. Allgemeine Kraftlosigkeit in den Armen, Hände sind pelzig.

Therapie: Seit drei Monaten Injektionen 2 x wöchentlich

Mittel zur Behandlung immunbiologischer
Zellbelastungsschwächen und Verfahren zu dessen Herstellung

Patentansprüche

1. Verfahren zur Herstellung eines pflanzlichen Redoxykatalysators (ROK), gekennzeichnet durch die folgenden Schritte:
 - (i) Blätter der Geranie (*Pelargonium odoratissimum*), der Nelke (*Eugenia caryophyllata*), der Myrrhe (*Commophora abyssinica*, *C. molmol*, *C. schimperi*) und/oder des Wacholders (*Juniperus communis*) zu zerkleinern und in Wasser aufzuschlämmen;
 - (ii) die erhaltene Suspension mit Alkalilauge auf einen pH-Wert von 9-11 einzustellen, bei 45-50°C 48 Stunden zu rühren und anschließend grob zu filtrieren;
 - (iii) das Filtrat mittels Dialyse auf einen pH-Wert von 6-7 einzustellen und dabei ausfallende Partikel abzuzentrifugieren;
 - (iv) den so erhaltenen Überstand an Kieselgel oder Aluminiumhydroxid zu chromatographieren;
 - (v) die Moleküle mit einem Molekulargewicht von kleiner 5000 und größer 30000 Dalton mittels Ultrazentrifugation zu entfernen; und
 - (vi) das die Fraktion mit einem Molekulargewicht von 5000 bis 3000 Dalton enthaltende Filtrat gegen 0,9 %ige NaCl-Lösung zu dialysieren und abschließend steril zu filtrieren.

Ampullen i.m.. Deutliche subjektive Zunahme des Kraftgefühls in den Armen, Taubheits- und Pelzigkeitsgefühl in den Extremitäten subjektiv fast verschwunden. Unsicherheitsgefühl und Stolpertendenz im linken Bein beim Gehen zwar graduell noch vorhanden, jedoch rückläufige Tendenz. Geplante Reduktion der Injektionen auf 1 x wöchentlich 2 Ampullen als Erhaltungsdosis.

Die nach obigen Beispielen I bis IV gemessenen Verbesserungen des Allgemeinzustandes der Patienten, die in den verbesserten Meßwerten bezogen auf die jeweiligen immunbiologische Zellbelastungsschwäche nachgewiesen wurden, zeigen die überraschenden Wirkungen des erfindungsgemäßen pflanzlichen Redoxkatalysators (ROK) im Hinblick auf einen positiven Einfluß auf den Krankheitsverlauf.

2. Pflanzlicher Redoxkatalysators (ROK), erhältlich nach dem Verfahren gemäß Patentanspruch 1.
3. Der pflanzliche Redoxkatalysators (ROK) gemäß Patentanspruch 2, wobei als Blätter die Blätter der Geranie (*Pelargonium odoratissimum*), die Blätter der Nelke (*Eugenia caryophyllata*), die Blätter des Wacholder (*Juniperus communis*) und die Blätter der Myrrhe (*Commophora abyssinica*, *C. schimperi*, *C. molmol*) verwendet werden.
4. Der pflanzliche Redoxkatalysators (ROK) gemäß Patentanspruch 2 oder 3, wobei die Temperatur in Schritt (ii) 48 Stunden lang bei 48°C gehalten wird.
5. Pharmazeutische Zusammensetzung, enthaltend den pflanzlichen Redoxkatalysators (ROK) gemäß einem der Patentansprüche 2 bis 4 sowie gegebenenfalls einen geeigneten Träger oder Verdünner.
6. Die pharmazeutische Zusammensetzung gemäß Patentanspruch 5, zusätzlich enthaltend Zidovudin (AZT).
7. Verwendung des pflanzlichen Redoxkatalysators (ROK) gemäß einem der Patentansprüche 2 bis 4 zur Prophylaxe und/oder Behandlung von immunbiologischen Zellbelastungsschwächen.
8. Die Verwendung des pflanzlichen Redoxkatalysators (ROK) gemäß einem der Patentansprüche 2 bis 4 zur Behandlung der immunbiologischen Zellbelastungsschwäche Krebs.
9. Die Verwendung des pflanzlichen Redoxkatalysators (ROK) gemäß einem der Patentansprüche 2 bis 4 zur Behandlung der immunbiologischen Belastungsschwäche AIDS.

10. Die Verwendung des pflanzlichen Redoxkatalysators (ROK) gemäß einem der Patentansprüche 2 bis 4 zur Behandlung einer immunbiologischen Belastungsschwäche gemäß einem der Patentansprüche 7 bis 9 zusammen mit AZT.
11. Die Verwendung gemäß Patentanspruch 10, wobei der pflanzliche Redoxkatalysator (ROK) und AZT in einem Gewichtsverhältnis von 100 000 : 1 bis 5 000 000 : 1 verwendet werden.

INTERNATIONAL SEARCH REPORT

Inte Application No
PCT/EP 95/03319

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K35/78 //(A61K35/78,31:70)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DATABASE WPI Section Ch, Week 8825 Derwent Publications Ltd., London, GB; Class D23, AN 88-171897 & JP,A,63 110 291 (NIPPON SHOKUBAI KAGAKU) , 14 May 1988 see abstract</p> <p style="text-align: center;">---</p>	
A	<p>DATABASE WPI Section Ch, Week 9431 Derwent Publications Ltd., London, GB; Class B04, AN 94-252718 & JP,A,06 183 987 (POLA CHEM IND INC) , 5 July 1994 see abstract</p> <p style="text-align: center;">---</p>	
A	<p>FR,A,2 588 475 (FITOUSSI MARCEL) 17 April 1987</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

21 December 1995

Date of mailing of the international search report

05.01.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Rempp, G

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 95/03319

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DE, A, 550 583 (GEORG BUCHNER) 12 May 1932 -----	

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 95/03319

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 7-11
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although Claims 7-11 are directed to a method for treatment of the human or animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 95/03319

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR-A-2588475	17-04-87	NONE	
DE-A-550583		NONE	

A. KLASSIFIZIERUNG DES ANMELDUNGSGEGENSTANDES
IPK 6 A61K35/78 //(A61K35/78,31:70)

Nach der Internationalen Patentklassifikation (IPK) oder nach der nationalen Klassifikation und der IPK

B. RECHERCHIERTE GEBIETE

Recherchierte Mindestprüfstoff (Klassifikationssystem und Klassifikationssymbole)
IPK 6 A61K

Recherchierte aber nicht zum Mindestprüfstoff gehorende Veröffentlichungen, soweit diese unter die recherchierten Gebiete fallen

Während der internationalen Recherche konsultierte elektronische Datenbank (Name der Datenbank und evtl. verwendete Suchbegriffe)

C. ALS WESENTLICH ANGESEHENE UNTERLAGEN

Kategorie	Bezeichnung der Veröffentlichung, soweit erforderlich unter Angabe der in Betracht kommenden Teile	Betr. Anspruch Nr.
A	<p>DATABASE WPI Section Ch, Week 8825 Derwent Publications Ltd., London, GB; Class D23, AN 88-171897 & JP,A,63 110 291 (NIPPON SHOKUBAI KAGAKU) , 14.Mai 1988 siehe Zusammenfassung ---</p>	
A	<p>DATABASE WPI Section Ch, Week 9431 Derwent Publications Ltd., London, GB; Class B04, AN 94-252718 & JP,A,06 183 987 (POLA CHEM IND INC) , 5.Juli 1994 siehe Zusammenfassung ---</p>	
A	<p>FR,A,2 588 475 (FITOUSSI MARCEL) 17.April 1987 ---</p>	
	-/-	

☒ Weitere Veröffentlichungen sind der Fortsetzung von Feld C zu entnehmen

☒ Siehe Anhang Patentfamilie

- * Besondere Kategorien von angegebenen Veröffentlichungen :
- * "A" Veröffentlichung, die den allgemeinen Stand der Technik definiert, aber nicht als besonders bedeutsam anzusehen ist
 - * "E" älteres Dokument, das jedoch erst am oder nach dem internationalen Anmeldedatum veröffentlicht worden ist
 - * "L" Veröffentlichung, die geeignet ist, einen Prioritätsanspruch zweifelhaft erscheinen zu lassen, oder durch die das Veröffentlichungsdatum einer anderen im Recherchenbericht genannten Veröffentlichung belegt werden soll oder die aus einem anderen besonderen Grund angegeben ist (wie ausgeführt)
 - * "O" Veröffentlichung, die sich auf eine mündliche Offenbarung, eine Benutzung, eine Ausstellung oder andere Maßnahmen bezieht
 - * "P" Veröffentlichung, die vor dem internationalen Anmeldedatum, aber nach dem beanspruchten Prioritätsdatum veröffentlicht worden ist
 - * "T" Spätere Veröffentlichung, die nach dem internationalen Anmeldedatum oder dem Prioritätsdatum veröffentlicht worden ist und mit der Anmeldung nicht kollidiert, sondern nur zum Verständnis des der Erfindung zugrundeliegenden Prinzips oder der ihr zugrundeliegenden Theorie angegeben ist
 - * "X" Veröffentlichung von besonderer Bedeutung, die beanspruchte Erfindung kann allein aufgrund dieser Veröffentlichung nicht als neu oder auf erfinderscher Tätigkeit beruhend betrachtet werden
 - * "Y" Veröffentlichung von besonderer Bedeutung, die beanspruchte Erfindung kann nicht als auf erfinderscher Tätigkeit beruhend betrachtet werden, wenn die Veröffentlichung mit einer oder mehreren anderen Veröffentlichungen dieser Kategorie in Verbindung gebracht wird und diese Verbindung für einen Fachmann naheliegend ist
 - * "A" Veröffentlichung, die Mitglied derselben Patentfamilie ist

Datum des Abschlusses der internationalen Recherche	Absenddatum des internationalen Recherchenberichts
21.Dezember 1995	05.01.96
Name und Postanschrift der Internationale Recherchenbehörde Europäisches Patentamt, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tlx. 31 651 epo nl, Fax: (+ 31-70) 340-3016	Bevollmächtigter Bediensteter Rempp, G

C.(Fortsetzung) ALS WESENTLICH ANGESEHENE UNTERLAGEN

Kategorie*	Bezeichnung der Veröffentlichung, soweit erforderlich unter Angabe der in Betracht kommenden Teile	Betr. Anspruch Nr.
A	DE,A,550 583 (GEORG BUCHNER) 12.Mai 1932 -----	

Feld I Bemerkungen zu den Ansprüchen, die sich als nicht recherchierbar erwiesen haben (Fortsetzung von Punkt 1 auf Blatt 1)

Gemäß Artikel 17(2)a) wurde aus folgenden Gründen für bestimmte Ansprüche kein Recherchenbericht erstellt:

1. ☒ Ansprüche Nr. 7-11
weil Sie sich auf Gegenstände beziehen, zu deren Recherche die Behörde nicht verpflichtet ist, nämlich
Bemerkung: Obwohl die Ansprüche 7-11 sich auf ein Verfahren zur Behandlung des menschlichen/tierischen Körpers beziehen, wurde die Recherche durchgeführt und gründete sich auf die angeführten Wirkungen der Verbindung/Zusammensetzung.
2. ☐ Ansprüche Nr. _____
weil sie sich auf Teile der internationalen Anmeldung beziehen, die den vorgeschriebenen Anforderungen so wenig entsprechen, daß eine sinnvolle internationale Recherche nicht durchgeführt werden kann, nämlich
3. ☐ Ansprüche Nr. _____
weil es sich dabei um abhängige Ansprüche handelt, die nicht entsprechend Satz 2 und 3 der Regel 6.4 a) abgefaßt sind.

Feld II Bemerkungen bei mangelnder Einheitlichkeit der Erfindung (Fortsetzung von Punkt 2 auf Blatt 1)

Die internationale Recherchenbehörde hat festgestellt, daß diese internationale Anmeldung mehrere Erfindungen enthält:

1. ☐ Da der Anmelder alle erforderlichen zusätzlichen Recherchegebühren rechtzeitig entrichtet hat, erstreckt sich dieser internationale Recherchenbericht auf alle recherchierbaren Ansprüche der internationalen Anmeldung.
2. ☐ Da für alle recherchierbaren Ansprüche die Recherche ohne einen Arbeitsaufwand durchgeführt werden konnte, der eine zusätzliche Recherchegebühr gerechtfertigt hätte, hat die Internationale Recherchenbehörde nicht zur Zahlung einer solchen Gebühr aufgefordert.
3. ☐ Da der Anmelder nur einige der erforderlichen zusätzlichen Recherchegebühren rechtzeitig entrichtet hat, erstreckt sich dieser internationale Recherchenbericht nur auf die Ansprüche der internationalen Anmeldung, für die Gebühren entrichtet worden sind, nämlich auf die Ansprüche Nr. _____.
4. ☐ Der Anmelder hat die erforderlichen zusätzlichen Recherchegebühren nicht rechtzeitig entrichtet. Der internationale Recherchenbericht beschränkt sich daher auf die in den Ansprüchen zuerst erwähnte Erfindung; diese ist in folgenden Ansprüchen erfaßt: _____

Bemerkungen hinsichtlich eines Widerspruchs

- ☐ Die zusätzlichen Gebühren wurden vom Anmelder unter Widerspruch gezahlt.
- ☐ Die Zahlung zusätzlicher Gebühren erfolgte ohne Widerspruch.

INTERNATIONALER RECHERCHENBERICHT

Angaben zu Veröffentlichungen, die zur selben Patentfamilie gehören

Internationales Aktenzeichen

PCT/EP 95/03319

Im Recherchenbericht angeführtes Patentedokument	Datum der Veröffentlichung	Mitglied(er) der Patentfamilie	Datum der Veröffentlichung
FR-A-2588475	17-04-87	KEINE	
DE-A-550583		KEINE	

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/06	A1	(11) International Publication Number: WO 97/2144 (43) International Publication Date: 19 June 1997 (19.06.97)
(21) International Application Number: PCT/RU96/00340 (22) International Filing Date: 10 December 1996 (10.12.96) (30) Priority Data: 95120403 14 December 1995 (14.12.95) RU PCT/RU96/00226 8 August 1996 (08.08.96) WO (34) Countries for which the regional or international application was filed: AT et al. (71)(72) Applicants and Inventors: BALAZOVSKY, Mark Borisovich [RU/RU]; ul. Nalichnaya, 3/21-90, St.Petersburg, 199106 (RU). KOZHEMYAKIN, Leonid Andreevich [RU/RU]; Pulkovskoe shosse, 13/2-5, St.Petersburg, 196240 (RU). (74) Agent: SPESIVTSEVA, Irina Jurievna; Neopharm Ltd., pr. Energetikov, 37, St.Petersburg, 195248 (RU).		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: CYTOKINE AND HEMOPOIETIC FACTOR ENDOGENOUS PRODUCTION ENHANCER AND METHODS OF USE THEREOF		
(57) Abstract <p>The invention relates to medicine, in particular to pharmacology and therapy. According to the invention method of stimulating endogenous production of cytokine and hemopoietic factors comprising introducing to a mammalian body in need of stimulation of cytokine or hemopoietic factor or both, an effective amount of oxidized glutathione, its pharmaceutically acceptable salt form, or/and its pharmaceutically acceptable derivative, for a period of time to stimulate said endogenous production to obtain a therapeutic effect wherein said oxidized glutathione, or/and its pharmaceutically acceptable salt form, or/and its pharmaceutically acceptable derivative is introduced parenterally or topically. According to the invention, oxidized glutathione or/and its pharmaceutically acceptable salt form or/and its pharmaceutically acceptable derivative is introduced along with an extender of the half life of said oxidized glutathione or/and its pharmaceutically acceptable salt form, or/and its pharmaceutically acceptable derivative.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CJ	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

CYTOKINE AND HEMOPOIETIC FACTOR ENDOGENOUS PRODUCTION ENHANCER AND METHODS OF USE THEREOF

Field of the Invention

The present invention relates to medicine and more particularly to pharmacology and therapy, and is intended to be used for preventing and treating various diseases by way of increasing endogenous production of cytokines and hemopoietic factors.

Background of the Invention

It has been known that a number of endogenously produced mammalian humoral factors, i.e. cytokines and hemopoietic factors possess important biological activities that are considerably helpful in treating various human diseases^{1,2}. Many of these factors are being tested in man, those with proven efficiency being commercially available as medicinal agents.

The following cytokines and hemopoietic factors are being most extensively researched in oncology: interleukin 2 (IL-2)^{3,4}, tumor necrosis factor alpha (TNF- α)⁵, erythropoietin, macrophage-granulocyte and granulocyte colony-stimulating factors (GM-CSF and G-CSF, respectively^{6,7}). No less actively is being studied the use of cytokines and hemopoietic factors for the treatment of infectious disease: interferons (IFN- γ and IFN- β)^{8,9,10}, colony-stimulating factors^{11,12}, and the like¹³. Colony-stimulating factors and erythropoietin are broadly used in hematology^{14,15}.

However, the medicinal use of these exogenously administered agents has its limitations associated with the lack of acceptable drug formulations or their exorbitant cost, a short half-life of these substances in biological media, difficulties in dose finding as well as numerous toxic and allergic effects^{16,17}, since even the recombinant products are more or less immunogenic to the human organism because of the processing fluctuations in the course of the artificial synthesis.

In this regard, in view of achieving a more invariable and significant therapeutic effect free of adverse reactions, it is preferable to induce the endogenous production of the autologous cytokines and hemopoietic factors immediately within the organism of a subject. The remedial effect due to such intrinsic stimulation is free of all the disadvantages associated with exogenously introduced cytokines and hemopoietic factors.

A number of compounds are currently being evaluated that stimulate endogenous

production of cytokines and hemopoietic factors in both experimental and clinical settings. There are universally known cases, including successful ones, of using microbial products for cancer therapy which in recent decades has been shown to be mediated via stimulation of the tumor necrosis factor endogenous production¹⁸. The products capable of evoking concomitant
5 production of various cytokines and hemopoietic factors have presently come to be known as multi-cytokine inducers. Among these are a killed streptococcal preparation, *Nocardia Opaca*, and other bacterial products^{19, 20, 21}. However, virtually all the substances possessing such capability are either killed microorganisms or microbial products or compounds having irregular composition, which results in their limited medicinal utility or even renders their therapeutic use
10 impracticable. Thus, the problem of finding a medically and pharmaceutically acceptable inducer of the cytokine and hemopoietic factor endogenous production has not heretofore been resolved.

Oxidized glutathione (also known as glutathione disulfide and GSSG) will often be referred to as GSSG in this application.

GSSG is known as a dimer of tripeptide glutathione (γ -glutamyl-cysteinyl-glycine)
15 where two molecules of the tripeptide with the above structure are linked via a covalent disulfide bond between the cystamine residues. Therefore, both the tripeptide glutathione (glutathione, reduced glutathione, GSH; hereinafter referred to as GSH) and its dimer GSSG are natural metabolites present in animal tissues and biological fluids. At the same time, the natural blood level of GSSG is not sufficient for inducing the cytokine endogenous production in both normal
20 and pathological conditions.

GSH is known to be one of the most important intermediates in the amino acid metabolism and a factor maintaining the intracellular homeostasis^{22,23}. The reducing properties of GSH and its function as a donor of reduction equivalents, which is due to the sulfhydryl moiety of the cystamine residue, are of key importance. This characteristic of GSH is responsible for the
25 substance playing a crucial part in one of the most important intracellular antioxidant systems, consisting of GSH as such and two enzymes of its reversible conversion into GSSG: glutathione peroxidase and glutathione reductase^{24,25}. The permanent functioning of said system is essential for inactivating or reducing endogenously generated oxidants as well as active metabolites of foreign substances^{26,27}.

30 GSH is also known to participate in detoxification reactions involving a group of enzymes collectively known as glutathione S-transferase²⁸. These enzymes are capable of conjugating the GSH molecule with various xenobiotics by forming a bond between the latter and glutathione via

the thiol moiety of the cystamine residue of the tripeptide. The subsequent degradation of the conjugate is catalyzed by the γ -glutamyl cycle enzymes, and may vary considerably depending upon the nature of the xenobiotic.

Under natural conditions, GSSG does not accumulate in amounts sufficient for inducing
5 cytokine and hemopoietic factor production, due to a constant reduction of GSSG to GSH. The GSSG reduction to GSH also actively progresses in the intestines and liver upon GSSG oral administration, and as any product made of amino acids, the substance is proteolytically degradable in the gastrointestinal tract.

GSSG is known to be used as a components of a nutritional supplement utilized as an
10 adjunct diet in treating patients²⁹. However, being a peptide substance, most of the orally administered GSSG is digested in the gastrointestinal tract with the remainder being reduced in the intestinal and hepatic cells to GSH and not entering the circulation. Therefore, the delivery of GSSG into the organism through the gastrointestinal tract may eliminate the possibility of the realization of its activity as a stimulator of endogenous production of cytokines and hemopoietic
15 factors.

An elevation of the GSH endogenous levels for medicinal utility is known to be suggested for boosting immunity³⁰ and treating toxemias, poisonings, diabetes, mellitus, cardiovascular, infectious and other disorders^{31, 32, 33}. Possible functions of GSH and GSSG appear in the literature.

20 Exogenous GSH or its direct (γ -glutamyl-cystamine, *n*-acetyl-cystamine, and *n*-acetyl-cystamine-glycine) or indirect (2-oxothiazolidine-4-carboxylate) biochemical precursors, or their salts and esters, are reportedly used as medicinal agents and dietary supplements in treating various diseases^{34, 35, 36, 37, 38}.

GSH is also claimed to be useful as a chemoprotective agent that prevents neurotoxicity
25 in cancer chemotherapy³⁹ as well as in combination with antineoplastics in order to augment their effect⁴⁰.

No reference, however, is currently available to GSSG as a medicine in its own right (sole substance) used to induce the endogenous production of cytokines and hemopoietic factors. The substance is known neither to have medicinal effects in human and animal diseases nor to be
30 applied as a pharmaceutical agent for treating illnesses.

Summary of the Invention

It is an object of the present invention to provide an active substance, and advantageous combinations of said substance and/or its derivatives with extenders and/or enhancers or modulators of its activity which are capable of inducing endogenous cytokine and hemopoietic factor production to an individual or a subject in need thereof.

“Subject in need thereof” as used in this application is intended to mean a mammal, *e.g.*, man, domestic animals and livestock including cats, dogs, cattle and horses, having one or more manifestations of a disease in which stimulation of endogenous cytokine or hemopoietic factor (or both) production would be considered beneficial by those skilled in the art. “Therapeutic agent” as used in this application is meant to include any drug form of GSSG-containing material or GSSG alone, which has a therapeutic effect on neoplastic, infectious, hematologic, immunologic or other diseases. Therapeutic effect, as will be further defined, indicates any effect in man and other mammals which is beneficial, including curative, preventative, allowing maintenance at a beneficial level, or is in any way advantageous in connection with the body of man and other mammals.

In accordance with the present invention, it is GSSG that upon parenteral administration induces the endogenous cytokine and/or hematopoietic factor production in an individual or subject in need thereof, in both health and disease.

Having performed studies in search for a medically and pharmaceutically acceptable inducer of the cytokine and hemopoietic factor endogenous production, the applicants discovered a new property of a previously known substance, oxidized glutathione (oxidized glutathione, glutathione disulfide, GSSG; hereinafter often referred to as GSSG).

Being administered parenterally or acting on isolated cells, the substance is capable of inducing production of several cytokines and hemopoietic factors in mammals (animals and humans) in both health and disease.

The inducer or stimulator of the endogenous cytokine and hemopoietic factor production is oxidized glutathione (GSSG) which is a dimer of reduced glutathione having the structure γ -glutamyl-cysteinyl-glycine, where the two molecules of the tripeptide are linked via a covalent disulfide bond between the cystamine residues.

According to the invention, a method is provided for stimulating endogenous production of cytokine and hemopoietic factors by introducing to a mammalian body in need of stimulation of cytokine or hemopoietic factor or both, an effective amount of oxidized glutathione for a

sufficient period of time to stimulate said endogenous production to obtain a therapeutic effect.

Preferably, the glutathione is introduced parenterally or topically. In a preferred form, the method is carried out by introducing the oxidized glutathione (GSSG) or its derivatives with an extender of half life and/or enhancers or modulators to enhance the desired effect of stimulating
5 endogenous production of cytokines and hemopoietic factors and producing a therapeutic effect in a body.

Preferably, the GSSG derivative is selected from the group of compounds representing a molecule of GSSG chemically modified by binding covalently as for example: with cysteamine - (2-mercaptoethylamine), lipoic acid (6,8-thioctic acid), carnosine (b-alanyl-hystidine), adenosine
10 (9-β-D-ribofuranosyladenine), methionine (2-amino-4-[methylthio]butanoic acid), and both the D and L forms of the amino acids set forth in this paragraph can be used.

Particularly desirable derivatives are GSSG covalently bound either to cysteamine (S-thioethylamine-glutathione disulfide), or to lipoic acid (bis-[6,8-thiooktanil]•glutathione disulfide), or to carnosine ([b-alanyl-hystidil]•glutathione disulfide), or to adenosine ([9-β-D-
15 ribofuranosyladenil]•glutathione disulfide), or to methionine (bis-[2-amino-4-[methylthio]butanoil]•glutathione disulfide), or mixtures thereof and including the D and/or L forms of amino acids herein.

Preferably, the extender is selected from the group consisting of pharmaceutically acceptable pro-oxidant compounds, (hydrogen peroxide, ascorbic acid) compounds capable of
20 forming both weak ionic and coordinating links which stabilize molecule of GSSG (dimethyl sulfoxide), or materials which are competitors of NADP-H-dependent reduction of GSSG into GSH catalyzed by glutathione reductase, compounds capable of producing reversible inhibition of reduction of NADP+ into NADP-H catalyzed by glucose-6-phosphate-dehydrogenase or by other NADP-H-dependent enzymes, or mixtures thereof.

25 Particularly desirable extenders are hydrogen peroxide, inosine, ascorbic acid, dimethyl sulfoxide, or cystamine or mixtures thereof.

Preferably, the enhancer/modulator is selected from the group consisting of methyl moiety donors (such as choline-chloride{[2-hydroxyethyl]trimethylammonium chloride} or S-adenosyl-methionine), representatives of intracellular redox-oxidative pairs (such as lipoic/dehydrolipoic,
30 folic/dehydrofolic, ascorbic/dehydroascorbic acids). An enhancer or modulator or enhancer/modulator as used herein is meant to be a material which increases or changes beneficially in terms of curative outcomes the therapeutic effect of GSSG or its derivatives, but is

not an extender of half life of the GSSG.

Particularly desirable enhancers or modulators are choline-chloride, S-adenosyl-methionine, lipoic (6,8-thioctic) and folic (pteroylglutamic) acids.

In the preferred form, GSSG is introduced to the body at a dose of from 0.01 to 0.5 mg of
5 GSSG base per kg of body weight for GSSG base and its salts, and from 0.01 to 1.0 mg for
GSSG derivatives, at least one time during each 24 hour period, although it can be continuously
injected or otherwise introduced to the body to have a 24 hour total dosage of from 0.01 to 0.5
mg per kg of body weight for GSSG base and its salts, and from 0.01 to 1.0 mg for GSSG
derivatives each 24 hour period. Preferably, administration and introduction to the body is
10 carried out until a desired stimulating effect increasing production of cytokines and hemopoietic
factors and providing a therapeutic effect is obtained.

According to the invention, a therapeutic agent for treating neoplastic, infectious,
hematologic, immunologic and other diseases is provided, comprising an effective amount of
oxidized glutathione, along with a pharmaceutically acceptable excipient. Preferably, the oxidized
15 glutathione for parenteral use is in a pharmaceutically acceptable solvent as, for example, an
aqueous solution including water, glucose solution, isotonic solutions of sodium chloride,
buffered salt solutions. Preferably, a pharmaceutically acceptable extender capable of enhancing
and prolonging therapeutic effect as by increasing the half life of oxidized glutathione; or a
pharmaceutically acceptable enhancer or modulator of GSSG activity by mechanisms other than
20 increasing the GSSG half life, is used along with the GSSG.

The applicants have for the first time shown that an immediate action of exogenous GSSG
or its salts on mammalian (human and laboratory animal) cells capable of producing cytokines and
hemopoietic factors, exerts stimulation on the synthesis of these molecules and their increased
level in the blood serum (*in vivo* conditions) or culture media (*ex vivo* or *in vitro* conditions).
25 The method suggested can bring about the effect of stimulating production of cytokines and
hemopoietic factors, and this effect is elicited by the administration of GSSG into the organism or
entering into the cultural media, as well as by the administration of GSSG in combination with
pharmacologically active formulations mediating either the prolongation of glutathione's retaining
the oxidized form or enhancing or beneficially modulating its activity. The studies performed by
30 the applicants have revealed GSSG and its formulations to possess a therapeutic effect in various
experimental and clinical pathological conditions.

The revealed GSSG-induced stimulation of the endogenous cytokine and hemopoietic factor production in the body results in antitumor, anti-infective, hemopoietic, immunomodulatory and other pharmacological effects resulting, in turn, to a greater or lesser extent therapeutic or preventive effect in various diseases.

5

Brief Description of the Drawings

The above and other objects, features and advantages of the present invention will be better understood from the following specification when read in connection with the accompanying drawing in which:

10 Figures 1a, 1b, 1c and 1d are charts showing cytofluorometric analysis of cells HL-60, cytofluorometric analysis of cells HL-60 in the presence of the preparation of this invention, cytofluorometric analysis of human lymphocytes, and cytofluorometric analysis of lymphocytes in the presence of the preparation of this invention, respectively, as will be described in the discussion of Example 4, relating to research of apoptosis-induced preparation activity in
15 cultivated mammalian cells; and

Figure 2 is a drawing of GSSG structure with notification of sites for chemical modifications when GSSG salts and derivatives are reproduced; and

Figures 3, 4, 5, 6 and 7 are drawings of compounds where GSSG is covalently bound to: to cysteamine (S-thioethylamine-glutathione disulfide, Fig. 3); lipoic acid (bis-[6,8-
20 thioktanil]•glutathione disulfide, Fig. 4); carnosine ([b-alanyl-hystidil]•glutathione disulfide, Fig. 5), or to adenosine ([9-β-D-ribofuranosyladenil]•glutathione disulfide, Fig. 6); methionine (bis-[2-amino-4-[methylthio]butanoil]•glutathione disulfide, Fig. 7)

Description of Preferred Embodiments

25 In accordance with the present invention, the medicinal agent suggested for treating neoplastic, infectious, hematologic, and other diseases, in which stimulation of the endogenous cytokine and hemopoietic factor production is appropriate, has an effective amount of GSSG and/or its pharmaceutically acceptable salts, and/or its pharmaceutically acceptable derivatives as its active principle. It is also advantageous to prepare a drug form of the medicinal agent as an
30 injectable solution containing 0.01 to 2.0% of GSSG base for GSSG itself and its salts, or 0.01 to 4.0% for GSSG derivatives.

The GSSG used as a therapeutic or medicinal agent in accordance with the present invention is shown in Figure 2. GSSG and/or its pharmaceutically acceptable salts, and/or its pharmaceutically acceptable derivatives is preferably used in a carrier or solution as, for example, isotonic solution of sodium chloride, glucose solution, other buffer and salt solutions. Any aqueous based or solvent based carrier or solvent can be used as long as the overall solution or dispersion is compatible with the body and pharmaceutically acceptable i.e., it does not cause any unwanted side effects in the body or unwanted interaction with GSSG and/or its pharmaceutically acceptable salts, and/or its pharmaceutically acceptable derivatives.

In the structural formula of Figure 2, points X_1 , X_2 , X_3 , X_4 , X_5 , and X_6 are noted as sites for chemical modification of the GSSG. Generally, the GSSG and/or its pharmaceutically acceptable salts, and/or its pharmaceutically acceptable derivatives is used in the form shown in solution or can be any of its physiologically and pharmaceutically acceptable soluble salts. The disodium and delithium salts where X_1 , X_4 , are either sodium ions or lithium ions or a mixture, are preferred for best solubility of the drug. X_1 , X_2 , X_3 , and X_4 can each be hydrogen if other substitutes are not used. Other salts of GSSG can be used, so long as they are pharmaceutically acceptable, i.e., do not adversely affect the body, for example, X_1 , X_2 , X_3 , and X_4 can all be (or one or more of them can be) potassium, calcium, zinc, molybdenum, vanadium, fluoride, mixtures thereof or any other pharmaceutically acceptable substitutes. Water soluble salts are preferred for use in this invention.

In the structural formula of Figure 3, points X_1 , (or probably X_1 , and X_2) is noted as site for covalent binding with cysteamine molecule(s) (2-mercaptoethylamine). In the structural formula of Figure 4, points X_5 , and X_6 are noted as sites for covalent binding with molecules of lipoic acid (6,8-thioctic acid). In the structural formula of Figure 5, point X_3 is noted as site for covalent binding with molecule of carnosine (b-alanyl-hystidine). In the structural formula of Figure 6, point X_2 is noted as site for covalent binding with molecule of adenosine (9- β -D-ribofuranosyladenine). In the structural formula of Figure 7, points X_5 , and X_6 are noted as sites for covalent binding with molecules of methionine (2-amino-4-[methylthio]butanoic acid).

In accordance with the present invention, it is expedient to use such GSSG or its derivative drug forms and/or pharmaceutical compositions that either prolong oxidized glutathione half-life in tissues and biological fluids, or augment, or beneficially modulate the revealed biological and therapeutic properties of GSSG.

In accordance with the present invention, with the purpose of augmenting, beneficial modulating, and/or prolonging the therapeutic effect of GSSG, its drug form (injectable solution) is suggested to contain GSSG and/or its derivatives as described above (see Fig. 3-7) together with pharmaceutically acceptable component (extender, enhancer/modulator), capable of
5 extending the half-life of GSSG and/or its derivatives or enhancing/modulating their biological and therapeutical effects. GSSG and/or its salts, and/or its derivatives can either be present in a single drug form together with the above mentioned extenders, enhancers/modulators (single injectable solution prepared beforehand or *ex tempore*), or be delivered into the body using separate drug forms: injectable solutions for GSSG and/or its salts, and/or its derivatives and/or
10 derivatives salts; and any pharmaceutically acceptable drug forms, dosage regimens, and administration routes for the above mentioned extenders, enhancers/beneficial modulators.

As a pharmaceutically acceptable GSSG derivative, one of the compounds, or of their pharmaceutically acceptable salts, where GSSG is covalently bound to: either cysteamine (S-thioethylamine-glutathione disulfide, see Fig. 3 for structural formula), or lipoic acid (bis-[6,8-
15 thiooktanil]•glutathione disulfide, see Fig. 4), or carnosine ([b-alanyl-hystidil]•glutathione disulfide, see Fig. 5), or adenosine ([9-β-D-ribofuranosyladenil]•glutathione disulfide, see Fig. 6), or methionine (bis-[2-amino-4-[methylthio]butanoil]•glutathione disulfide, see Fig. 7), can be offered for application.

This is because the presence of one of the aforementioned molecules (cysteamine, lipoic
20 acid, carnosine, adenosine, or methionine) as a constituent part of a modified GSSG molecule, stabilizes structure of the corresponding derivative making it more resistant against proteolysis and/or reduction to GSH. As another way of stabilizing molecule of GSSG, its salts, or its derivatives/derivative salts, and protecting them against proteolysis and/or reduction, a replacement of one or more of L-amino-acids constituting the molecule of both GSSG and the
25 aforementioned derivatives with their D-forms, can be implemented.

All of pharmaceutically acceptable GSSG or derivatives most preferably can be used as the medicinal agents in the injectable form of 1.0% solution with dosage range of from 0.01 to 0.5 mg of GSSG base per kg of body weight for GSSG base and its salts, and from 0.01 to 1.0 mg for GSSG derivatives, with preferable concentration range of from 0.5% to 5.0% one or more
30 times a day, by one or more day pulses or continuously until a desired therapeutic effect has been achieved. As a pharmaceutical acceptable component or extender to prolong glutathione permanence in oxidized form, 0.003% hydrogen peroxide and/or 5.0% ascorbic acid can be

offered for application. This is because in the presence of hydrogen peroxide or ascorbic acid, a donor of reactive oxygen intermediates (that is an oxidant), GSSG is reduced by glutathione reductase to GSH at a lesser speed, thereby conditioning a slower reduction of GSSG introduced exogenously into biological media.

5 Hydrogen peroxide preferably can be used in amounts of from 0.03 to 0.0003% by weight of solutions used (from 1.0 to 5.0 ml of solutions, regardless whether they contain or do not contain GSSG and/or its salts, and/or its derivatives/derivative salts). Ascorbic acid preferably can be used in amounts of from 0.1 to 10% by weight of solutions used (from 1.0 to 10.0 ml of solutions, regardless whether they contain or do not contain GSSG and/or its salts, and/or its
10 derivatives/derivative salts).

Usage of an acceptable concentration of hydrogen peroxide (H_2O_2) and/or ascorbic acid in formulation of the drug form for parenteral administration, as well as usage of any other prooxidant compounds (donors of active oxygen form), makes it possible to realize only one of possible methods of the prolongation of oxidized glutathione and/or its derivative half-life in the
15 biological fluids and tissues and, thereby, to enhance and prolong the pharmaceutical effect of GSSG and/or its derivatives.

We have also found some other pharmaceutically acceptable components or extenders capable of mediating the slowdown of the reduction of exogenous GSSG and/or its derivatives into GSH in biological media. Such, in particular, are: the compounds capable of forming weak ionic
20 and/or coordinating links which stabilize molecules of GSSG, for example, dimethyl sulfoxide; the factors capable of setting up competitive relations with a reduced form of the nicotinamide adenine dinucleotide phosphate or NADP-H, for example, inosine (and other derivatives of hypoxanthine); as well as the agents reversibly inhibiting the processes of reduction of the oxidized form of NADP⁺ into NADPH, for example, cystamine (2,2'-Dithio-bis[ethylamine]) and
25 other inhibitors of glucose-6-phosphate-dehydrogenase.

Besides hydrogen peroxide and ascorbic acid, one of other pharmacologically accepted components capable to prolong the oxidized glutathione half-life can be dimethyl sulfoxide, which stabilize GSSG or its derivative molecules by forming both weak ionic and coordinating links with atoms of GSSG. Dimethyl sulfoxide is used most preferably as 7.0% (v/v) solution and
30 preferably as a solution of from 0.1% to 30% by volume (from 1.0 to 30.0 ml of solutions or more when applied epicutaneously/through instillations, regardless whether they contain or do not contain GSSG/GSSG salts and/or its derivatives/derivate salts).

Since reduced NADP-H is the key cofactor of glutathione reductase system catalyzing the reduction of GSSG into GSH, any pharmaceutically acceptable compounds or biophysical influence retarding the reduction of GSSG or blocking biological oxidation of NADP-H by glutathione reductase will facilitate preservation of GSSG/GSSG salts and/or its
5 derivates/derivate salts from reduction in biological media and, therefore, will enhance and prolong its curative effect.

Due to conducted research we were the first to discover that GSSG pharmaceutical and medicinal effect will reinforce, when GSSG used in combination with agents capable of competition with NADP-H, as well as with compounds reversibly inhibiting the enzymatic
10 reaction, catalyzed by glucose-6-phosphate-dehydrogenase which mediates the reduction of the oxidized form of NADP+. Reversible inhibitors or pentose phosphate pathway of glucose oxidation can be used.

Thus, besides hydrogen peroxide, ascorbic acid and dimethyl sulfide one of other pharmacologically accepted components capable to prolong the oxidized glutathione half-life can
15 be inosine (hypoxanthine-9-D-ribofuranoside) used most preferably as 0.1% solution and preferably as a solution of from 0.1% to 5% by weight (from 1.0 to 5.0 ml of solutions, regardless whether they contain GSSG/GSSG salts and/or its derivates/derivate salts.

The investigations carried out showed inosine to facilitate biological and therapeutical effects of GSSG. It was demonstrated that this property of inosine is based on its ability to
20 compete with NADP-H, and thereby, to retard GSSG reduction into GSH. Moreover, we have also found that other hypoxanthine derivatives (including inosine, nucleoside ones, hypoxanthine riboside and other nucleoside derivatives of inosine) possess this property as well.

Also, besides hydrogen peroxide, ascorbic acid, dimethyl sulfoxide and inosine, cystamine (2,2'-Dithio-bis[ethylamine]) is another pharmaceutically acceptable agent conditioning a slower
25 reduction of GSSG, if used most preferably as 0.1% solution and preferably as a solution of from 0.1% to 3% by weight (for example 1.0 to 5.0 ml of solutions, regardless whether they contain GSSG/GSSG salts and/or its derivates/derivate salts)..

Our research showed cystamine to facilitate biological and therapeutical effects of GSSG. The effect is due to the cystamine ability to act as a reversible inhibitor of key enzyme of the
30 pentose phosphate pathway, glucose-6-phosphate-dehydrogenase, mediating reduction of NADP+ into NADP-H.

As pharmaceutically acceptable components capable of enhancing or beneficially modulating biological and therapeutic effects of GSSG and/or its derivatives, several groups of chemical compounds have been shown to augment, diversify or beneficially alter effects of GSSG and/or its derivatives. Therefore several enhancers/beneficial modulators of effects of
5 GSSG/GSSG salts and/or its derivatives/derivate salts can be assigned to the following groups of chemicals.

Donators of methyl groups, such as choline-chloride and S-adenosyl-methionine used in combination with GSSG (and/or its salts/derivatives) have appeared to be more effective compared with GSSG alone (and/or its salts/derivatives) when these agents are used for treating
10 animals with experimental pathologic conditions of immunologic and infectious nature. At that, it has been shown that choline-chlorine can be used in patients most preferably as 10% solution and preferably as a solution of from 1.0% to 20% by weight (from 1.0 to 5.0 ml or solutions, regardless whether they contain GSSG or its derivatives). S-adenosyl-methionine can be used in patients most preferably as 5.0% solution and preferably as a solution of from 1.0% to 10% by
15 weight (from 1.0 to 5.0 ml of solutions, regardless whether they contain either GSSG and/or its derivatives).

Compounds, which are capable of formation intracellular redox-oxidative pairs (lipoic, folic and ascorbic acids) have also been found to augment GSSG/derivative effects in immunologic, infectious, or other diseases (diabetes mellitus). Lipoic acid can be used in patients
20 most preferably as 0.5% solution and preferably as a solution of from 0.1% to 1.0% by weight (from 1.0 to 5.0 ml of solutions, regardless whether they contain either GSSG and/or its derivatives). Folic acid can be used in patients most preferably as 0.5% solution and preferably as a solution of from 0.1% to 1.0% by weight (from 2.0 to 5.0 ml of solutions, regardless whether they contain either GSSG and/or its derivatives).

Thus, the present invention also suggests the method to enhance or beneficially modulate the ability of GSSG to stimulate endogenous production of cytokines and hemopoietic factor which presupposes the usage a pharmaceutical composition including GSSG and/or its derivatives and an additional component or components able to prolong the oxidized glutathione half-life (extenders) or to enhance/modulate beneficially biological and therapeutical effects of GSSG
30 and/or its derivatives (enhancers/beneficial modulators). GSSG and/or its salts, and/or its derivatives can either be administered combined in a single dosage form with both extenders and enhancers/modulators, or can be delivered into a body separately from both extenders and

enhancers/modulators, using different pharmaceutically acceptable administration routes for each constituent of any combination used. This can be achieved for example by the administration of pharmaceutically acceptable compositions including drug forms of GSSG/GSSG salts and/or GSSG derivatives/derivative salts; and pharmaceutically acceptable compositions including drug forms of other products, able to prolong the oxidized glutathione half-life (extenders), and/or able to enhance/modulate beneficially therapeutical effects of GSSG/GSSG salts and/or GSSG derivatives/derivative salts. As used herein, the term "GSSG derivatives" means either S-thioethylamine-glutathione disulfide, or bis-[6,8-thiooctanil]•glutathione disulfide, or [b-alanyl-histidil]•glutathione disulfide, or [9-β-D-ribofuranosyladenil]•glutathione disulfide, or bis-[2-amino-4-[methylthio]butanoil]•glutathione disulfide, with one or more of L-amino-acids constituting the molecule GSSG being replaced with its D-form and given at the same dosage range (of from 0.01 to 1.0 mg/kg).

As used herein, the term "extenders" means hydrogen peroxide preferably 0.003%, ascorbic acid preferably 5.0% or other compounds with oxidant activity; dimethyl sulfoxide preferably 7.0%, or other compounds capable of forming weak ionic and/or coordinating links which stabilize molecule of GSSG; inosine (hypoxanthine-9-D-ribofuranoside) preferably 0.1%, or its derivatives including inosine nucleosides; and also cystamine (2,2'-Ditio-bis[ethylamine] preferably 0.1%, or other compounds, capable to produce reversible inhibition of glucose-6-phosphate-dehydrogenase, the key enzyme of the pentose phosphate pathway.

As used herein, the term "enhancers/beneficial modulators" or "enhancers/modulators" means choline-chloride preferably 10%, S-adenosyl-methione preferably 5.0% or other pharmaceutically acceptable donators of methyl groups; lipoic acid preferably 0.5%; folic acid preferably 0.5% or other compounds, which are capable of formation intracellular redox-oxidative pairs. Any other chemical compound or physical influence, which is capable of enhancing and/or modulating beneficially any biological or therapeutical effects of GSSG/derivatives mentioned in this application should also be considered as "enhancers/modulators."

As used herein, the term "epicutaneously/through instillations" means any physiologically and/or medically acceptable administration route when there is a remedy/medicine application on skin surface or superficial mucous membrane (epicutaneous, or cutaneous, or topical, or local use), or when there is an intracavitary remedy/medicine use through its introduction into a natural and/or artificial cavity of (or space within) a body, such as stomach, urinary bladder,

vagina, rectum, abdominal or pleural cavities, intraarticular space, airways, maxillary sinus, and the like, or any pathological, and/or wound cavity.

It is found that the parenteral (intravenous, intraperitoneal, intramuscular, *etc.*) administration of GSSG and/or its salts, and/or its derivatives in combination with an extender or enhancer/modulator stimulates endogenous production of TNF- α , IFN- α and IFN- γ , IFN-B, IL-1B, IL-1, IL-2, IL-6, IL-10, G-CSF, colony stimulating factors, erythropoietin, and GM-CSF in organism of experimental animals in a larger degree than with the application of GSSG alone and/or its salts, and/or its derivatives. GSSG and/or its derivatives and any extender or enhancer/modulator can be administered with the use of both the single dosage form or different pharmaceutically acceptable dosage forms (as well as dosage regimens and administration routes) for each constituent of any combination used.

The studies carried out prove the ability of the above mentioned compounds to enhance and/or beneficially alter the biological and therapeutical effects of GSSG and/or salts and/or derivatives, which makes evident the expediency of their use in combination with GSSG and/or salts and/or derivatives, to treat neoplastic, infectious, hematological and other diseases in which stimulation of the endogenous cytokine and hemopoietic factor production is considered beneficial by those skilled in the art.

Thus, in accordance with the present invention, for the purpose of enhancing and prolonging the GSSG therapeutical effect, it is preferred that a final drug formulation of GSSG or its salts or derivatives/derivative salts (1-5 ml of solution for injections) should contain additional pharmaceutically acceptable components able to either prolong the GSSG, salt or derivative half-life in the biological media or to enhance/modulate beneficially their biological or therapeutical effects. Any of proposed pharmaceutically acceptable components can also be administered separately from GSSG and/or its derivatives, with the use of any other pharmaceutically acceptable dosage form, as well as dosage regimen, and route of administration.

These pharmaceutically acceptable components, which are other than GSSG and its derivatives, and their most preferable concentrations and dosages for treating human beings can be the following:

- a) 0.003% hydrogen peroxide with the acceptable concentration range of from 0.03 to 0.0003% by weight and dosage range of from 1.0 to 5.0 ml and more when administered epicutaneously or through instillations;

5.0% ascorbic acid with the acceptable concentration range of from 0.1 to 10% by weight and dosage range of from 1.0 to 10.0 ml and more when administered epicutaneously or through instillations;

or any other pharmaceutically acceptable pro-oxidant compounds with activity of the donors of reactive oxygen intermediates;

- 5 b) 7.0% (v/v) dimethyl sulfoxide with the acceptable concentration range of from 0.1% to 30% by volume and dosage range of from 1.0 to 30.0 ml and more when administered epicutaneously or through instillations;
- 10 any other pharmaceutically acceptable compounds capable to stabilize GSSG or its derivative molecule by forming both weak ionic and coordinating links with atoms of GSSG;

- c) 0.1% inosine (hypoxanthine-9-ribofuranoside) with the acceptable concentration range of from 0.1% to 5.0% by weight and dosage range of from 1.0 to 5.0 ml and more when administered epicutaneously or through instillations;

15 any other pharmaceutically acceptable competitors of NADP-H-dependent reduction of GSSG into GSH catalyzed by glutathione reductase;

- d) 0.1% cystamine (2,2'-Dithio-bis[ethylamine]) with the acceptable concentration range of from 0.1% to 3.0% by weight and dosage range of from 1.0 to 5.0 ml and more when administered epicutaneously or through instillations;

20 any other pharmaceutically acceptable compounds able to produce reversible inhibition or reduction of NADP⁺ into NADP-H catalyzed by glucose-6-phosphate-dehydrogenase or by other NADP-dependent enzymes.

- e) 10% choline-chloride with the acceptable concentration range of from 1.0% to 20% by weight and dosage range of from 1.0 to 5.0 ml and more when administered epicutaneously or through instillations;

25 5.0% S-adenosyl-methionine with the acceptable concentration range of from 1.0% to 10% by weight and dosage range of from 1.0 to 5.0 ml and more when administered epicutaneously or through instillations;

 any other pharmaceutically acceptable compounds able to serve as donor of methyl groups;

- 30 f) 0.5% lipoic acid with the acceptable concentration range of from 0.1% to 1.0% by weight and dosage range of from 1.0 to 5.0 ml and more when administered

epicutaneously or through instillations;
any other pharmaceutically acceptable compounds able to form intracellular redox-oxidative pairs.

At the same time, the data were obtained to testify the direct antitumor effect of GSSG, GSSG salts or GSSG derivatives administered alone or in combination with the pharmaceutically acceptable compounds prolonging oxidized glutathione half-life in biological media or enhancing/modulating the effects thereof. Moreover, the GSSG or GSSG derivative effect was proved to be different for normal and tumor cells. Our *in vitro* research with the use of normal and tumor cells revealed that the GSSG or its derivatives alone, or their pharmaceutically acceptable compositions containing extenders and/or enhancers/modulators initiated tumor cell death in apoptosis like manner. In case of normal cells, they did not undergo destruction.

It is an object of the present invention to provide a method for treating neoplastic, infectious, hematologic and other diseases in which stimulation of the endogenous cytokine and hemopoietic factor production is advantageous. The method comprises parenteral administration of GSSG and/or its derivatives as the medicinal agent in the injectable drug form at 0.01 to 0.5 mg of GSSG base per kg body weight or 0.01 to 1.0 mg/kg for GSSG derivatives, one or more times a day, by one or more day pulses or continuously until a desired therapeutic effect has been achieved. It is essential that either GSSG as medicinal agent or its drug forms and/or pharmaceutical compositions be administered strictly parenterally so that to prevent or minimize its deregulation or reduction (to GSH) taking place in the gastrointestinal tract upon oral administration. However, any of proposed pharmaceutically acceptable components such as extenders, enhancers/modulators can also be administered separately from GSSG and/or its derivatives, with the use of any other pharmaceutically acceptable dosage form, as well as a dosage regimen, and a route of administration. At that, the GSSG and/or its derivatives with or without extenders and/or enhancers/modulators can also be applied topically to the body at a dose consistent with the parenteral dose as for example 0.01 to 0.5 mg of GSSG base per square meter of skin or topical areas of the body being treated (with 0.01 to 1.0 mg per a square meter for GSSG derivatives).

Provided the GSSG or its derivative molecule is protected from proteolysis and/or reduction to GSH, it would be advantageous to administer the agent orally and/or intralesionally (*in situ*) (wound, tumor, etc.).

The examples given below confirm that the parenteral (intraperitoneal, intravenous,

intramuscular, subcutaneous, etc.) use of GSSG and/or its derivative results in inducing the endogenous production of *inter alia* TNF- α , IFN- α and IFN- γ , IL-1, IL-2, IL-6, IL-10, erythropoietin, and GM-CSF in mammals, which elicits a significant therapeutic effect in animals and humans suffering from neoplastic or infectious disease, hemopoiesis and immunity suppression of different origin, and other diseases in which stimulation of the endogenous cytokine and hemopoietic factor production would be considered beneficial by those skilled in the art.

From the experimental findings (see Examples) it follows that the previously unknown GSSG capability of inducing the endogenous cytokine and hemopoietic factor production and exerting beneficial effects in various diseases, is not associated with an increase in GSH levels, because GSH testing in a wide range of doses and concentrations has revealed neither stimulation of the endogenous cytokine and hemopoietic factor production nor the therapeutic effect observed with the use of GSSG and/or its derivatives.

GSSG can be used along with other medicaments without causing unwanted interaction in the body. For example, patients treated with known drugs such as lithium, ibuprofen, aminophylline, antibiotics, AZT, calcium antagonists, tamoxifen, hormones, interferon, and others can be treated simultaneously with GSSG.

As used herein, the term "therapeutic effect" means any improvement in the condition of a patient or animal treated according to the subject method, including obtaining a preventative or prophylactic effect, or any alleviation of the severity of signs and symptoms of a disease and its sequelae, including those caused by other treatment methods (e.g., chemo- and X-ray therapy), which can be detected by means of physical examination, laboratory or instrumental methods and considered statistically and/or clinically significant by those skilled in the art.

As used herein, the term "prophylactic effect" means prevention of any worsening in the condition of a subject treated according to the method of the invention, as well as prevention of any exacerbation of the severity of signs and symptoms of a disease or its sequelae, including those caused by other treatment methods (e.g. chemo- and X-ray therapy), which can be detected by means of physical examination, laboratory or instrumental methods and considered statistically and/or clinically significant by those skilled in the art.

As used herein, the terms "neoplastic and infectious disease", "hemopoiesis and immunity depression of various origin", and "other diseases" mean any neoplastic and infectious disease, any condition caused or accompanied by the erythroid or myeloid suppression, or a reduction in

quantitative or functional immunity parameters, as well as any other disease or pathological condition in which stimulation of the endogenous cytokine and/or hemopoietic factors including but not limited to TNF- α , IFN- α , and INF- γ , IL-1, IL-2, IL-6, IL-10, erythropoietin, and GM-CSF, production would be considered advantageous by those skilled in the art.

5 The non-limiting examples given below demonstrate feasibility of the invention.

The active principle, the GSSG peptide capable of inducing the endogenous cytokine and hemopoietic factor production, may be obtained by conventional peptide synthesis techniques⁴¹.

Thereby obtained peptide (GSSG) is subsequently used in animals and humans (*in vivo*) as the GSSG base, or as a pharmaceutically acceptable GSSG salt, or as a pharmaceutically
10 acceptable GSSG derivative in an injectable drug form prepared by dissolving the bulk substance in injectable water, or in any pharmaceutically acceptable solvent, with the resultant concentration of the active compound being 0.01-2.0% by weight of GSSG base for GSSG and its salts (with 0.01 to 4.0% by weight for GSSG derivatives).

For an *in vitro* use in experimental settings, GSSG or its derivatives may be dissolved in
15 biologically acceptable solvents such as culture media, isotonic saline solutions, glucose solutions and the like. Preferably an aqueous carrier or solvent is used, although and physiological and other solvents or carrier can be used. For topical application, organic solvents or carriers may be used in the form of ointments, pastes, creams or suppositories for body orifice applications.

The drug form for human and animal use should be prepared under sterile and pyrogen-
20 free conditions while exerting every effort to prevent chemical or bacterial contamination, thereby providing a sterile, pyrogen free treating agent or drug form.

The GSSG or its derivatives injectable drug form has been tested in both animal studies and pilot human trials.

The use of the maximum achievable concentration of the GSSG sodium salt solution
25 (10.0%, 100 mg/mL) in injectable water (or in normal saline, or in 0.003% hydrogen peroxide, or in 0.1% cystamine), and the maximum tolerable volumes administered to mice intra-peritoneally (IP < 2.0 mL), intravenously (IV, 0.5 mL), and intramuscularly (IM, 0.05 mL), have made it feasible to reach GSSG dosage levels 5000 mg/kg (IP), 1350 mg/kg (IV), and 135 mg/kg (IM), i.e. 1000, 270, and 27 times, respectively, the maximum recommended human dose of 0.5 mg/kg.

30 In none of the cases either animals' deaths or any toxic signs were observed, showing GSSG in injectable drug form to be essentially non-toxic.

The results of nonclinical evaluation of biological, pharmacological, and therapeutical properties of GSSG, as well as its drug forms with or without 0.003% hydrogen peroxide, or 0.1% inosine, or 0.1% cystamine, are presented in Examples #1-8.

5

Example #1

Effect of GSSG and its drug forms on cytokine production by human peripheral blood mononuclear leukocytes in vitro

Oxidized glutathione (GSSG), as well as its drug forms containing 0.003% hydrogen peroxide, or 0.1% inosine, or 0.1% cystamine, were evaluated for their effect on cytokine
10 production by human peripheral blood mononuclear leukocytes *in vitro*.

The leukocytic cytokine production was triggered by adding a mitogen, concanavalin A (ConA) to the cell culture immediately after introducing the test substances. In 24 hours of the cellular exposure to ConA and the test articles, the culture supernatants were sampled and stored until cytokine determination at -70°C.

15

With the aim of evaluating the functional status of the cells and their capacity of responding to the mitogen in the presence of the test articles at each concentration level, the control cell cultures, containing the test articles in identical concentrations, were incubated for 72 hours following the initial concomitant introduction of ConA and the test substances. 16 hours prior to the incubation completion, ³H-thymidine was added, and the label rate of incorporation
20 into DNA was interpreted as the criterion of the cellular test system functional state.

Venous blood from male healthy volunteers was collected into plastic heparinized tubes (endotoxin tested). PMNL fraction was isolated by centrifugation in density gradient of Ficoll and sodium diatrizoate (Histopaque-1077; Sigma).

25

Cell concentration was adjusted to 2×10^6 per mL of "complete" culture medium (RPMI 1640, Sigma) containing: HEPES (20 mM); L-glutamine (2mM); Gentamicin (50 µg/mL); fetal calf serum (10%). All the reagents used were of "cell culture tested" grade, Sigma. Cell viability was estimated by the Trypan blue exclusion method and 100 µL of cell suspension (200,000 cells) was placed into each well of flat bottom 96-well sterile micro titer plates for tissue cultures. Cells from each subject were placed into no less than 39
30 wells.

The five following final concentrations of the test articles (GSSG, as well as its drug forms containing 0.003% H₂O₂, or 0.1% inosine, or 0.1% cystamine) were evaluated:

5000 µg/mL; 500 µg/mL; 50 µg/mL; 5 µg/mL; and 0.5 µg/mL. Each concentration was established in no less than 6 wells by adding 50 µL of "complete" medium containing the appropriate quantity of the previously dissolved test articles. Another 6 wells were used for control cultures and contained no GSSG: 50 µL of "complete" medium, or
5 correspondingly, "complete" medium containing 0.003% H₂O₂, or 0.1% inosine, or 0.1% cystamine, were added.

Immediately after the test articles had been entered into the cultures, 50 µL of "complete" medium containing ConA (Sigma, cell culture tested) in a quantity required for a final concentration of 4.0 µg/mL, was added to all the wells excepting 3 additional ones which
10 served for evaluation of spontaneous ³H-thymidine uptake (without ConA).

After a twenty four hour incubation at 37°C and 5% of CO₂, contents of 3 wells (from each sextuplet of identical wells) were taken out, centrifuged, and the supernatants were frozen and kept at -70°C until the cytokine assay. Cultures in the other 3 wells (of each sextuplet were incubated further under the conditions described above.

15 Fifty six hours after the incubation had begun, 1.0 µCi of ³H-thymidine was added into all the remaining cultures, the plates were incubated for another 16 hours, and then the contents of the wells were harvested and transferred onto glass-fiber filters which were consequently treated with 5% trichloroacetic acid and ethanol. The filters were dried and their radioactivity (counts per minute, cpm) was determined using liquid scintillation
20 counter, Betaplate 1205 (LKB).

Mean radioactivity values for triplicates of identical cultures were used to calculate the index of mitogenic stimulation: the ratio of averaged cpm values of ConA stimulated cultures to averaged cpm values of unstimulated ones (3 wells without ConA). This stimulation index for wells, where the test articles were present in various concentrations,
25 served as a criterion of cellular functional status, and ability of the cells to respond to mitogenic stimulation.

Supernatants of 24-hour culture triplicates were subsequently assayed for cytokine content only if their 72-hour matched control culture triplicates developed mitogenic response to ConA with value of the stimulation index in the range from 15 to 50.

Concentrations of interleukin-1b), interleukin-6 (IL-6), tumor necrosis factor α (TNF α), and interferon α (IFN α) were determined by ELISA using commercial reagent kits (Medgenix, Belgium) and were expressed in pg/mL of culture supernatants.

The salient findings given in Tables 1-4. As can be seen from Tables 1 and 2, the adding
5 of GSSG into the culture media resulted in statistically significant and dose-dependent stimulation of the cytokine production by human mononuclear leukocytes. In addition, the presence of hydrogen peroxide leads to increase control (no GSSG) levels of IL-6 and TNF- α . Besides that, being used in combination with hydrogen peroxide GSSG exerts a more pronounced (1.5-2 fold) stimulatory effect on the production of the cytokines on study: for IL-1 β - at 5.0-5000 μ g/mL
10 concentration levels; for IL-6 and TNF- α - in the entire concentration range; and for IFN- α - at 500 and 5000 μ g/mL.

The application of GSSG in 0.1% inosine solution and 0.1% cystamine solution results in a significant and dose-dependent increase of cytokine production, particularly with respect to IL-6 and TNF α (Tables 3 and 4).

15 Thus, the GSSG effect on the human peripheral blood mononuclear leukocytes *in vitro* manifests in considerable stimulation of the cytokine release into culture media, thereby confirming the stimulatory effect of GSSG on the natural cytokine-producing capacity of the human blood cells. The use of GSSG in combination with hydrogen peroxide, inosine, as well as cystamine results in a more prominent effect of GSSG in respect of induction of endogenous
20 cytokine production.

Example #2

*Effect of GSSG and its drug forms on cytokine and hemopoietic factor
production as well as on hemopoiesis and immunity parameters in
25 cyclophosphamide-induced hemo- and immunodepression*

Both oxidized (GSSG) and reduced (GSH) glutathione, as well as GSSG drug forms containing 0.003% hydrogen peroxide, or 0.1% inosine, or 0.1% cystamine, were evaluated in a murine model of hemo- and immunodepression induced by a single administration of cytostatic cyclophosphamide (CP).

30 The study was designed to evaluate the effect of a 5-day long administration of the test articles on the capability of the CP-treated murine splenocytes to produce IL-2 and GM-CSF *in*

vitro. In addition, the number of blood leukocytes and lymphocytes and the bone marrow cellularity (number of karyocytes) were determined at 8 days after CP administration. Some animals receiving CP were then challenged with sheep red blood cells (SRBC), and the humoral immune response to the antigen was evaluated.

5 Male CBA mice (18 to 20g body weight) were given a single intraperitoneal injection of CP in a dose of 50 mg/kg. Five groups of animals (with no less than 15 mice in each) were formed. Group description is represented below.

· Control groups:

- 10 ☐ #1 - *intact animals* receiving a single injection of normal saline (NS) instead of CP injection, which further were treated with test article vehicle (normal saline);
- 15 ☐ #2 - *control animals* receiving a single CP injection, which further were treated with test article vehicle (normal saline);
- 15 ☐ #3 - animals receiving a single CP injection, which further were treated with *s reference article* (GSH dissolved in normal saline) in a dose of 5 mg/kg,;

· Test groups:

- 20 ☐ #4 - animals receiving a single CP injection, which further were treated with the *test article* (GSSG dissolved in normal saline) in a dose of 5 mg/kg;
- 25 ☐ #5 - animals receiving a single CP injection, which further were treated with a variant of the *test article drug form* (GSSG dissolved in normal saline containing 0.003% H₂O₂) with a GSSG dose of 5 mg/kg;
- 25 ☐ #6 - animals receiving a single CP injection, which further were treated with a variant of the *test article drug form* (GSSG dissolved in normal saline containing 0.1% inosine) with a GSSG dose of 5 mg/kg;
- 30 ☐ #7 - animals receiving a single CP injection, which further were treated with a variant of the *test article drug form* (GSSG dissolved in normal saline containing 0.1% cystamine) with a GSSG dose of 5 mg/kg;

30 Twenty four hours after the CP injection, 5 animals in each group were immunized with SRBC (107 cells in 0.5 mL of NS, intra peritoneally).

On day 3 after the CP injection (24 hours after the immunization) the intraperitoneal injections of the test or reference articles were started (as it has been described above). Injections were performed during 5 days: once a day, daily.

5 Twenty four hours after the completion of 5 day treatment course (on the 8th day after the CP injection), mice were euthanized and splenocyte cultures were aseptically prepared for assessment of spontaneous production of IL-2 and GM-CSF by the spleen lymphocytes *in vitro*.

Simultaneously, blood and marrow samples were collected for blood leukocyte and lymphocyte, and marrow nucleated cell counted.

10 Serum samples from immunized animals were tested on level of SRBC agglutinins (the day 8 after the CP injection, and the day 7 after the immunization).

Table #5 shows the parameters of IL-2 and GM-CSF production by splenocytes, bone marrow and blood cellular indices, and the immune response to sheep red blood cells in mice receiving the test articles against the background of cyclophosphamide induced hemo- and
15 immunodepression.

As is seen from the data, the use of both GSSG and GSSG solution in hydrogen peroxide brings IL-2 and GM-CSF splenocytic production almost back to normal whereas GSH shows no such effect. Also, both GSSG and its hydrogen peroxide solution exert a significant restorative effect on the bone marrow and blood parameters as well as immune response to SRBC.

20 Tables ##6 and 7 give data on effects of pharmacologically active compositions containing GSSG (in combination with 0.1% of inosine, or 0.1% cystamine) on tested parameter variations in mice with CP-induced hemo- and immunodepression. The findings show significant enhancing GSSG effects by inosine and cystamine components with respect of IL-2b and GM-CSF production stimulation and restoration of bone marrow and blood cellularity. As it could be seen,
25 GSH did not exhibit such stimulation. The maximum stimulation was achieved with the combination of GSSG and 0.1% inosine.

Thus, the use of the subject method in CP-induced hemo- and immunocompromised animals results in a prominent stimulation of IL-2 and GM-CSF endogenous production together with restoration of the bone marrow and blood cellular indices as well as immune response
30 development to sheep red blood cells.

Example #3

Effect of GSSG and its drug forms on cytokine and hemopoietic factor production as well as on hemopoiesis and immunity parameters in radiation-induced hemo- and immunodepression

5 Both oxidized (GSSG) and reduced (GSH) glutathione, as well as GSSG drug forms containing 0.003% hydrogen peroxide, or 0.1% inosine, or 0.1% cystamine, were evaluated in a murine model of hemo- and immunodepression induced by a single irradiation in a total dose of 1 Gy.

10 The study was designed to evaluate efficacy of 7-day daily administration of the test articles (with the dosing started 2 hours post-exposure) on the capability of the splenocytes from mice exposed to radiation to produce IL-2 and GM-CSF *in vitro*. In addition, the number of blood leukocytes and lymphocytes and the spleen and bone marrow cellularity (number of karyocytes), as well as splenic and medullary colony-stimulating capacity, were determined at 8 days post-exposure.

15 Male CBA mice (18 to 20 g body weight) were irradiated with single dose of 180 kV X-rays filtered with 0.5mm Cu (at 15 mA, distance - 70 cm, duration 2 min. and 28 sec.). The total absorbed dose comprised approximately 1 Gy. Five groups of animals (with no less than 12 mice in each) were formed. Group description is represented below.

20 Control groups:

- ☐ #1 - *intact animals* receiving a sham irradiation procedure to reproduce a stress impact, which further were treated with test article vehicle (normal saline);
- ☐ #2 - *control animals* irradiated in a dose of 1 Gy, which further were treated with test article vehicle (normal saline);
- ☐ #3 - animals irradiated in a dose of Gy, which further were treated with *reference article* (GSH dissolved in normal saline) in a dose of 5 mg/kg;

Test groups:

- ☐ #4 - animals irradiated in a dose of Gy, which further were treated with the *test article* (GSSG dissolved in normal saline) in a dose of 5 mg/kg;

30

- ☐ #5 - animals irradiated in a dose of Gy, which further were treated with a variant of the *test article drug form* (GSSG dissolved in normal saline containing 0.003% H₂O₂) with a GSSG dose of 5 mg/kg;
- 5 ☐ #6 - animals irradiated in a dose of Gy, which further were treated with GSSG in normal saline containing 0.1% inosine) with a GSSG dose of 5 mg/kg;
- ☐ #7 - animals irradiated in a dose of 1 Gy, which further were treated with GSSG in normal saline containing 0.1% cystamine) with a GSSG dose of 5 mg/kg;

10 Two hours after the irradiation the intraperitoneal injections of the test or reference articles were started (as it has been described above). Injections were performed during 7 days: once a day, daily.

Twenty four hours after the completion of 7 day treatment course (on the 8th day after the irradiation), mice were euthanized and splenocyte cultures were aseptically prepared
15 for assessment of spontaneous production of IL-2 and GM-CSF by the spleen lymphocytes *in vitro*.

Simultaneously, blood, spleen and marrow samples were collected for blood leukocyte and lymphocyte, and spleen and marrow nucleated cell counting.

Additionally, hemopoietic colony formation ability of spleen and bone marrow cells was
20 assessed by the method of direct count of colony forming units (CFU) in the spleens of irradiated CBA mice receiving intravenously spleen or bone marrow cells obtained from animals of control or test groups.

Splenocytic IL-2 and GM-SCF levels, blood, bone marrow, and spleen cellular indices we well as colony-stimulating capacity numbers (colony-forming units, CFU) in the bone marrow and
25 spleen of the irradiated animals at 8 days post-exposure, are summarized in Tables 8, 9, 10.

As is evident from the data of the tables, administration of GSSG, or its drug forms containing 0.003% hydrogen peroxide, or 0.1% inosine, or 0.1% cystamine, results in statistically significant recovery of IL-2 and GM-CSF production by splenocytes, whereas GSH produces no significant effect.

30 Furthermore, both GSSG alone and its pharmacologically active compositions exerted a significant normalizing effect on the blood, spleen, and bone marrow cellularity. In several instances the effect of GSSG dissolved in hydrogen peroxide has been found to be more

prominent. For example, while GSSG *per se* exhibited no statistically significant effect (as compared to controls) on IL-2 splenocytic production, blood leukocytes, bone marrow cellularity, and bone marrow colonies, GSSG in hydrogen peroxide did produce a statistically meaningful effect. If compared with hydrogen peroxide, both inosine and cystamine were found to exert more prominent effect of enhancing the GSSG action, with the maximal effect being achieved in case of active composition of GSSG with inosine.

Thus, the use of the subject method in animals developed radiation-induced hemo- and immunodepression results in pronounced stimulation of the endogenous IL-2 and GM-CSF production, and also leads to an accelerated recovery of the cellular compositions of the blood, lymphoid and hemopoietic organs as well as colony-forming activity of the bone marrow and spleen.

Example #4

Effect of GSSG and its drug forms on the process of proliferation and apoptosis of normal and tumor cells

The ability of oxidized glutathione (GSSG), as well as its drug forms containing 0.003% hydrogen peroxide, or 0.1% inosine or 0.1% cystamine, to influence processes of a cellular proliferation and/or death was evaluated using normal or tumor cells. To this end, GSSG, or its drug forms had been incubated for 24 hours with cells of myeloid line HL-60 and normal human lymphocytes isolated from peripheral blood of healthy volunteers. Subsequent evaluation of the cell cycle parameters was carried out by the flow cytofluorometry technique.

Venous blood of a healthy volunteers was collected into heparinized test-tubes which had been tested for endotoxin. A mononuclear fraction of blood leukocytes were obtained by centrifugation in gradient of ficol-metrizoat (Histopaque, Sigma). Cell concentration was adjusted to 2×10^6 cells per 1 ml of "complete" cell culture medium (RPMI 1640), containing 20 mM HEPES, 2 mM glutamine, 50 μ g/mL gentamicin and 10% fetal calf serum. Cell viability was estimated by the Trypan blue exclusion method, then the cell suspension was placed into wells of 96-well microliter plates - 200,000 cells per well. Cells of HL-60 line were grown in RPMI-1640 medium with the addition of 10% fetal calf serum. Cultivation was carried out in closed flasks, the medium volume was 12 mL, it was changed every four days by centrifugation. The nature of the cells growth was

suspensive. Evaluation of the test solution of GSSG (5000 µg/mL), as well as GSSG solutions containing 0.003% hydrogen peroxide, or 0.1% cystamine, was carried out using 6 cellular samples of normal lymphocytes and HL-60 cells for each test solution. 50 µL of each test solution were added to one or the other cell culture and thereafter cells were cultivated for 24-96 hours. Then, they were tested by the flow cytofluorometry to estimate DNA content in the cell nuclei. In case of apoptosis-like cellular death, the portion of cell nuclei with normal content of DNA became reduced, while the portion of cell nuclei containing abnormally small DNA quantity became larger.

The analysis procedure was following: after incubation completion, cells were centrifuged and transferred to a standard phosphate isotonic buffer pH 7.4, containing RNA-ase A (20µg/mL), ethidium bromide (fluorometric indicator for double stranded nucleic acid, 10 µg/mL) and MgCl₂ (5 mM). After the cells were disintegrated by nonionic detergent Triton X-100 (final concentration 0.1%). The suspension of cell nuclei thus obtained was analyzed by flow cytofluorometry with an argon laser as a source of light (wave length 488 nm). The red fluorescence due to DNA bound ethidium bromide was taken to be the measure of DNA content in the cell nuclei. In addition, corresponding samples were studied microscopically for revealing concomitant changes in cell morphology.

The study results are presented in Tables 11, 12 and Figure 1). The table 11 shows the presence of GSSG or its drug forms promoted proliferation of normal lymphocytes of healthy volunteers, which resulted in increase in their number, while flow cytofluorometry analysis did not reveal any changes characteristic for apoptosis-like cell death (Figure 1c-d).

Observation carried out on cell cultures of the tumor cells of myeloid line HL-60 revealed ability of GSSG (as well as its drug forms) to slowdown the proliferation of transformed cells. Table 12 shows that GSSG compositions with hydrogen peroxide, inosine and cystamine inhibit cell HL-60 proliferation better than GSSG alone. The flow cytofluorometry analysis demonstrates the slowdown of cell growth of the HL-60 line cells was associated with characteristic morphological indications of apoptosis-like death: sphere-like cells became multi-fragmented with plural interceptions, the number of cell nuclei with normal content of DNA fell down, while there was an increase in portion of nuclei with abnormally low DNA content (Fig. 1a-1b).

Thus, the results obtained enable to declare the dual functional properties of GSSG and its drug forms which selectively induce proliferation slowdown and apoptosis-like death of tumor

cells while accelerate proliferation of normal human cells (lymphocytes) without any signs of their apoptosis. The application of GSSG in combination with inosine produces the most prominent effect of GSSG in respect of normal cells.

5

Example #5

Effect of GSSG and its drug forms on progression of experimental tumors in mice.

An antitumor activity of GSSG, as well as its drug forms containing 0.003% hydrogen peroxide or 0.1% inosine, or 0.1% cystamine, was evaluated in the two mouse models of the tumor process induced by the intraperitoneal inoculation of leukemia P388 and leukemia L1210
10 cells. An influence of 7 day course of test article daily administration was studied in respect of variations of serum cytokine levels (IL-1, IL-2, IL-6, IFN α , TNF). In parallel, the tumor progression was estimated using the two integral indices: pace of mouse weight gain due to accumulation of ascitic fluid, and by animal mean survival time after inoculation.

The study was carried out on DBA/2 mice weighing 18-21 g. First, tumor cell passage
15 was performed using 6 animals for each cell line. For this, cells kept at the temperature of the liquid nitrogen were de-frozen and adjusted to the concentration of 5×10^6 cells/mL by sterile Hanks' solution. Then, 6 mice were intra peritoneally inoculated with 0.2 mL of each line cellular suspension.

Ascitic fluid was collected 6 days after the inoculation with L1210 cells and 8 days after
20 the inoculation with P388 ones. Thus obtained, the samples of passaged tumor cells were used for the main experiments. The fluid liquid was dissolved by sterile Hanks' solution so that cell concentration be 5×10^6 cells/mL for P388 cells and 5×10^5 cells/mL for L1210 cells.

Nine groups of animals with no less than 15 mice each were formed for experiments with
25 either tumor cell line. Mice were inoculated with 0.2 mL of resultant cell suspensions per mouse (10^6 P388 cells/mouse, and 10^5 L1210 cells/mouse). 24 hours after the tumor cells inoculation, animals were given the first injections of the test articles or vehicles. The test article injections were made daily till the 14th day of the experiment or till the animal death. The volume of solutions injected comprised 0.01 mL/g body weight.

30 Description of nine groups of animals formed for experiments with either tumor cell line is given below.

Control groups:

- ☐ #1 - *intact animals* receiving imitation of tumor cell inoculation (injection of normal saline) which further were treated with normal saline throughout the entire experiment;
- ☐ #2 - *control animals*, inoculated with tumor cells, which further were treated with test article vehicle (normal saline);

Control groups:

- ☐ #3 - experimental animals, inoculated with tumor cells, which further were treated with test article (GSSG dissolved in normal saline) in a dose of 5 mg/kg;
- ☐ #4 - experimental animals, inoculated with tumor cells, which further were treated with a variant of test article drug form (GSSG dissolved in normal saline containing 0.003% of hydrogen peroxide), with a GSSG dose of 5 mg/kg;
- ☐ #5 - experimental animals, inoculated with tumor cells, which further were treated with a variant of test article drug form (GSSG dissolved in normal saline containing 0.1% of inosine), with a GSSG dose of 5 mg/kg;
- ☐ #6 - experimental animals, inoculated with tumor cells, which further were treated with a variant of test article drug form (GSSG dissolved in normal saline containing 0.1% cystamine), with a GSSG dose of 5 mg/kg;
- ☐ #7 - experimental animals, inoculated with tumor cells, which further were treated with a variant of drug form component (normal saline containing 0.03% of hydrogen peroxide), without GSSG;
- ☐ #8 - experimental animals, inoculated with tumor cells, which further were treated with a variant of drug form component (normal saline containing 0.1% of inosine), without GSSG;
- ☐ #9 - experimental animals, inoculated with tumor cells, which further were treated with a variant of drug form component (normal saline containing 0.1% of cystamine), without GSSG;

Tables 13 and 14 contain results on test article efficacy evaluation as to variations of cytokine endogenous production, as well as data on integral parameters of the tumor process progression. The results obtained show that both GSSG and its drug forms have a substantial

cytokine inducing effect, reliably retard (if compared to the control groups) the accumulation of ascitic fluid and increase the mean survival time. GSSG alone and GSSG together with 0.003% of hydrogen peroxide increase more remarkably the IL-1 and IFN α serum levels, whereas GSSG in combination with 0.1% inosine and 0.1% cystamine cause a larger increase in IL-2, IL-6, TNF α serum levels.

The most prominent antitumor effect in respect to slowdown of ascitic fluid accumulation and prolongation of the mean survival time for either tumor models (P388 and L1210 leukemia) were obtained with GSSG in combination with 0.1% cystamine.

Therefore, animal treatment according to present invention led to: significant increasing in endogenous production of IL-2, IL-6, IFN α and TNF α ; and a reliable inhibition of progression of experimental tumors and prolongation of the mean survival time.

New properties of a previously known substance - oxidized glutathione (GSSG), and its pharmacologically active compositions, containing 0.003% hydrogen peroxide, or 0.1% of inosine, or 0.1% cystamine, found in the pre-clinical studies, are thought to be sufficient to declare that GSSG and its pharmacological formulations possess an obvious biological and pharmacological activity, as well as a therapeutic effect. This justifies the application of the corresponding drug forms of GSSG along and GSSG in combination with pharmaceutically acceptable components capable of extending the oxidized glutathione half life, for preventing and treating the diseases in which stimulation of endogenous production of cytokines and hemopoietic factors is advantageous and considered beneficial by those who skilled in the art.

The following examples (##9-26) of the GSSG drug forms clinical use support the idea of utilizing GSSG as an inducer of the endogenous cytokine and hemopoietic factor production in man, and provide for the method for disease treatment based on the above GSSG properties.

Example #6

Effect of lithium salt of GSSG, S-thioethylamine-GSSG and their drug forms on the process of apoptosis of normal and tumor cells

The ability of S-thioethylamine-GSSG and lithium salt of oxidized glutathione (GSSG), as well as their drug forms containing 0.003% hydrogen peroxide, or 0.1% inosine or 0.1% cystamine, or 7% dimethyl sulfoxide (DMSO) to influence processes cell death and apoptosis regulation was evaluated using normal or tumor cells. To this end, these substances had been incubated for 72 hours with cells of rat embrional fibroblasts (REF) and the same cells,

transformed with adenoviral E1A gene in complementation with ras-oncogene (e-ras cell line). Subsequent evaluation of the cellularity of experimental samples was carried out by counting the quantity of cell per milliliter (for REF cell line) or clones in dish (for e-ras cell line).

5 Cells were cultivated on DMEM medium supplemented with 10% fetal calf serum and 50 mg/mL gentamicin. Cultivation was carried out in Petri dishes.

REF cells was cultivated with initial density of 800 000 cell per mL, evaluation of the cellularity was performed at 0, 24, 48 and 72 hours of incubation with the test articles.

E-ras cells were seeded at a cell density of 300 cells per 5 cm dish. 7 days after growth of e-ras cells had been started the quantity of clones was evaluated and the test articles were added into the dishes.

10 Evaluation of the test solution of lithium GSSG salt and S-thioethylamine-GSSG (5000 mg/mL), as well as lithium GSSG salt and S-thioethylamine- GSSG solutions containing 0.003% hydrogen peroxide, or , 0.1% inosine or 0.1% cystamine, or 7% DMSO, was carried out using 6 cellular samples for each test solution.

15 50 mL of each test solution were added to one or the other cell culture and thereafter cells were cultivated for 24-72 hours. For the test-system for estimation of apoptosis regulation UV-induced cell death was triggered in a dose of 4 Dj. Test articles were added immediately after irradiation. Then, the quantity of cell per milliliter (for REF cell line) or clones in dish (for e-ras cell line) were monitored every 24 hours. For determination of DNA-fragmentation the electrophoresis in agarose gel was used at standard settings.

25 The study results are presented in Tables 15-18. The table 15 and 16 show that the presence of lithium salt of GSSG or S-thioethylamine- GSSG or their drug forms didn't promote apoptosis of normal cells (REF line). Observation carried out on cell cultures of the e-ras cells revealed ability of lithium salt of GSSG or S-thioethylamine- GSSG (as well as of their drug forms) to induce a transformed cell death.

30 The tables 17 and 18 show that the presence of lithium salt of GSSG or S-thioethylamine-GSSG or their drug forms do not promote the apoptosis of normal cells (REF line) induced by UV-irradiation. Observations carried out on e-ras cell cultures revealed ability of lithium salt of GSSG or S-thioethylamine- GSSG (as well as their drug forms) to potentiate death of the transformed cells.

Thus, the results obtained enable to postulate the duality of functional properties of lithium salt of GSSG or S-thioethylamine-GSSG and their drug forms which selectively induce apoptosis-like death of tumor cells without any signs of apoptosis in normal cells. Besides, all the test articles were able to decrease the apoptosis processes of normal cells induced by UV-irradiation and, were able to potentiate these processes in transformed cells. The application of S-thioethylamine-GSSG in combination with DMSO produced a more prominent effect than that of lithium salt of GSSG in respect of transformed cells.

Example #7

Effect of lithium salt of GSSG and S-thioethylamine-GSSG and their drug forms on progression of experimental tumors in mice.

An antitumor activity of lithium salt of GSSG and S-thioethylamine-GSSG, as well as their drug forms containing 0.003% hydrogen peroxide, 0.1% inosine, 0.1% cystamine, or 7% dimethyl sulfoxide (DMSO) was evaluated in the three mouse models of the tumor process induced by the intraperitoneal inoculation of leukemia P388, leukemia L1210 cells and Erlich adenocarcinoma cells. An influence of 7 day course of test article daily administration was studied in respect of tumor progression, which was estimated using the two integral indices: pace of mouse weight gain due to accumulation of ascitic fluid, and by animal mean survival time after inoculation.

The study was carried out on DBA/2 mice weighing 18-21 g. First, tumor cell passage was performed using 6 animals for each cell line. For this, cells kept at the temperature of the liquid nitrogen were de-frozen and adjusted to the concentration of 5×10^6 cells/mL by sterile Hanks' solution. Then, 6 mice were intra peritoneally inoculated with 0.2 mL of each line cellular suspension.

Ascitic fluid was collected 6 days after the inoculation with L1210 cells, 8 days after the inoculation with P388 ones and 18 days after inoculation with Erlich adenocarcinoma cells. Thus obtained, the samples of passaged tumor cells were used for the main experiments. The fluid liquid was dissolved by sterile Hanks' solution so that cell concentration be 5×10^6 cells/mL for P388 cells and Erlich adenocarcinoma cells, 5×10^5 cells/mL for L1210 cells.

Eleven groups of animals with no less than 15 mice each were formed for experiments with either tumor cell line. Mice were inoculated with 0.2 mL of resultant cell suspensions per mouse (10^6 P388 and Erlich adenocarcinoma cells/mouse, and 10^5 L1210 cells/mouse). 24 hours after the tumor cells inoculation, animals were given the first
5 injections of the test articles or vehicles. The test article injections were made daily till the 14th day of the experiment or till the animal death. The volume of solutions injected comprised 0.01 mL/g body weight.

Description of nine groups of animals formed for experiments with either tumor cell line is given below.

- 10 • Control groups:
 - #1 - *intact animals* receiving imitation of tumor cell inoculation (injection of normal saline) which further were treated with normal saline throughout the entire experiment;
 - #2 - *control animals*, inoculated with tumor cells, which further were
15 treated with test article vehicle (normal saline);
- Experimental groups:
 - #3 - experimental animals, inoculated with tumor cells, which further were treated with test article (S-thioethylamine-GSSG dissolved in normal saline) in a dose of 5 mg/kg;
 - 20 • #4 - experimental animals, inoculated with tumor cells, which further were treated with a variant of test article drug form (S-thioethylamine-GSSG dissolved in normal saline containing 0.003% of hydrogen peroxide), with a dose of 5 mg/kg;
 - #5 - experimental animals, inoculated with tumor cells, which further were
25 treated with a variant of test article drug form (S-thioethylamine-GSSG dissolved in normal saline containing 0.1% of inosine), with a dose of 5 mg/kg;
 - #6 - experimental animals, inoculated with tumor cells, which further were treated with a variant of test article drug form (S-thioethylamine-GSSG
30 dissolved in normal saline containing 0.1% cystamine), with a dose of 5 mg/kg;

- 5 □ #7 - experimental animals, inoculated with tumor cells, which further were treated with a variant of test article drug form (S-thioethylamine-GSSG dissolved in normal saline containing 7% DMSO), with a dose of 5 mg/kg;
- #8 - experimental animals, inoculated with tumor cells, which further were treated with test article (Li salt of GSSG dissolved in normal saline) in a dose of 5 mg/kg;
- #9 - experimental animals, inoculated with tumor cells, which further were treated with a variant of test article drug form (Li salt of GSSG dissolved in normal saline containing 0.003% of hydrogen peroxide), with a dose of 10 5 mg/kg;
- #10 - experimental animals, inoculated with tumor cells, which further were treated with a variant of test article drug form (Li salt of GSSG dissolved in normal saline containing 0.1% of inosine), with a dose of 5 mg/kg;
- 15 □ #11 - experimental animals, inoculated with tumor cells, which further were treated with a variant of test article drug form (Li salt of GSSG dissolved in normal saline containing 0.1% cystamine), with a dose of 5 mg/kg;
- #12 - experimental animals, inoculated with tumor cells, which further were treated with a variant of test article drug form (Li salt of GSSG dissolved in normal saline containing 7% DMSO), with a dose of 5 mg/kg;
- 20 □ #13 - experimental animals, inoculated with tumor cells, which further were treated with a variant of drug form component (normal saline containing 0.003% of hydrogen peroxide), without GSSG;
- #14 - experimental animals, inoculated with tumor cells, which further were treated with a variant of drug form component (normal saline containing 0.1% of inosine), without GSSG;
- 25 □ #15 - experimental animals, inoculated with tumor cells, which further were treated with a variant of drug form component (normal saline containing 0.1% of cystamine), without GSSG;
- 30 □ #16 - experimental animals, inoculated with tumor cells, which further were treated with a variant of drug form component (normal saline containing 7% of DMSO), without GSSG;

Tables 19 - 21 contain results on test article efficacy evaluation on integral parameters of the tumor process progression.

The most prominent antitumor effect in respect to slowdown of ascitic fluid accumulation and prolongation of the mean survival time for either tumor models (P388, L1210 leukemia and
5 Erlich adenocarcinoma) were obtained with S-thioethylamine-GSSG in combination with 0.1% inosine and 7% DMSO.

Example #8

*Effect of zinc salt of GSSG and S-thioethylamine-GSSG and their drug forms on the course of
10 Experimental Allergic Encephalomyelitis (EAE), the experimental model of Multiple Sclerosis*

The action of the zinc salt of GSSG in the combination with S-thioethylamine-GSSG in 0.003% solution of H₂O₂ (10 mg GSSG and 100 mg S-adenosyl-methionine in 1 ml) and S-thioethylamine-GSSG in 5% solution of ascorbinic acid were assessed in the model of EAE.

Within the frames of this study the influence of 10 day course of the named combinations on the
15 cellular contents of blood (leukocyte, lymphocyte, monocyte, neutrophil count) was assessed. To assess cellular hypersensitivity to myelin basic protein and antigen of neuronal membranes, *in vitro* migration activity of leukocytes in the peripheral blood was investigated in the presence of these antigens. We also used capillary method of reaction of inhibition of leukocyte migration (RILM). Neurological evaluation was carried out as well.

20 The study was done on male quinea-pigs with body weight 400-500 g.

Encephalitis - inducing substance - myelin basic protein (MBP) was obtained from the bull spinal cord with the use of the method of column chromatography and emulsified on complete Freund adjuvant. Immunization of the animals was performed via inoculation of encephalitis-inducing mixture subcutaneously to the front paws (MBP+complete Freund adjuvant). Latency period of
25 clinically expressed EAE averaged about 14-15 days, with minimum of 12 days.

Control groups:

- #1 - Intact animals in which physiological solution was used;

- #2 - animals exposed to with encephalitis-inducing mixture who then received physiological solution.

Experimental groups:

- 5 • #3 - animals exposed to encephalitis-inducing mixture who then received zinc salt of glutation (GSSG-Zn) in the combination with S-adenosyl-methyonine in 0.003% solution of H₂O₂, 5 mg of GSSG base per kg of body weight.
- #4 - animals exposed to encephalitis-inducing mixture who then received S-thioethylamine-GSSG in 5% solution of ascorbinic acid, 5 mg of GSSG base per kg of body weight

10 Neurological evaluation (scoring):

- 1 muscle weakness, discoordination of movements;
- 2 paresis of paws, urinary bladder atonia, urination disorders;
- 3 motor and functional palsies (pelvic organs);
- 4 blood circulation and thermoregulation disorders;
- 15 5 agony, Cheyne-Stocks breathing.

Methods for cellular immunity evaluation

1. Reaction of Inhibition of Leukocyte Migration (RILM) - is a variant of Delayed Hypersensitivity reaction in vitro. Basics of the method: changes in migration activity of peripheral blood leukocytes during contact with MB in glass capillaries. Migration zones are measured with ocular micrometer of the microscope. Migration index is calculated as the extent of migration of the cells with antigen to spontaneous migration (without antigen) ratio. Statistically significant is the change of the index by more than 0.2, ie migration index less than 0.8 is considered suppression.
2. Spontaneous adhesion of blood leukocyte and its changes during contact with MBP.
25 Migration of blood cells via vessel endothelium is a key moment in the development of

inflammatory lesions in EAE. This process is determined by the combined action of adhesive molecules, expressed on leukocytes and endothelium. Suppression of adhesive properties of leukocytes by antigen indicates specific sensitization of immunized animals; changes in this parameter during inhibition characterizes immunotropic properties of the drug towards cellular immunity.

3. Adhesive activity of the cells is studied by the test of adhesion to micropanels Falcon Plastic 3034 with fluorescent assessment of the results and is expressed as the number of cells that adhere to the panels spontaneously or after antigen exposure.

Calculation of the adhesion index:

$$(1 - \text{adhesion with antigen/spontaneous}) \times 100 \text{ adhesion}$$

Index > 30 shows the reaction of suppression of spontaneous adhesion.

24 hours after the completion of the treatment with test articles survived animals were killed and the number of spleen cells was counted in sterile conditions. In the same time blood samples were taken to assess cellular counts.

Data reflecting the effects of the test articles on animal survival and neurological status are represented in tables 22 and 23. According to these data, the use of GSSG-Zn and methyonil preparations helps increase survival of the animals and significantly decrease neurological symptoms of EAE (see tables 22 and 23).

In tables 24 and 25 the results indicating the influence of the test articles on immunological EAE parameters are shown. The data demonstrate a significant effect of the test articles on the parameters of sensitization of blood lymphocytes to brain antigens. In the same time there is a significant decrease in sensitization of lymphocytes in RILA (Table 24) and RILM (Table 25).

Example #9

Effect of GSSG drug form on the endogenous and erythropoietin production in patients having neoplastic disease

Data presented in this example demonstrate the GSSG stimulatory effect on the endogenous cytokine and hemopoietic factor production in cancer patients. GSSG solution (5 mg/mL) was administered intravenously, slowly, every other day a 5 mg per injection. The cytokine endogenous production was determined by their blood levels prior to the first administration (with blood collected 24 hours before dosing) and after the third and the seventh injections. The cytokine levels were assessed by immunoenzyme technique using commercially available kits (Medgenix, Belgium), and expressed as pg/mL of culture medium.

As seen from the data given in Table 26, a pronounced stimulation of the endogenous cytokine (IL-1 β , IL-6, TNF- α , IFN- α) and erythropoietin was noted as soon as after three first injections of GSSG. After the seventh administration (14 days of treatment) a manifold increase in the cytokines and erythropoietin blood levels was observed in the majority of cases.

Example #10

Stimulation of the endogenous and erythropoietin production in a patient suffering from colorectal cancer complicated with chemotherapy-induced hemodepression

A 44-year old female patient was operated for colorectal mass grown through the ovary and metastases in the mesenteric and omental lymph nodes (T₄N₃M₁). Postoperatively, 5-fluorouracil chemotherapy was conducted (total course dose 5.5 g) with resultant severe hemotoxicity.

One month after the chemotherapy the patient was reexamined, and ultrasonography of the peritoneum and computed tomography of the liver revealed an oval-shaped 13 x 10 mm solitary metastasis in the left liver lobe. Repeat blood counts showed incomplete recovery of the blood indices (leukopenia, lymphopenia, anemia, and thrombocytopenia of various severity were noted) rendering further chemotherapy impossible).

Laboratory parameters prior to the use of the oxidized glutathione drug form (5 mg of GSSG in 1 mL of 0.003% hydrogen peroxide) are listed in Table 27. The treatment according to the subject method was commenced with GSSG given intravenously for seven days, 5 mg once daily. After a 3-day interval, the treatment was resumed with 15 mg daily dose, IV, 10 days. This course was followed by a 7-day recess after which the therapy was continued with GSSG being given every other day IM, 15mg daily (a total of 20 injections).

50 days following commencement of the treatment the patient was reevaluated, and ultrasonography of the peritoneum and computed tomography of the liver showed a considerable

shrinkage (more than 50% of the pretreatment size) of the solitary hepatic metastasis. The post-treatment immunological indices are given in Table 27.

As seen from the data, both red and white blood cell counts have significantly improved, platelets almost completely recovered, ESR reduced, CD4+, CD8+, NK cell numbers increased,
5 A considerable stimulation of the endogenous cytokine and erythropoietin production, with TNF (together with increased natural killers) being probably responsible for the regression of the hepatic metastasis. These changes were accompanied by an improved general condition of the patient.

This clinical case indicates apparent therapeutic efficacy of the subject method. The
10 administered therapy resulted in significant stimulation of the endogenous cytokine and hemopoietic factor production, reduction in hepatic metastasis size, normalization of immunity parameters, and overall improvement in the patient's wellness.

Example #11

15 *Stimulation of the endogenous cytokine production in
an AIDS patient with crypto coccal meningitis*

A 28-year old male was admitted with a previously confirmed diagnosis of AIDS, stage 3/4C (WHO staging system) in moderately grave condition. The patient presented with paroxysmal headache, dizziness, and vomiting. Weight 47 kg, Karnofsky score 60, torpid, fevers
20 up to 39°C, dyspnea at rest.

Neurological examination revealed nuchal rigidity and diminished knee, ankle, biceps and triceps reflexes. Cerebrospinal fluid culture was positive for *Cryptococcus neoformans* which served the basis for making the diagnosis of cryptococcus meningoencephalitis, and the AIDS stage was refined as 4C.

25 A vigorous infusion therapy was started. In addition to palliative therapy the patient received a course of Fungizone (Amphotericin B) with no positive outcome. The neurologic symptomatology and the patient's general state continued to deteriorate. A low to moderate grade fever (37.5-38.5°C) persisted.

By the time oxidized glutathione was started (5 mg/mL), the patient had a significant drop
30 in CD4+ and CD8+ peripheral blood counts as well as anemia and overall lymphopenia (see Table 28).

The patient received the treatment to the subject method for 3 months (1 mL of the GSSG solution per administration). During the first month of treatment the patient was dosed every other day (first 10 days intravenously, the rest of the month - intramuscularly); during the second month the patient received the drug every three days (first 10 days IV, the rest of the month - subcutaneously).

By the middle of the first month therapy, the patient's condition improved significantly with the neurologic sign alleviated and low-grade fever not exceeding 37.5°C. In the course of treatment, the patient's cerebrospinal fluid was mycologically examined twice (cytology, cultures, latex-agglutination test for crypto coccal antigen). Towards the end of the first month therapy the number of viable *Crypto coccal neoformans* organisms was found to be considerably reduced. By the end of the second month the cytological, culture, and immunologic tests showed cerebrospinal fluid to be free of the pathogen. Because of the drastic improvement in the patient's state, during the third month the drug was given once weekly IM.

The hematology/immunology findings upon the therapy completion are given in Table 28. As evident from the table, the anemia signs have reduced and a significant increase in the number of lymphocytes and their subsets has taken place. These findings constitute AIDS restaging from 4C to 4B.

Noteworthy is the sizable elevation of the cytokine blood levels, with IL-2, IL-6, and IFN- γ playing the key role in the host defense against pathogenic fungi.

At discharge, the patient's condition was found satisfactory with body weight being 60 kg (weight gain made up 21.7% of the admission), normal body temperature, Karnofsky score of 90, and no neurological signs.

Example #12

Stimulation of the endogenous cytokine production and therapeutic effect in patients with AIDS complicated by isosporiasis

A 38-year old male had been observed for 2 years with the diagnosis of AIDS, stage 3C (WHO Staging System). During the preceding year, recurrent episodes of oral and esophageal candidiasis had been recorded as well as chronic intestinal isosporiasis manifested by poor appetite, nausea, frequent vomiting and watery stools containing blood and mucus. Repeatedly used cotrimoxazole (trimethoprim plus sulfamethoxazole, TMP-SMX) had produced unsteady remissions with rapid recurrence of the symptomatology. During the last month prior to

admission another relapse of isosporiasis had occurred. The treatment with cotromoxazole, emodium (loperamide) had brought no relief. The patient's condition had been gradually deteriorating: refractory fever 38°C and above, 6-7 loose bloody and mucous stools a day, vomiting, advancing weight loss (15% of the premorbid weight in one year). The patient had
5 been admitted with progressive worsening of his condition.

On admission, the patient presented with moderately grave condition, Karnofsky score of 50, fever 38.2°C, emaciation (body weight 42 kg), virtually total lack of subcutaneous fat, pallor of skin, the signs of oral and esophageal candidiasis. Stool examination revealed a large number of *Isospora belli* oocysts.

10 By the time the therapy according to the subject method was started, the patient had lymphopenia, marked decline in CD4+ and CD8+ lymphocytes, hypoproteinemia (see Table 29).

The patient received the oxidized glutathione drug form (5 mg of GSSG in 1 mL 0.003% hydrogen peroxide) for 2 months (1 mL of the GSSG solution per administration). During the first month of treatment the patient was dosed every other day (first 10 days intravenously, the
15 rest of the month - intramuscularly); during the second month the patient received the drug every three days (first 10 days IV, the rest of the month - subcutaneously).

The patient's condition began to noticeably improve after the first two weeks of treatment. By the end of the first month therapy the patient moved bowels no more than 102 times a day with stools being blood-free; body temperature only occasionally exceeded 37°C. At
20 the end of the second month stool reexamination showed feces to be negative for *Isospora belli*. Because of the drastic improvement in the patient's state, during the third month the drug was given prophylactically once weekly IM. No relapses of the disease were noted.

The findings of hematology/blood chemistry evaluations upon the therapy completion are given in Table 29. As seen from the table, hypoproteinemia has reduced, the number of
25 lymphocytes and their subsets considerably increased with the resultant restaging of AIDS to 3B stage according to the WHO Staging System.

Noteworthy is the marked increase of the cytokine blood levels, with IL-2 and IFN-γ known to play an important part in the host defense against protozoan infections.

As a result of the therapy administered the patient's condition improved drastically,
30 fatigue alleviated, appetite regained. The weight gain comprised 30% of the admission value, Karnofsky score - 90. On physical examination the patient's condition was rated as satisfactory. During 1.5 month follow-up no diarrhea relapses were reported.

Example #13*Stimulation of the endogenous erythropoietin production and therapeutic effect in patient with hypoplastic anemia and pancytopenia*

5 A 37-year old male had been observed for about a year with anemia of unknown origin the severity of which had been gradually building up. For 10 months he had been troubled with fatigability, dizziness, frequent nasal bleedings, unusual susceptibility to respiratory infections, three episodes of pneumonia with one of them being croupous pneumonia. During the year the patient had lost 10% of his usual weight. Repeated outpatient treatment with oral and
10 intravenous iron preparation, folic acid, B vitamins, including B₁₂, had produced no effect. One admission the patient presented with moderately grave condition, dyspnea on moderate exertion, bruises, and isolated petechial spots. Successive hematology analyses have revealed moderately severe to severe fairly hypochromic (color index 0.7-0.9) normocytic anemia ($1.5-2.5 \times 10^{12}/L$), anisocytosis and poikilocytosis, moderate leukopenia, and thrombocytopenia within $50-80 \times 10^9/L$.

15 An aggressive infusion therapy with iron preparations, folic acid, cyanocobalamin, vitamins, prednisone, and repeated erythrocyte transfusions resulted in only marginal relief.

Bone marrow differential (punch biopsy) revealed marked hypocellularity with medullary cavities populated predominantly with fat cells. Both myeloid and erythroid lineages are significantly suppressed with the erythroid/myeloid ration noticeably diminished. Megakaryocytes
20 are scant in number with relative increase in nondifferentiated cells, plasma cells, and blasts. Iron stores are enriched. Diagnosis: hypoplastic anemia of unknown origin, pancytopenia.

Complete blood count and erythropoietin levels by the time the oxidized glutathione drug form (5 mg GSSG in 1 mL of 0.003% hydrogen peroxide) was started are given in Table 30. As is evident from the table, the laboratory findings are consistent with those characteristic of
25 hypoplastic anemia with no typical increase of erythropoietin blood level, however. Moreover, the erythropoietin level was found to be considerably below the lower normal limit (9.2 pg/mL with the reference range 30-170 pg/mL corresponding to 3-17 mIU/mL).

The oxidized glutathione formulation therapy was started with intramuscular injections of 1 mg GSSG b.i.d. for three days. Further the dose was escalated up to 5 mg b.i.d. for 7 days.
30 Blood counts have shown less severe anemia. From that point, the drug form was dosed at 10 mg IM once daily for 10 days and then, the RBC counts steadily recovering, the therapy was

switched to IV administration of GSSG, once every three days for 30 days. Vitamins and iron preparations were given concomitantly *per os*.

The hematology findings and erythropoietin levels obtained 50 days following the subject treatment onset are listed in Table #30. As is easy to see from the data, both RBS and WBC counts significantly improved, as did the platelet counts, ESR reduced, erythropoietin levels exceeded the upper normal limit. Clinically, fatigue, dizziness, and dyspnea disappeared. On examination, no petechial spots or bruises could be found with no nasal bleedings observed or reported. The weight gain made up 5.5 kg (8% of the premorbid weight).

Bone marrow reexamination (punch biopsy upon therapy completion) found the myeloid tissue to occupy 60% of the medullary cavities with erythroid/myeloid ratio in the myeloid tissue isles exceeding the norm. There were normoblastoid hyperplasia signs with megaloblastoid cells found in normoblast congregations. Mast cells were encountered, megakaryocytes were present in abundance. Iron stores appeared to be somewhat enriched.

This clinical case indicates a clear therapeutic efficacy of the drug form. Due to the treatment administered the initially suppressed endogenous erythropoietin production received a potent boost. As a result, the hematology parameters virtually recovered and the anemia clinical signs resolved. The patient was discharged in satisfactory condition.

Example #14

Stimulation of endogenous cytokine production and the therapeutic effect in a patient with a stomach cancer, peritoneal metastases, ascites, plenomegaly and cholestatic hepatitis

A 33-year old patient was diagnosed as having stomach neoplasm for more than 2 years (adenocarcinoma of moderate differentiation degree). In 1993 the patient was operated for malignant stomach ulcer and numerous dense lymph nodes were found in the *porte hepatis* which were considered to be metastases.

In January 1994 the course of chemotherapy (5FU) was complicated by the severe cholestasis and percutaneous drainage of the left and right liver ducts was undertaken, that 6 month later was followed by the choledochojunostomy with changeable transliver drains with Brown's anastomosis.

In November 1995 the state of the patient worsened. According to the examinations the patient experienced an active secondary hepatitis. The liver was enlarged and painful and protruded from the costal arch up to 5-6 sm. Blood chemistry indices proved to be persistently

abnormal: bilirubin - 40.0 due to indirect (up to 31.0); activity of amino transferases - approximately 6 times higher than upper normal limit, hypoalbuminemia was up to 26%; and there was also hypergammaglobulinemia; hypercholesterolemia was up to 10.2 $\mu\text{mol/l}$.

During fibrogastroscopy (November, 1995) tumor of stomach located in the middle area of the stomach body and extended about 8 cm was confirmed. The tumor was solid-like. Stomach walls were rigid. Histology examination defined the tumor as adenocarcinoma of moderate degree laparotomy. Ascites was found with plural metastases all over the peritoneum, splenomegaly. The patient was identified as inoperable.

A decision was taken to apply GSSG drug form containing 0.1% inosine. The drug was injected parenterally (intramuscular and intravenous), and additionally, the drug form was used via local injections around the tumor tissue with the help of endoscope. An average doses which were used for intramuscular and intravenous injections - 0.1-0.5 mg/kg, and for local injections - up to 50 mg *in situ*. Parenteral injections of the drug were applied every other day, b.i.d. (intravenous injections at the morning, and intramuscular ones - at the evening), during three weeks, and after that - two times in a week, during four weeks. Two months after the beginning of the treatment with the drug form used fibrogastroduodenoscopy showed that esophagus was passable, mucous membrane was pink, cardia rosette was partly closed. On empty stomach moderate amount of foamy secret was in the stomach, which was intensively colored with bile. the tumor extent was 5 cm. At the same time, substantial improvement of hematology and blood chemistry indices was found.

Four month after, the liver protruded 1 cm beyond the rib arch. On palpation the liver was not painful. Supersonic examination showed the appearance of fibrous tissue instead on the place of some areas previously affected with tumor tissue. Fibrogastroduodenoscopy performed in May, 1996, showed that the esophagus was partly closed. There was light turbid liquid in the stomach, which contained saliva. Mucous membrane was pink. The tumor was 3.6 cm in extent with the stomach walls being elastic. Duodenum was passable.

By comparison with results of examination conducted before treatment with the use of the GSSG drug form mentioned (November, 1995) the tumor was shrunk in its extent for 55%. Simultaneously there were significant beneficial changes in hepatic tests, hematology and immunology indices (see table 31).

Thus, the treatment according to the present invention resulted in partial regress of neoplastic process with simultaneous obvious beneficial changes in hematology, blood chemistry and immunology parameters, and significant improvement of life quality.

5

Example #15

Stimulation of endogenous cytokine production and the therapeutic effect in a patient with skin cancer (Merkel's cell carcinoma), local lymph node metastases and chemotherapy-hemo- and induced immunodepression

10 A male patient, 64 years old, has been under medical supervision since August, 1995 when a hyperemic painless mass appeared in scapular area, which progressively grown in size. After a month time the mass spread over the axillary space, kept increasing, and became painful. A fever appeared (38.9°C. Histological and immunological examination in October, 1995 made the diagnosis clear: neuroendocrinal form of skin cancer (Merkel's cell carcinoma) stage III.

15 In December, 1995 the patient was given a course of CMF chemotherapy (cyclophosphamide+methotrexate+fluorouracil) without appreciable curative effect. At the same time an obvious hemopoiesis depression (leukocytes $2.4 \times 10^9/L$) developed with simultaneous growth of cervical and superclavicular lymph nodes associated with local skin hyperemia.

In January-February 1996 chemotherapy scheme was changed:

20 cysplatine+cyclophosphamide (CP instead of CMF). The chemotherapy brought about the following complications - cytopenia (leukocytes - $1.4 \times 10^9/l$), cardiotoxicity in the form of ischemia deterioration. After the 2nd course of chemotherapy a substantial tumor progression was observed: necrosis in the left subaxillary area with fistula formation; edema of the left arm; infiltrating growth into soft tissues in the area of the left shoulder and the left subaxillary tissues;
25 intoxication; persistent fever (38.8°C). Because of inefficacy of chemotherapy and the obvious progression of the process, it was decided to administer a course of GSSG drug form in combination with 0.1% cystamine, together with chemotherapy (CMF).

After 10 daily injections of the GSSG drug form used (intravenously and intramuscularly, the dose 0.1-0.5 mg/kg per an injection), it was noticed: the following changes in the patient's
30 status was revealed: improved quality of life (good appetite, mobility); ulceration drying out, abolition of suppurative discharge; fistula scarring, 30% tumor shrinkage; normal body temperature; limitation of hyperemic areas, the improvement of hematology indices.

The 3rd and 4th courses of chemotherapy (CMF) were carried out together with GSSG drug form (intravenous and intramuscular injections, b.i.d., intravenous dose 0.5 mg/kg; and intramuscular dose 0.2 mg/kg). Parenteral administration of the preparation was 3 times in a week, with local injections in the two spots around the tumor through the endoscope once a week (up to 25 mg for each spot). The following results was obtained: tumor process regression; good endurance of chemotherapy, the disappearance of pain syndrome, constant improvement of life quality, restoration of immunity and hemopoiesis, increasing level of cytokines and hemopoietic factors (see table 32).

In two months the treatment with the use of the present invention there was a stable level of endogenous production of cytokines and hemopoietic factors; the diminution of the left cervical and supraclavicular lymph nodes; the 70% shrinkage of tumor size in two dimensions; positive shifts in immunology indices; lack of chemotherapy hemo-depression.

The clinical observation proves the clear curative effect of the treatment according to the present invention: together with the obvious stimulation of endogenous production of cytokines and hemopoietic factors there were a substantial decrease in tumor size, improvement of life quality, and beneficial changes in hematology, blood chemistry and immunology parameters.

Example #16

Therapeutical effect of GSSG series preparations in patient with severe form of acute virus hepatitis

A 32-year old male was hospitalized into infectious clinic with symptoms of pigment metabolism disorder: icterus of skin and mucous membranes; dark urine; light-colored faeces, high level of urobilinogen. The physical status of the patient was quite severe: body temperature - 38,8°C, influenza-like and arthralgic syndromes. The patient's liver was enlarged more than on 4-5 cm. Acute virus hepatitis was diagnosed. The specified diagnosis was acute virus hepatitis "B". Severe form of the disease with acute hepatic insufficiency.

The first course of the treatment with the use of GSSG series preparations comprised intravenous injections of GSSG-Na₂ in 0.1% solution of folic acid, once a day during 7 days at a dose of 0.1-0.5 mg/kg of body weight.

The second course of the treatment comprised intravenous injections of GSSG-Zn in 0.1% solution of inosine once a day during 7 days at a dose of 0.1mg/kg of body weight.

The third course comprised intravenous injections of GSSG-Na₂ in 5% solution of ascorbic acid every other day during 7 days at a dose of 0.1-0.5 mg /kg of body weight. Simultaneously the same formulation was injected intramuscularly at the same dose one time a day.

The data in table 33 show the beneficial changes hematology/immunology parameters, decrease in (or/and normalization of) hepatitis laboratory markers. Thus, elimination of pathologic process and the patient's recovery occurred to be 1.5-2 months earlier than ordinary period of recovery in acute virus hepatitis.

Example #17

10 *Therapeutical effect of GSSG series preparations in patient with chronic virus hepatitis in stage of exacerbation*

A 56-year old female was hospitalized into infectious clinic with complaint of physical status worsening, weakness, fatigue and irritability, anorexia, nausea. She also had some GIT symptoms, pain in right sub-costal area and body temperature up to 38,5°C.

15 **On examination:** The general status of the patient was of middle severity. Palpation revealed splenomegaly and hepatomegaly. Liver protruded 3 cm from under the rib arch. Sclerae and mucous membranes were subicteric.

Ultrasonic examination: Liver was remarkably enlarged, v. portae was 15 mm, the gall-bladder wall was thickened, pancreas had normal structure, spleen was enlarged (578 x 168 mm) and
20 thickened. Kidneys were without remarked alterations of structure.

During 2 weeks the patient was receiving desintoxication and antiviral therapy (Roferon-A, a recombinant α_2 -interferon). Because of a further disease progress and inefficacy of the therapy used, the decision was taken to try the treatment with GSSG series preparations.

Intravenous injections of GSSG-Na₂ in 10% solution of choline-chloride were applied during 7
25 days, (once a day at a dose of 0.1-1.0 mg /kg of body weight).

Intravenous injections of bis-methionil-GSSG in 5% solution of ascorbic acid were applied during the subsequent 10 days (once a day at a dose of 0.1-0.5 mg/kg of body weight). Simultaneously, intramuscular injections of GSSG-Na₂ in 0.1% solution of inosine were applied during these 10 days (once a day at a dose of 0.01-0.5 mg/kg of body weight).

One month after the aforementioned treatment with GSSG series preparations the patient's physical condition improved significantly. Only the complaints of weakness and fatigue remained. Diminution in algetic and dyspeptic syndromes was remarkable, body temperature was normal. Some beneficial changes in laboratory indices were observed (see table 34). Ultrasonic examination revealed the same extent of splenomegaly and hepatomegaly.

Due to the certain improvement in the patient's status, but remaining of hepatic lesion signs the decision was taken to apply another course of treatment with the use of GSSG series preparations. After the second course of the completely the same treatment the patient had no complaints. Pain and dyspeptic signs were absent. Ultrasonic examination revealed diminution in spleen and liver dimensions. Palpation revealed liver protruded 1,5 cm from under the rib arch. (For laboratory data see table 34).

Thus, the application of combined therapy with the use of GSSG series preparations conditioned a remarkable curative effect, with improvement in physical status and life quality, stabilization and reversion of the pathologic process, beneficial laboratory changes.

15

Example #18

Therapeutical effect of GSSG series preparations in patients with acute peritonitis

1. A 78-year old female was hospitalized with diagnosis of incarcerated ventral hernia, acute intestinal obstruction with necrosis of the small intestine and developing toxic phase of acute peritonitis. During the surgical operation approximately 800 ml of feculent effusion with flakes and fibrin clots was found in and removed from the abdominal cavity. Incarcerated part of small intestine was necrotized.

A partial resection of the small intestine with creating anastomose was performed. A probe was conducted into the small intestine through the esophagus and stomach and placed to ileocecal angle. During postoperative period the evacuation of intestine contents was performed once a day. After that 150 ml of 0.1% solution of folic acid in dimethyl sulfoxide (DMSO), comprising 10 ml of 1% GSSG disodium salt solution was instilled into the small intestine. Simultaneously 0.1% solution of folic acid and 1% GSSG disodium salt solution was injected intravenously at a dose from 0.01 to 0.1 mg/kg once a day during the 4 days.

An adequate peristalsis restored on the 2nd day after surgery. The probe was removed on the 8th day. The patient was checked out from the hospital on the 19th day.

2. A 16-year old male was hospitalized with a diagnosis of acute commissure-induced obstruction of small intestine with development of the peritonitis; toxic phase.

During the operation approximately 600 ml of feculent effusion with flakes and fibrin clots was found in and removed from the abdominal cavity. The patient had a prominent commissure process. A commissurotomy was made. A probe was conducted into the small intestine through the esophagus and stomach and placed to ileocecal angle.

During postoperative period the evacuation of bowel contents was performed once a day. After that 150 ml of 0.1% solution of folic acid in dimethyl sulfoxide (DMSO), comprising 10 ml of 1% GSSG disodium salt solution was injected into the small intestine. Simultaneously 0.1% solution of folic acid and 1% GSSG disodium salt solution was injected intravenously at a dose from 0.01 to 0.1 mg/kg once a day during the 4 days.

An adequate peristalsis renewed on the 2nd day, and probe was removed on the 8th day after surgery. The patient was checked out from the hospital on the 11th day.

15

Example #19

Therapeutical effect of GSSG series preparations in patient with cancer of the prostate

A 63-year old male was hospitalized in urology department with the suspicion of prostate cancer. Palpation revealed the enlarged, dense prostate. X-ray examination of thorax revealed metastasis in frontal parts of IV-VII ribs, as well as in cranium, vertebrae, pelvic and femoral bones. Cancer of prostate was diagnosed with multiple bone metastasis (T₂N₂M₁).

Course of treatment was applied during the 30 days and was conducted by the following scheme:

1. Intravenous injections of GSSG-Zn in 1% solution of inosine were made during 10 days once a day at a dose of 0.01-0.5 mg/kg of body weight.
2. During the next 10 days injections of S-thioethylamine-GSSG were made endolymphatically once a day at a dose of 0.1-1.0 mg/kg of body weight.
3. During the next 10 days intravenous injections of GSSG-Zn in 1% solution of inosine were made every other day at a dose of 0.01-0.5 mg/kg of body weight.

After the treatment course the patient's condition improved significantly, pain in groin area became of less intensity, episodes of frequent urination reduced up to 2-3 times a night, edema of lower extremities decreased. Hematological examination revealed some beneficial changes (table 35).

- 5 After checking out the patient received intramuscular injections of GSSG-Zn in 1% solution of inosine twice a week at a dose of 0.01-0.5 mg/kg of body weight.

More than 1 year later the patient was hospitalized again at the same urology department for examination and conducting of the repeated course with GSSG series preparations. The treatment scheme with the use of the GSSG series preparations was identical. The main
10 therapeutical effects 3 months after the end of the second treatment session was considered as the following: Improvement in life quality; absence of lower extremity edema; regression of enlarged lymph nodes; absence of disury manifestations; decrease in size of prostate; beneficial X-ray dynamics (calcification of some particular metastasis in ribs and vertebrae); restoration of hematology and immunology indices.

15

Example #20

Therapeutical effect of GSSG series preparations in patient with cancer of the pancreas

- In May 1996 56 year old male patient was admitted to the II surgical division of the Hospital N122. On admission the patient's condition was severe. The patient complained on: continuous
20 band-like pain in the upper part of the abdomen, that worsened when the patient was lying on the back, appetite loss, nausea, vomiting, flatulence, diarrhea. Karnofsky index 40. On palpation: pain and tension of the abdominal muscles at the site of projection of the pancreas (Kerte's symptom). Pancreas was solid, with uneven surface, enlarged. The liver was solid, 4 cm below the lower rib.
- 25 On ultrasonic examination: pancreas was enlarged (head 7 cm, body 4 cm, tail 2.5 cm) with uneven borders, solid. Virsung duct was enlarged 0.7 cm. Liver was enlarged, right lobe 18 cm, left lobe 10 cm. Lower edge was rounded. Its edges were uneven, the structure was nonhomogeneous with multiple hyperechogeneous foci in the parenchyma (metastases).
Diagnosis - cancer of the pancreas with liver metastases (T3N2M1).

Treatment: detoxification, protease inhibitors, narcotic analgesics.

Due to the fatal severity of the patient's condition and absence of any alternative treatment the decision was made to use treatment with GSSG series preparations.

5 The treatment scheme: zinc salt of GSSG (0.01-0.5 mg/kg) intravenously (every day twice a day for 10 days). For the next 10 days - zinc salt of GSSG (0.01-0.5 mg/kg/day) intravenously, every other day and zinc salt GSSG in 7% dimethyl sulfoxide (0.1-1.0 mg/kg/day) endolymphatically. For the next 10 days (third decade) zinc salt of GSSG (0.01-0.5 mg/kg/day) intravenously, twice a week.

10 After a month treatment patient's condition was moderately severe; periodical moderate pain in the left subcostal region. Karnofsky index - 60. Narcotic analgesics were stopped, appetite increased. There was a tendency to improvement in the blood parameters.

During 3 weeks after the completing intravenous treatment course the patient was receiving zinc salt of GSSG (0.01-0.5 mg/kg) once a week, intramuscularly.

15 In June 1996: the patient was again admitted to the II surgical division of the hospital 122 for investigation and for conducting a new session of treatment with the use of GSSG series preparations.

20 On examination: marked improvement of the clinical condition and blood parameters (see Table 36). The patient's condition was almost satisfactory. Complains on a periodic weak pain in the left subcostal region. Karnofsky index - 70. On palpation - some tenderness in the site of the projection of the head and body of the pancreas; the organ was less solid with a smoother surface.

On ultrasonic examination: some decrease in the size of pancreas (head 6.3 cm, body 3.2 cm, tail 2.1 cm). Virsung duct 0.4 cm. The liver was enlarged; the right lobe 16.5 cm, the left one - 9.5 cm. Contours of the liver were uneven, structure - nonhomogeneous. Fibrosis of the *porta hepatis*. Multiple hyperechogeneous shadows in the liver parenchyma.

25 The treatment scheme for the second session of therapy with GSSG series preparations was the following. For the first 10 days, S-thioethylamine-GSSG was infused every day via catheter into the hepatic artery (0.1-1.0mg/kg/day).

After that the zinc salt of GSSG (0.01-0.5 mg/kg) was given intravenously every day, for 10 days. Being checked out the patient received supportive therapy with the zinc salt of GSSG intravenously (0.01-0.5 mg/kg/day), once a week, for 1 month.

In September 1996 the patient was again admitted to the Hospital N122 for examination and the
5 third session of therapy. Clinical condition did not change by that time. For blood parameter variations see table 36.

On ultrasonic examination: pancreas had the same characteristics as before. Liver was slightly enlarged, the right lobe - 15 cm, the left lobe - 8 cm, lower edge rounded, edges were definite and smooth, parenchyma was nonhomogeneous due to hypo and hyperechogeneous foci (fibrosis and
10 calcificates).

Thus the following clinical effects were considered as prominent and significant: improvement of the quality of life; stabilization of the neoplastic process; resolution of some metastases; restoration of immunology and hematology indices; improvement in results of ultrasonic examination.

15

Example #21

Therapeutical effect of GSSG series preparations in patient with diabetes mellitus

Female patient of 18 year old was admitted to the Division of Endocrinology of the Hospital N16. Diagnosis: insulin dependent diabetes mellitus (type I). Severe form of insulin resistance, diabetic angioretinopathy grade IV, initial symptoms of diabetic polyneuropathy III from the age
20 14. The disease started with precomatose state, blood glucose varied from 18.4 to 28.0 mmol/l, ketoneuria (acetone), and glucosuria up to 12%. Total Insulin dose at the disease onset: SU-Insulin 68 units, "ICS" 269 units. Previously was hospitalized several times. Dose of Insulin reached 500 units in 1994-1996. At that time blood glucose was 19.6-24.3 mmol/l, glucosuria was 4-6%, positive ketones in urine.

25 In September 1996 the patient was admitted to consider modification of treatment with the dose of ICS insulin 500 units, ICS-A 100 units, SU-Insulin 5- units. On admission Insulin dose was the following: B-insulin 480 units, SU insulin 22 units

Blood sugars:

- 9 A.M. 11.4 mmol/l
- noon 11.1 mmol/l
- 2 P.M. 13.9 mmol/l
- 5 P.M. 16.7 mmol/l
- 5 • 6 A.M. 10.7 mmol/l

Glucosuria - up to 670 mmol, ketones +++.

Due to the severity of the patient's insulin resistance and after the patient's agreement the decision was made to use GSSG series preparations.

10 Treatment scheme: intravenously for 10 days, once a day GSSG- Na_2 in 0.5% solution of lipoic acid (0.01-0.5 mg/kg/day).

For the next 10 days, intravenously, every other day - zinc salt GSSG in 0.5% solution of lipoic acid (0.01-0.5 mg/kg/day).

For the next 10 days (third decade) sodium salt GSSG- Na_2 in 5% solution of ascorbic acid, intramuscularly, once a day for 20 days (0.1-0.5 mg/kg/day).

15 After the treatment session had been completed the insulin treatment was modified. SU insulin was started, several injections per hour, sustained release insulin canceled.

The dose of insulin was gradually decreased, and the patient was discharged with the following insulin regimen:

	6A.M.	4 units SU-insulin
20	9P.M.	50 units
	2 P.M.	36 units
	7 P.M.	36 units
	11 P.M.	8 units (total dose 134 units).

25 Blood sugars got to normal and did not exceed 8 mmol/l even after meals. After the patient was discharged she received therapy with GSSG series preparations as an out-patient for a month.

Treatment scheme was the following:

During a month - sodium salt of GSSG in 0.5% solution of lipoic acid (0.01-0.5mg/kg), intramuscularly, every other day.

During the 2 successive months the patient had two episodes of hypoglycemia (1.8-2.2 mmol/l), and that forced to decrease insulin doses. Thus, after the two months of treatment following

5 insulin regimen was implemented:

6 A.M.	4 units SU-insulin
9 P.M.	36 units
2 P.M.	12 units
7 P.M.	12 units
10 11 P.M.	4 units (total dose 68 units).

The patient's condition was satisfactory, no complains. See table 37 for changes in blood parameters. Thus the following clinical effects seem to be substantial: stopped insulin resistance; decreased insulin dose, improvement of the quality of life and laboratory parameters.

15

Example #22.

Therapeutical effect of GSSG series preparations in patient with lung cancer

Diagnosis: Cancer of the upper lobe of the right lung (T3N2M0) extending into superior caval vein and pulmonary artery. Metastases to mediastinal lymph nodes.

20 In September 1995 a male patient of 59 was admitted to the surgical division of the Institute of Pulmonology with suggested lung neoplasm. On admission the patient was complaining of periodical fever up to 38.4°C, decreased appetite, 8 kg weight loss, dyspnea after movement.

On several chest CT scans (29.08.96) the size of the right lung was decreased due to hypoventilation of the upper lobe. Pulmonary tree looked different on the right side. Right upper
25 lobe bronchus was narrowed and deformed, with a focal shadow 4.0x5.0x6.0 cm. There probably was an enlargement of paramediastinal lymph nodes. No fluid in pleural cavities.

On bronchoscopy: lymphangiitis of the lateral wall of the lower 1/3 of trachea, lymphangiitis and infiltration of the lateral wall of the right main bronchus, compressive and infiltrative stenosis of the right upper lobe bronchus (lateral wall) of the 1-2 degree.

On diagnostic thoracotomy: (14.09.95) uneven dense formation of the upper lobe of the right lung 4.0x5.0x6.0 cm, growing into upper parietal pleura. On intraoperative examination, after pericardium was opened it became obvious that neoplasm extended into superior caval vein and pulmonary artery. Histologically, neoplasm was identified as low differentiation (small cell) carcinoma. The case was considered inoperable.

The patient's state continued to deteriorate: right supraclavicular node enlarged (3.5x4.0cm). The patient was transferred to the Institute of Oncology for chemotherapy. After the first treatment course of Cisplatin combined with Etoposide the patients' condition deteriorated significantly: nausea and vomiting, alopecia, increased transaminases, creatinine, leukopenia.

Due to the severity of the patient's disease and absence of any alternative treatment the decision was made to use compassionate treatment with lithium salt of GSSG.

From the first injections of GSSG-Li (0.01-0.5 mg/kg per day, intravenously/intramuscularly alternative days for 14 days), the quality of life improved significantly (Karnofsky index 80 (60), appetite increased, dyspnea decreased).

After 2 weeks' treatment with lithium salt of GSSG in 0.003% solution of H₂O₂ blood indices substantially improved (leukocyte count, red cell count, creatinine, transaminases), and that permitted to try another chemotherapy course (Cisplatin combined with Etoposide). Compared with the first course, there were no complications during the second one when the patient was receiving Li-GSSG: there was no nausea, vomiting, there was an increase in appetite (5kgs weight gain); results of clinical and biochemical blood tests were within normal limits.

After the second chemotherapy course therapy with GSSG series preparations was resumed: lithium salt of GSSG in 3% of dimethyl sulfoxide (0.01-0.5 mg/kg per day intravenously/intramuscularly 3 times a week during 14 days).

Then the patient received another chemotherapy course in the Institute of Oncology. There were no complications during the third chemotherapy course. Result of blood tests were within normal limits. There were a complete resolution of the enlarged right supraclavicular lymph node and X-ray demonstrated improvement of the primary lesion; no signs of atelectasis, additional shadows

were neither found in mediastinum, nor paratracheally; trachea had a normal location; there was no residual cavity.

Thus the 2 courses of chemotherapy combined with GSSG series preparations (lithium salt of GSSG) led to satisfactory quality of life, systemic regression of the neoplasm, restoration of
5 laboratory parameters which was associated with a stable increase in endogenous production of cytokines and hematopoietic factors (see Table 38). Later on the patient was receiving GSSG-Li₂ at a dose rate 0.01-0.5 mg/kg, every other day for 14 days a month during a year.

One year later (14.10.96)

On chest CT scan there was a site of fibrous changes in the right upper lobe bronchus
10 1.5x1.5x2.0 cm. There were no new infiltrative or fibrous changes in lung tissue. Lumens of the trachea and bronchi in both lungs were neither narrowed nor deformed. There was no mediastinal and lung root lymph node enlargement. No fluid in pleural cavities.

CONCLUSION:

Combined treatment with chemotherapeutic regimens and GSSG-Li₂ produced remarkable
15 potentiation of the chemotherapeutic effect with its acceptable chemotherapy tolerability. Generally, the effect of the combination led to tumor regression, liquidation of metastases, restoration of immune and hematopoietic systems, a better quality of life.

Example #23.

20 *Therapeutical effect of GSSG series preparations in patient with sigmoid cancer*

Diagnosis: Cancer (undifferentiated adenocarcinoma) of the rectosigmoid region of the colon (T4N0M0), complicated by right-sided adnextumor, right-sided tuboovarian abscess, diffuse phlegmonous-purulent peritonitis.

In June 1996 a female patient of 48 was urgently admitted to the IInd surgical division of the
25 Central Hospital N122 with the above mentioned diagnosis.

Operation: loop sigmoidostomy, abdominal cavity cleaning and draining. The patient's condition was severe: Karnofsky 30, fever 39-40°C. Despite aggressive therapy clinical condition continued to deteriorate and complicated with bilateral pneumonia. Additional intensive therapy with

antibiotics (Cefalosporins and Penicillins - Claforan 6 g/day, Ampicillin/Oxacillin 2 g/day) did not result in desirable effect.

Due to inefficacy of the treatment the decision was made to use compassionate treatment with GSSG-Zn₂.

- 5 For one week the patient received GSSG-Zn₂ in 0.1% solution of cystamine 0.01-0.5 mg/kg per day IV and IM together with the previous complex therapy. After one weeks' treatment the patient's physical status improved substantially, appetite increased, weakness disappeared, sleep normalized, local healing of the wound accelerated. There was a tendency for normalization of blood parameters (see Table 39), there were no X0ray signs of pneumonia.
- 10 Those positive effects permitted to perform the second stage of the surgical treatment — to repeat laparotomy with resection of proctosigmoid region of colon and right adnexa with ovary. Postoperative period was characterized by right-sided lower lobe pleuropneumonia. Again, GSSG-Zn₂ in 0.1% cystamine solution was added to the treatment (0.01-0.5 mg/kg every day intravenously and intramuscularly during a week). Clinical and radiological signs of pneumonia
- 15 resolved within 3 days.

There were no complications of the postoperative wound. Sutures were removed on the seventh day. Patient was discharged in satisfactory condition to be followed up as an out-patient.

- General effects can be summarized as follows: improvement of the quality of life; potentiation of antibacterial therapy; restoration of laboratory indices; acceleration of wound-healing; possibility
- 20 of radical surgical treatment.

Example #24.

Therapeutical effect of GSSG series preparations in patient with pancreas/duodenum cancer

Diagnosis: Cancer of the pancreas extending into the duodenum (T3N2M1).

- 25 In January 1996 a male patient of 67 was admitted to the II surgical division of the Hospital N122 with obstructive jaundice. Diagnosis - infiltrative stricture of the main bile duct. Surgery: transcutaneous- transhepatic external-internal drainage.

In February 1996 - cholecystectomy, choledocho-duodenoanostomosis (Jurash procedure). Patient was suffering from severe pain in the right subcostal area irradiating to the back, and narcotic analgesics were prescribed. No appetite. Weight loss 13 kg per month. Karnofsky index 40. Periodical nausea, vomiting, steatorrhea. Increased amylase and lipase in blood serum, amylase in urine, anemia. In the projection of the head of the pancreas tumorous object could be palpated. On fibrogastroduodenoscopy: infiltration of duodenal mucosa down to the Vater's papilla.

Due to the severity of the patient's disease, progressive deterioration and absence of any alternative treatment the decision was made to use compassionate treatment with GSSG-Zn₂ in dimethyl sulfoxide (DMSO).

After 2 weeks' treatment the patient's condition obviously improved. Karnofsky index - 80. Continuous pain decreased, though the patient was suffering from periodical moderate pains, narcotics were canceled. No nausea or vomiting; weight gain 4 kg; improvement in blood parameters (see Table 40).

Clinical and laboratory improvement permitted to introduce combined treatment with high-dose chemotherapy (5-Fluoruracil - 10 g/course) which was combined with GSSG-Zn₂. During 3 days the patient was receiving Fluoruracil endolymphatically (day 1 - 3g, day 2 - 3 g, day 3 - 4 g) and high doses of GSSG-Zn₂ in DMSO (0.1-1.0 mg/kg per day).

The patient tolerated treatment without hematological and other toxic complications. (for blood parameters see Table 40). During the 3 consecutive months (February-April) the patient received supporting doses of GSSG-Zn₂ in DMSO (0.01-0.3 mg/day, intravenously and intramuscularly, 2 times a week). Patient's condition was quite good; Karnofsky index 90. No pains; good appetite; weight gain — 8 kg.

3 months later (May, 1996), a 3 day course of high-dose chemotherapy together with GSSG-Zn₂ was conducted (total dose of fluoruracil - 10g; GSSG-Zn₂ 0.1-1.0 mg/kg, daily) without complications reported. The patient was discharged in satisfactory condition to be followed up as an out-patient. Treatment with GSSG-Zn₂ was continued for 3 successive months (0.01-0.5 mg/kg IV and IM 2 times a week).

6 months later (September 1996): the third course of high-dose chemotherapy according to the scheme shown above, with no complications. Patient's condition was satisfactory; Karnofsky

index 90. Good appetite; no nausea or vomiting; Weight gain 12 kg from the beginning of the observation. On gastroduodenoscopy — significant decrease in infiltration of duodenal mucosa with signs of stabilizing the neoplastic process.

Thus the following effect of the combination of GSSG-Zn₂ and chemotherapy regimen can be stressed: improvement of the quality of life; resolution of pain; beneficial laboratory changes; stabilization of the neoplasm process; good tolerance of chemotherapy.

Example #25.

Therapeutical effect of GSSG series preparations in patient with severe postoperative complications

10

Diagnosis: Post-intubation scar stenosis of the trachea, tracheoesophageal fistula, post operative empyema of the right pleural cavity.

15

A male 22 year old patient was admitted to the surgical division of the State Scientific Center of Pulmonology of the Ministry of Health of Russia Federation in March 1996 after linear stent of the trachea was placed. After it was removed there was a relapse of the tracheal stenosis and the signs of tracheoesophageal fistula appeared. Due to this in April 1996 the operation was performed: circular resection of the trachea, closure of the TE fistula, omentoplastics.

20

During the postoperative period right-sided pleural empyema developed. Despite massive antibiotic therapy, detoxification and pleural cavity drainage, the patient's state was very severe. The patient was pale, pulse 120/min, rhythmic, BP 90/50 mm Hg, breathing rate 28/min, slightest physical exertion caused dyspnea, t 38.8-39.6°C.

On chest X-ray: increased density of the left lung due to diffuse infiltration (edema). Paracostally in the lateral areas along the rib cage and posteriorly in the interlobular fissures there was a lot of fluid. Enlarged median shadow in the upper region.

25

Significant leukocytosis ($30 \times 10^9/l$), increased neutrophil count, increased ESR (58mm/h), hypertransaminasemia (see Table 41).

Due to the severity of the patient's disease, pulmonary insufficiency and absence of any alternative treatment the decision was made to use compassionate treatment with lithium salt of GSSG (GSSG-Li₂) in a complex therapy.

5 Right after the first injections of GSSG-Li₂ (0.01-0.5 mg/kg per day) there was a certain positive effect - decreased intoxication (decrease of temperature to 37.3C), pulse 88/min, resolved pulmonary insufficiency. That positive effect due to the use of the treatment became stronger after the following injections (0.01-0.5 mg/kg per day, intravenously for 5 days).

After another week of treatment with GSSG-Li₂ (0.01-0.5 mg/kg/day) combined with antibiotics (Claforan 6g/day, Ampicillin plus Oxacillin, 2g/day) the patient's state was satisfactory. No
10 complains; pulse 80/min, BP 115/70 mm Hg, breathing slightly decreased on the right, in all regions.

No local inflammation after thoracotomy. Granulating wound in the site of posterior thoracotomy without secretions. Bronchoscopy showed wide anastomosis without granulation. Chest X-ray - normal.

15 After a month of treatment with GSSG-Li₂ (0.01-0.5 mg/kg every other day IV and IM for 3 weeks) the patient's condition was satisfactory. Blood parameters within normal limits (see Table 41).

Summarized effect: quick regression of the purulent process; potentiation of the effect of antibacterial therapy; beneficial blood changes; detoxification; restoration of laboratory
20 parameters.

Example #26.

Therapeutical effect of GSSG series preparations in patients with multiple sclerosis

We examined and treated 19 patients with cerebrospinal form of Multiple sclerosis (MS) aged 23-
25 52 (Table 42). All patients were admitted to the hospital during exacerbation. Diagnosis was verified according to the recommendations of the International association of MS studies (1992). There was a prevalence of patients with progressive MS with relapses. In 5 patients length of relapse was one month; in 7 - one to three months, in 7 - over three months.

The 90 days' course of treatment was carried out in the following way:

1. GSSG-Na in 10% solution of S-adenosyl-methionine intravenously, once a day for 10 days, daily dose - 0.01-0.5 mg/kg
2. Two weeks' break
- 5 3. GSSG-Zn in 10% solution of S-adenosyl-methionine intravenously, every other day for 20 days, daily dose 0.01-0.5 mg/kg
4. Two weeks' break
5. bis-methionil-GSSG in 5% solution of ascorbic acid (vitamin C) intravenously and intramuscularly, alternating routes of administration (one day each), daily dose 0.01-10 0.5 mg/kg for 30 days.

Patients' investigation was carried out before treatment, one month after the beginning of the treatment, the 3 and 6 months after the beginning of the treatment. CD3+, CD4+, CD8+, CD20+ lymphocyte counts were measured in peripheral blood with immunofluorescent method using monoclonal antibodies; CD4+/CD8+ ratio was counted (Table 43). Cellular immunity was15 assessed with the Reaction of Suppression of Leukocyte Adhesion in the presence of neuro-specific antigens: S-100 protein, neuronal membrane antigens, myelin basic protein (Table 44). 25 blood donors and patients with radiculopathy were used as the control group.

Initial state of the immune system was characterized by decrease total CD3+ count, significant decrease in CD4+ count, increase in CD8+ count, dysbalance between subpopulations of helpers20 and suppressors, increase in CD20+ count.

After the treatment there was an improvement in cellular immunity parameters - normalization of CD3+ count, CD4+ count, and CD8+ (T-suppressors) count. In the same time there was a decrease in sensitization of lymphocytes to one or several of the brain tissue antigens. There also was a phenomenon of immunological inversion of S-100 and myelin basic protein levels (Table25 44).

Restoration of immune system was accompanied by resolution of neurological symptoms in 84% of patients.

Endogenous level of IFN α and γ and TNF was measured in patients' serum and cerebrospinal fluid (CSF) (Table 45). An increase in IFN- α during patients' treatment should be stressed. TNF level correlated with neurological disability, measured by Kurtzke score.

Humoral immunity was assessed by the following parameters: B-lymphocytes were
5 counted by measuring superficial immune globulins in immunofluorescent test, IgA, IgM, IgG level were measured by radical immunodiffusion in gel, circulating immune complexes were precipitated in polyethylenglycole (Table 46). Before treatment all patients had significant increase in circulating immune complexes and IgM, and decrease in IgG. IgG level was significantly lower than in the control group.

10 Neurological condition of all patients during this course of treatment have more or less improved, there was a decrease in motor index of Hauzer, and improvement in quality of life.

While specific embodiments of the invention have been shown and described, many modifications are possible. For example, other ingredients which do not affect the action of
15 GSSG its derivatives and/or both its extenders, and enhancers/modulators may be intermixed with GSSG alone or in combination with its both extenders, and enhancers/modulators for application to the body. The dosage forms can be packaged in kit form along with syringe or applicator of any type. Preferably instructions for application to a specific diseases are included in any kit, including the therapeutic agent. We indicate below preferred applications of GSSG or/and its
20 derivatives with or without both extenders, and enhancers/modulators in doses from 0.01 to 0.5 mg of GSSG base per kg of body weight for GSSG and its salts (0.01 to 1.0 mg per kg for the GSSG derivatives) for one or more days intravenously, intramuscularly, intralymphatically, epicautaneously, or intracavitary for up to 6 months as has been found effective for the diseases noted below.:

25 A prophylactic, therapeutic use of the methods and therapeutic agents of this invention can be made for immunodeficiency states where individuals have been exposed to radioactive and chemical affliction in cases of accidents such as nuclear disasters.

Where the both various extenders and various enhancers/modulators have been noted, other specific extenders which prolong the half life of the oxidized glutathione, or/and other
30 specific enhancers/modulators altering beneficially GSSG/derivative effects may be used. In some

cases, one or more of the both different extenders and different enhancers/modulators can be used in combination.

While the drug for parenteral use is preferably in solution form, in some cases colloidal suspensions and the like can be used. Similarly, topical application can include the use of pharmaceutically acceptable ointments, creams and other bases such as petrolatum bases which do not interact with the GSSG/derivatives, as well as with both extenders and enhancers/modulators. Such base materials are known in the art (petrolatum, lanolin, spermaceti, with *inter alia* addition of acetylsalicylic acid).

Infectious and Immunopathology Diseases

Note: *all dosage rates given in the following section below are indicated for GSSG and its salts from the account of "GSSG base". Because concept of "GSSG base" is not completely correct for GSSG derivatives, it is appropriate to define that generally the corresponding dosage rates for the derivatives should be within the interval of from the same as for GSSG lower level, up to a level which is two-three fold as much as upper one for GSSG and its salts.*

AIDS: dosage rate - from 5 to 30 mg per day, entire course is of 6 month duration, with 2 week break after each month;

- the administration regimen during the first week - a single injection daily, alternating regimen: one day - intravenous injection, every other day - intramuscular injection;

- during the second week - twice a day: one time intravenously (in the morning), other time intramuscularly (in the evening);

- the third and the forth weeks - three times a week: 1st time - intravenous injection, 2nd and 3rd time - intramuscular injection;

In case of encephalopathy it is recommended lumbar injections of the medicine once a week during three weeks.

Hepatitis: dosage rate - from 5 to 10 mg per day, entire course is from 1 to 2 months;

- during the first three weeks - a single injection daily, alternating regimen: one day - intravenous injection, every other day - intramuscular injection;

- afterwards: - two or three injections per a week, 1st time - intravenous injection. 2nd and 3rd time

- intramuscular injection;

Herpes: the medicine administration course is the same as in hepatitis.

Tuberculosis: Inactive phase: dosage rate - from 5 to 10 mg per day, entire course is of 6 months, with 2 week break after each month and 1 month break after the 3 months of the medicine administration.

- during the first three weeks - a single injection daily, alternating regimen: one day - intravenous injection, every other day - intramuscular injection;
- during the forth week - two or three injections per a week, 1st time - intravenous injection, 2nd and 3rd time - intramuscular injection;

Active phase: dosage rate - from 5 to 10 mg per day, entire course is of 6 months, the administration regimen in an active phase is the same as in inactive phase.

- 10 Meningitis: dosage rate - from 5 to 90 mg per day, entire course is of 2 months;

- during the first two weeks - twice a day: one time intravenously (in the morning), other time intramuscularly (in the evening);
- afterwards: - two or three injections per a week, 1st time - intravenous injection, 2nd and 3rd time - intramuscular injection;

- 15 Lumbar injections of the medicine - a single injection daily is recommended during three days.

Peritonitis: the medicine administration course is the same as in meningitis (except for lumbar injections).

Sepsis: dosage rate - from 5 to 60 mg per day, entire course is no less than 1 months up to full normalization of clinical state and blood data;

- 20 - during the first two or tree weeks - twice a day: one time intravenously (in the morning), other time intramuscularly (in the evening);
- - afterwards: - two or three injections per a week, 1st time - intravenous injection, 2nd and 3rd time - intramuscular injection;

- 25 Purulent post-operative infectious complications - the medicine administration course is the same as in sepsis.

Immunodepression: dosage rate - from 5 to 20 mg per day, entire course is of 6 months, with 2 week break after each month;

- during the first three weeks - a single injection daily, alternating regimen: one day - intravenous injection, every other day - intramuscular injection;
- 30 - during the forth week - two or three injections per a week, 1st time - intravenous injection, 2nd and 3rd time - intramuscular injection;

Immunodeficiencies of infectious, radiation, or toxic origin: dosage rate is from 5 to 30 mg per day; the medicine administration course is the same as in immunodepression.

Multiple sclerosis: dosage rate is from 5 to 20 mg per day, entire course is of 3 months with 2 week break after each month, and after 6 month break - the repeating of entire course;

- 5 - the 1st month of the entire course: a single injection daily, alternating regimen: one day - intravenous injection, every other day - intramuscular injection;
- the 2nd month of the entire course: three injections per a week, 1st time - intravenous injection, 2nd and 3rd time - intramuscular injection;
- the 3rd month of the entire course: two intramuscular injections per a week, with dosage rate
- 10 from 5 to 10 mg.

Neurodegenerative diseases: the medicine administration course is the same as in multiple sclerosis.

Alzheimer's sclerosis: the medicine administration course is the same as in multiple sclerosis.

- 15 Amyotrophic lateral sclerosis: the medicine administration course is the same as in multiple sclerosis.

Glomerulonephritis: dosage rate is from 5 to 30 mg per day, entire course is from 1 to 3 months with 2 week break after each month;

- during the first two weeks - a single injection daily, alternating regimen: one day - intravenous
- 20 injection, every other day - intramuscular injection;
- afterwards: - two or three injections per a week, 1st time - intravenous injection, 2nd and 3rd time - intramuscular injection;

Collagenoses: - the medicine administration course is the same as in glomerulonephritis.

- Rheumatoid arthritis: - the medicine administration course is the same as in
- 25 Glomerulonephritis.

Systemic lupus erythematosus: - the medicine administration course is the same as in Glomerulonephritis.

- Allergic diseases: - the medicine administration course is the same as in
- Glomerulonephritis, along with the topical application of ointment (1-3% containing the active
- 30 compound) - during 2 weeks, a single application per day, afterwards: - two applications per a week.

Psoriasis: - the medicine administration course is the same as in Glomerulonephritis, along with the topical application of ointment (1-3% containing of the active compound) - during 2 weeks, a single application per day, afterwards: - two applications per a week.

Neoplasms: dosage rate is from 5 to 90 mg per day, entire course is from 1 to 6 months
5 with 2-4 week break after each month;

- a single injection daily, alternating regimen: one day - intravenous injection, every other day - intramuscular injection, without or along with endolymphatic application (dosage rate - from 30-90 mg per day) during 10 days, and local application (regional perfusion) by catheterization (dosage rate - from 30-90 mg per day) during 7 days, three or four applications per week;

10 - the treatment scheme is recommended along with polychemiotherapeutic treatment.

Metastatic processes and hemoblastoses: dosage rate is from 5 to 90 mg per day, entire course is from 1 to 6 months with 2-4 week break after each month;

- a single injection daily, alternating regimen: one day - intravenous injection, every other day - intramuscular injection, along with local application (regional perfusion) by catheterization
15 (dosage rate - from 30-90 mg per day) during 7 days, three or four applications per week.

Lympho proliferative diseases (Lymphogranulomatosis and Lymphoma): dosage rate is from 5 to 90 mg per day, entire course is from 1 to 6 months with 2-4 week break after each month;

- during the first three weeks - a single injection daily, alternating regimen: one day - intravenous
20 injection, every other day - intramuscular injection, along with endolymphatic application (dosage rate - from 30-90 mg per day) during first 10 days;

- afterwards: - the same treatment scheme in combination with glucocorticoides and cytostatics.

Source of literature:

- 25 1. Holmlund J. T. Cytokines. Cancer Chemother Biol Response Modif. 1993. 14P 150-206.
2. Hansson M., Soderstrom T. The colony stimulating factors Med Oncol Tumor Pharmacother. 1993. 10(1-2). P 5-12.
3. Dillman R. O. The clinical experience with interleukin-2 in cancer therapy. Cancer Biother. 1994 Fall. 9(3). P 183-209.
- 30 4. ¹ Whittington R., Faulds D. Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs. 1993 Sep. 46(3). P 446-514.

5. ¹ Hieber U., Heim M. E. Tumor necrosis factor for the treatment of malignancies. *Oncology*. 1994 Mar-Apr. 51(2). P 142-53.
6. Morstyn G., Sheridan W. P. Hematopoietic growth factors in cancer chemotherapy. *Cancer Chemother Biol Response Modif*. 1993. 14P 353-70.
- 5 7. Neidhart J. A. Hematopoietic cytokines. Current use in cancer therapy. *Cancer*. 1993 Dec 1. 72(11 Suppl). P 3381-6.
8. Murray H. W. Interferon-gamma and host antimicrobial defense: current and future clinical applications. *Am J Med*. 1994 Nov. 97(5). P 459-67.
9. Cirelli R., Tyring S. K. Interferons in human papillomavirus infections. *Antiviral Res*. 1994 Jul. 24(2-3). P 191-204.
- 10 10. Sher A., Coffman R. L. Regulation of immunity to parasites by T-cells and T-cell derived cytokines. *Annu. Rev. Immunol.*, 1992, 10, P. 385-409.
11. Gillan E., Plunkett M., Cairo M. S. Colony-stimulating factors in the modulation of sepsis. *N Engl J Med*. 1993 Feb. 1(1). P 96-109.
- 15 12. Nelson S. Role of granulocyte colony-stimulating factor in the immune response to acute bacterial infection in the nonneutropenic host: an overview. *Clin Infect Dis*. 1994 Feb. 18 Suppl 2P S197-204.
13. Offenstadt G., Guidet B., Staikowsky F. Cytokines and severe infections. *Pathol Biol (Paris)*. 1993 Oct. 41(8 Pt 2). P 820-31.
14. Nemunaitis J. Use of hematopoietic growth factors in marrow transplantation. *Curr Opin Oncol*. 1994 Mar. 6(2). P 139-45.
- 20 15. Mittelman M., Lessin L. S. Clinical application of recombinant erythropoietin in myelodysplasia. *Hematol Oncol Clin North Am*. 1994 Oct. 8(5). P 993-1009.
16. Forman A. D. Neurologic complications of cytokine therapy. *Oncology (Huntingt)*. 1994 Apr. 8(4). P 105-110; discussion 113, 116-7.
- 25 17. Hack C. E., Ogilvie A. C., Eisele B., Eerenberg A. J., Wagstaff J., Thijs L. G. C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2. *Intensive Care Med*. 1993. 19 Suppl 1P S19-28.
18. Hieber U., Heim M. E. Tumor necrosis factor for the treatment of malignancies. *Oncology*. 1994 Mar-Apr. 51(2). P 142-53.
- 30 19. Saito M. OK-432, a killed streptococcal preparation, in the treatment of animal and human cancer and its mechanisms of action. *Forum on Immunomodulators*. Ed. Guenounou M. John Libbey Eurotext, Paris, 1995, P. 1-11.
20. Barot-Ciorbaru R., Bona C. Immunomodulators from *Nocardia opaca*. *Forum on Immunomodulators*. Ed. Guenounou M. John Libbey Eurotext, Paris, 1995, P. 1-11.

21. Bloy C., Morales M., Guenounou M. RU 41740 (Biostim), an immunomodulating agent from bacterial origin. Ed. Guenounou M. John Libbey Eurotext, Paris, 1995, P. 1-11.
22. Meister A. Anderson M.E. Glutathione. *Annu. Rev. Biochem.*, 1983, 52:711-60.
23. Beutler E. Nutritional and metabolic aspects of glutathione. *Review. Annu. Rev. Nutr.*, 1989, 9:287.
- 5 24. Textbook of biochemistry: with clinical correlations. Ed. Devlin T.M., 3rd ed. 1992, Wiley-Liss, Inc., NY. p. 522-525.
25. Kehrer J.P., Lund L.G. Cellular reducing equivalents and oxidative stress. *Free Radic Biol Med.* 1994 Jul. 17(1). P 65-75.
26. Michiels C., Raes M., Toussaint O., Remacle J. Importance of S-glutathione peroxidase, catalase, and
10 Cu/Zn-SOD for cell survival against oxidative stress. *Free Radic Biol Med.* 1994 Sep. 17(3). P 235-48.
27. Cohen G. Enzymatic and nonenzymatic sources of oxyradicals and regulation of antioxidant defenses. *Ann N Y Acad Sci.* 1994 Nov 17, 738. P 8-14.
28. Beckett G.J., Hayes J.D. Glutathione S-transferase: biomedical applications. *Advan. Clin. Chem.* 1993, vol. 30, P. 281-380.
- 15 29. Composition and method for disease treatment. PCT/US/92/04653.
30. Droge W., Schulze-Osthoff K., Mihm S., Galter D., Schenk H., Eck H. P., Roth S., Gmunder H. Functions of glutathione and glutathione disulfide in immunology and immunopathology. *FASEB J.* 1994 Nov. 8(14). P 1131-8.
31. Sardesai V., M. Role of antioxidants in health maintenance. *Nutr Clin Pract.* 1995 Feb. 10(1). P 19-25.
- 20 32. Giugliano D., Ceriello A., Paolisso G. Diabetes mellitus, hypertension, and cardiovascular disease: which role for oxidative stress? *Metabolism.* 1995 Mar. 44(3). P 363-8.
33. Keusch G. T. Antioxidants in infection. *Nutr Sci Vitaminol (Tokyo).* 1993. 39 Suppl P S23-33.
34. Dipeptide compound having pharmaceutical activity and compositions containing them. US Patent 4,761,399.
- 25 35. γ -L-Glutamyl-L-cysteine ethyl ester and pharmaceutical compositions containing the same as an effective ingredient. US Patent 4,927,808.
36. Therapeutic agents for ischemic heart diseases. US Patent 4,968,671.
37. Method for insuring adequate intracellular glutathione in tissue. EP 0 502 313 A2.
38. Composition and method for disease treatment. PCT/US/92/04653.
- 30 39. Glutathione as a hemoprotective agent. PCT/EP/93/01494.
40. Pharmaceutical compositions having antineoplastic activity. US Patent 4,871,528.

41. Sokolovsky M., Wilchek M., Patchornik A. On the synthesis of cysteine peptides. J. Amer. Chem. Soc. 1964, Mar. 86(6), P 1202-6.

What is claimed is:

CLAIMS

1. A method of stimulating endogenous production of cytokines and hemopoietic
5 factors comprising introducing to a mammalian body in need of stimulation of cytokines or hemopoietic factors or both, an effective amount of an oxidized glutathione form selected from the group consisting of oxidized glutathione, a pharmaceutically acceptable oxidized glutathione salt, a pharmaceutically acceptable glutathione derivative or mixtures thereof, for a period of time to stimulate said endogenous production to obtain a therapeutic effect.
- 10 2. A method in accordance with the method of claim 1, wherein said glutathione form is introduced parenterally.
3. A method in accordance with the method of claim 1, wherein said glutathione form is introduced topically.
4. A method in accordance with the method of claim 1, wherein said glutathione
15 form is introduced along with an extender of the half life of said oxidized glutathione and/or its pharmaceutically acceptable salt form, and/or its pharmaceutically acceptable derivative.
5. A method in accordance with the method of claim 1, wherein said glutathione form is introduced along with an enhancer/beneficial modulator of the biological or therapeutical effects of said glutathione form.
- 20 6. A method in accordance with the method of claim 4, wherein said extender is selected from the group consisting of pro-oxidant compounds, agents capable of forming weak ionic or coordinating links stabilizing the oxidized glutathione molecule, materials which are competitors of reduced form of nicotinamide adenine dinucleotide phosphate -dependent reduction of oxidized glutathione into reduced glutathione catalyzed by glutathione reductase, compounds
25 capable of producing reversible inhibition of reduction of oxidized form of nicotinamide adenine dinucleotide phosphate into reduced form of nicotinamide adenine dinucleotide phosphate catalyzed by glucose-6-phosphate-dehydrogenase or by other reduced form of nicotinamide adenine dinucleotide phosphate-dependent enzymes, or mixtures thereof.
7. A method in accordance with the method of claim 6, wherein said extender is
30 peroxide.
8. A method in accordance with the method of claim 6, wherein said extender is ascorbic acid.

9. A method in accordance with the method of claim 9, wherein said extender is dimethylsulfoxide.
10. A method in accordance with the method of claim 6, wherein said extender is inosine
- 5 11. A method in accordance with the method of claim 6, wherein said cystamine.
12. A method in accordance with the method of claim 5, wherein said enhancer/beneficial modulator is selected from the group consisting of methyl moiety donors, and representatives of intracellular redox-oxidative pairs, or mixtures thereof.
- 10 13. A method in accordance with the method of claim 12, wherein said enhancer/beneficial modulator is choline-chloride.
14. A method in accordance with the method of claim 12, wherein said enhancer/beneficial modulator is S-adenosyl-methionine.
- 15 15. A method in accordance with the method of claim 12, wherein said enhancer/beneficial modulator is lipoic acid.
16. A method in accordance with the method of claim 12, wherein said enhancer/beneficial modulator is folic acid.
17. A method in accordance with the method of claim 2, wherein said glutathione form is introduced at a dose of from 0.01 to 0.5 mg of oxidized glutathione base per kilogram of body weight for oxidized glutathione base and oxidized glutathione salts (from 0.01 to 1.0 mg per
- 20 kg for oxidized glutathione derivatives) at least one time each 24 hour period until said desired therapeutic effect is obtained.
18. A method in accordance with the method of claim 17, wherein said glutathione form is introduced parenterally in a pharmaceutically acceptable solution at a concentration of from 0.01 to 2.0% by weight of oxidized glutathione base for oxidized glutathione base and
- 25 oxidized glutathione salts (from 0.01 to 4.0% by weight for oxidized glutathione derivatives).
19. A method in accordance with the method of claim 18, wherein said solution further includes, or is administered in a combination with an extender selected from the group consisting of 0.03% to 0.0003% (w/v) hydrogen peroxide, 0.1% to 10%(w/v) ascorbic acid, 0.1% to 30% (v/v) dimethylsulfoxide, 0.1% to 5% (w/v) inosine, 0.1% to 3% (w/v) cystamine, or
- 30 mixtures thereof.
20. A method in accordance with the method of claim 1, wherein said mammalian body is in need of stimulation of cytokine or hemopoietic factor production to treat a condition

selected from the group consisting of neoplastic, infectious, hematologic, immunologic (ischemic, diastrophic, degenerative) and other diseases.

21. A method in accordance with the method of claim 20, wherein said disease is infectious.

5 22. A method in accordance with the method of claim 20, wherein said disease is hematologic.

23. A method in accordance with the method of claim 20, wherein said disease is immunologic.

10 24. A method in accordance with the method of claim 20, wherein said disease is neoplastic.

25. A method in accordance with the method of claim 20, wherein said disease is selected from the group consisting of AIDS, hepatitis, herpes, tuberculosis, meningitis, peritonitis, sepsis, and purulent post-operative complications caused by infection.

15 26. A method in accordance with the method of claim 20, wherein said disease is selected from a group consisting of immunodepression, multiple sclerosis, alzheimer sclerosis, neurodegenerative diseases, amyotrophic lateral sclerosis, glomerulonephritis, collagenosis, rheumatoid arthritis, lupus, psoriasis, diabetes mellitus and allergic disease.

20 27. A method in accordance with the method of claim 20, wherein said disease is selected from the group consisting of metastatic spreading, hemoblastosis, malignant tumors, lymphogranulomatous and lymphomas, immunodeficiency caused by radioactive or chemical affliction.

28. A method in accordance with the method of claim 1, 2, 3, 4, or 5 wherein said oxidized glutathione is in a salt form.

25 29. A method in accordance with the method of claim 1, wherein said salt is the disodium salt.

30 30. A method in accordance with the method of claim 1, wherein said salt is the dilithium salt.

31. A method in accordance with the method of claim 1, wherein said salt contain one or more atoms of potassium.

32. A method in accordance with the method of claim 1, wherein said salt contain one or more atoms of calcium.

33. A method in accordance with the method of claim 1, wherein said salt contain one or more atoms of zinc.

34. A method in accordance with the method of claim 1, wherein said salt contain one or more atoms of molybdenum.

5 35. A method in accordance with the method of claim 1, wherein said salt contain one or more atoms of vanadium.

36. A method in accordance with the method of claim 1, wherein said salt contain one or more atoms of fluoride.

10 37. A method in accordance with the method of claim 1, 2, 3, 4 or 5 wherein a pharmaceutically acceptable derivative of oxidized glutathione is introduced to a mammalian body in need of stimulation of cytokines or hemopoietic factors or both.

38. A method in accordance with the method of claim 1, wherein said oxidized glutathione derivative is oxidized glutathione is covalently bound to cysteamine (S-thioethylamine-glutathione disulfide).

15 39. A method in accordance with the method of claim 1, wherein said oxidized glutathione derivative is oxidized glutathione is covalently bound to lipoic acid (bis-[6,8-thiooktanil]•glutathione disulfide).

20 40. A method in accordance with the method of claim 1, wherein said oxidized glutathione derivative is oxidized glutathione is covalently bound to a member of the group consisting of carnosine ([b-alanyl-hystidil]•glutathione disulfide) and adenosine ([9-β-D-ribofuranosyladenil]•glutathione disulfide).

41. A method in accordance with the method of claim 1, wherein said oxidized glutathione derivative is oxidized glutathione is covalently bound to methionine (bis-[2-amino-4-[methylthio]butanoil]•glutathione disulfide).

25 42. A therapeutic agent for treating neoplastic, infectious, hematologic, immunologic and other diseases in which stimulation of the endogenous cytokine and hemopoietic factor

production is considered beneficial, said therapeutic agent comprising an effective amount of oxidized glutathione, and/or a pharmaceutically acceptable salt, and/or a pharmaceutically acceptable derivative, said oxidized glutathione, a tripeptide, γ -glutamyl-cysteinyl-glycine, where two molecules of the tripeptide are linked via covalent disulfide bond between the cysteine
5 residues, as an active substance, along with a pharmaceutically acceptable excipient.

43. The therapeutic agent of claim 42, wherein said substance is formulated in the form of a sterile injectable solution of oxidized glutathione, and/or a pharmaceutically acceptable salt, and/or a pharmaceutically acceptable derivative, in pharmaceutically acceptable solvent.

44. A therapeutic agent of claim 43, in a combination with a pharmaceutically
10 acceptable extender capable of enhancing and prolonging a therapeutic effect of said agent by increasing the half-life of oxidized glutathione.

45. A therapeutic agent in accordance with claim 44, wherein said extender is hydrogen peroxide.

46. A therapeutic agent in accordance with claim 44, wherein said extender is ascorbic
15 acid.

47. A method in accordance with the method of claim 44, wherein said extender is dimethyl sulfoxide.

48. A therapeutic agent in accordance with claim 44, wherein said extender is inosine.

49. A therapeutic agent in accordance with claim 44, wherein said extender is
20 cystamine.

50. A therapeutic agent of claim 43, in a combination with a pharmaceutically acceptable enhancer/beneficial modulator capable of enhancing and/or altering beneficially a therapeutic effect of said agent by mechanisms other than increasing the half-life of oxidized glutathione.

25 51. A therapeutic agent in accordance with claim 50, wherein said enhancer/beneficial modifier is choline-chloride.

52. A therapeutic agent in accordance with claim 50, wherein said enhancer/beneficial modifier is S-adenosyl-methionine.

53. A therapeutic agent in accordance with claim 50, wherein said enhancer/beneficial
30 modifier is lipoic acid.

54. A therapeutic agent in accordance with claim 50, wherein said enhancer/beneficial modifier is folic acid.

55. A method of enhancing and prolonging the ability of oxidized glutathione, and/or its pharmaceutically acceptable salt, and/or its pharmaceutically acceptable derivative to stimulate endogenous production of cytokine and hemopoietic factor wherein oxidized glutathione, and/or its pharmaceutically acceptable salt, and/or its pharmaceutically acceptable derivative is either used
5 in a pharmaceutical composition containing at least one additional pharmaceutically acceptable components, or administered in combination with such component, said method comprising obtaining a solution of oxidized glutathione, and/or its pharmaceutically acceptable salt, and/or its pharmaceutically acceptable derivative, and intermixing therewith an extender, said extender being selected from the group consisting of a donor of reactive oxygen intermediates, agent
10 capable of forming weak ionic and/or coordinating links stabilizing the oxidized glutathione molecule, hypoxanthine derivatives, a reversible inhibitor of pentose phosphate pathway of glucose oxidation, or mixtures thereof.

56. A method in accordance with the method of claim 55, wherein said extender is hydrogen peroxide.

15 57. A method in accordance with the method of claim 55, wherein said extender is ascorbic acid.

58. A method in accordance with the method of claim 55, wherein said extender is dimethyl sulfoxide.

59. A method in accordance with the method of claim 55, wherein said extender is
20 inosine.

60. A method in accordance with the method of claim 55, wherein said extender is cystamine.

61. A method of enhancing and/or beneficially modulating the ability of oxidized glutathione and/or its pharmaceutically acceptable salt, and/or its pharmaceutically acceptable
25 derivative to stimulate endogenous production of cytokine and hemopoietic factor wherein oxidized glutathione and/or its pharmaceutically acceptable salt, and/or its pharmaceutically acceptable derivative is either used in a pharmaceutical composition containing at least one additional pharmaceutically acceptable component other than that prolonging the half-life of oxidized glutathione or administered in combination with such component, said method
30 comprising obtaining a solution of oxidized glutathione and/or its pharmaceutically acceptable salt, and/or its pharmaceutically acceptable derivative and intermixing therewith or administration in a combination with an enhancer/beneficial modulator, said enhancer/beneficial modulator being

selected from the group consisting of a methyl moiety donator, representative of intracellular redox-oxidative pairs, or mixtures thereof.

62. A method in accordance with the method of claim 61, wherein said extender/beneficial modifier is choline-chloride.

5 63. A method in accordance with the method of claim 61, wherein said extender/beneficial modifier is S-adenosilmethionine.

64. A method in accordance with the method of claim 61, wherein said extender/beneficial modifier is lipoic acid.

65. A method in accordance with the method of claim 61, wherein said
10 extender/beneficial modifier is folic acid.

66. A method of utilizing oxidized glutathione and/or its pharmaceutically acceptable salt, and/or its pharmaceutically acceptable derivative, said oxidized glutathione being a dimer of reduced glutathione, a tripeptide with structure γ -glutamyl-cysteinyl-glycine, where two molecules of the tripeptide are linked via covalent disulfide bond between the cystein residues, as
15 a stimulator of endogenous production of cytokine and/or hemopoietic factors for preparation of pharmaceutical drugs for treating neoplastic, infectious, hematologic, immunologic and other diseases in which stimulation of the endogenous cytokine and/or hemopoietic factor production is considered beneficial.

67. A method of stimulating production of cytokine and hemopoietic factors
20 comprising introducing to mammalian cells in need of stimulation of cytokine or hemopoietic factors or both, an effective amount of oxidized glutathione and/or a pharmaceutically acceptable salt, and/or a pharmaceutically acceptable derivative, for a period of time to stimulate said endogenous production to obtain a therapeutic effect.

68. A method in accordance with the method of claim 67, wherein said cells are in a
25 mammalian body and said oxidized glutathione and/or its pharmaceutically acceptable salt, and/or its pharmaceutically acceptable derivative is introduced into said body at a rate of from 0.01 to 0.5 mg of oxidized glutathione base per kg of body weight for oxidized glutathione base and oxidized glutathione salts (with 0.01 to 1.0 mg/kg for oxidized glutathione derivatives), at least one time a day for at least one day.

69. A method in accordance with the method of claim 68, wherein said drug is
30 introduced into said body in an injectable solution form, wherein said oxidized glutathione and/or a pharmaceutically acceptable salt, and/or a pharmaceutically acceptable derivative is present in

such solution at a concentration of from 0.01 to 2.0% of oxidized glutathione base by weight for oxidized glutathione base and oxidized glutathione salts (with 0.01 to 4.0% for oxidized glutathione derivatives).

70. A method in accordance with the method of claim 69, wherein said injectable drug
5 solution comprises an extender selected from the group consisting of hydrogen peroxide, ascorbic acid, dimethyl sulfoxide, inosine, and cystamine; or such an extender is administered separately.

71. A method in accordance with the method of claim 69, wherein said injectable drug
solution comprises an enhancer/beneficial modulator selected from the group consisting of
choline-chloride, S-adenosilmethionine, lipoic or folic acid; or such an enhancer/beneficial
10 modulator is administered separately.


72. A method in accordance with the method of claim 67, wherein said cells are in a
mammalian body and said oxidized glutathione or/and its pharmaceutically acceptable salt, and/or
its pharmaceutically acceptable derivative is introduced topically to a topical area at a dose of
from 0.01 to 0.5 mg of oxidized glutathione base per square meter of topical area for oxidized
15 glutathione base and its salts (with 0.01 to 1.0 mg per square meter for oxidized glutathione
derivatives)

Figure 1a


Cytofluorimetry analysis of
cells HL-60

**Figure 1b**


Cytofluorimetry analysis of
cells HL-60 in the presence
of the preparation

**Figure 1c**

Cytofluorimetry analysis of
human lymphocytes


**Figure 1d**

Cytofluorimetry analysis of
human lymphocytes in the
presence of the preparation




**Research of apoptosis-induced preparation activity in cultivated
mammal cells.**

Fiugre 1




Glutathione oxidized-Glutathione disulfide (GSSG)


Figure 2.




S-Thioethylamine-GSSG




Bis(Lipoil)-GSSG
bis-[DL-6,8,thioctic acid]-glutathione disulfide



Karnosil-GSSG
 β -alanyl-L-histidyl-L-glutathione disulfide



Adenosil-GSSG
[9-β-D-ribofuranosyladenil]-glutathione disulfide



Bis(Methionyl)-GSSG
bis-[L-2-amino-4-[methylthio]butanoic acid γ-glutathione disulfide

Figure 7.

Table 1. GSSG effect on *in vitro* cytokine production by human mononuclear leukocytes. (M±m)

GSSG (μg/mL)	Cytokine production (pg/mL)			
	IL-1β	IL-6	TNFα	IFNα
5000	259±36.8*	2518±264*	1900±206*	511±64.1*
500	275±39.3*	2113±132*	1525±163*	514±56.2*
50	202±24.9*	1910±205*	813±90.8*	407±51.4*
5.0	88.5±13.5*	550±61.3*	314±44.7*	109±12.1
0.5	56.0±9.1	430±55.6	99.1±11.6	130±14.9
Control (RPMI)	46.0±6.8	129±12.4	88.7±9.3	98.3±14.0

(*) — differences are statistically significant ($p < 0.01$) as compared to the control.

Table 2. Effect of GSSG in combination with 0.003% hydrogen peroxide on *in vitro* cytokine production by human mononuclear leukocytes. (M±m)

GSSG (μg/mL)	Cytokine production (pg/mL)			
	IL-1β	IL-6	TNFα	IFNα
5000	720±81.3*	4035±518*	2640±355*	849±102*
500	650±67.1*	4007±419*	2100±294*	905±141*
50	511±55.1*	3859±425*	1308±164*	468±69.3*
5.0	212±31.7*	1680±207*	502±86.4	160±37.0
0.5	63.0±7.8	851±111	318±47.8	98.3±18.7
Control (RPMI+0.003% H ₂ O ₂)	51.0±7.4	970±140	410±57.0	125±20.8

(*) — differences are statistically significant ($p < 0.01$) as compared to the control.

Table 3. Effect of GSSG in combination with 0.1% inosine on *in vitro* cytokine production by human mononuclear leukocytes. (M±m)

GSSG (μg/ml)	Cytokine production (pg/mL)			
	IL-1β	IL-6	TNFα	IFNα
5000	665±73,5*	5720±498*	5900±317*	1010*±160,5*
500	790±68,85*	3840±352*	4520±*366	1318±152*
50	416±44,0*	4910±205*	1869±90,8*	311±51,4*
5.0	205,8±18,3*	2680±196*	765±67,1*	117±10,4*
0.5	183±20,0*	1505±138*	597±48,6*	66,3±7,8*
Control (RPMI+0.003% H ₂ O ₂)	60,9±5,59*	131±11,7*	83,5±9,6*	89,5±10,0*

(*) — differences are statistically significant ($p < 0.01$) as compared to the control.

Table 4. Effect of GSSG in combination with 0.1% cystamine on *in vitro* cytokine production by human mononuclear leukocytes. (M±m)

GSSG (μg/ml)	Cytokine production (pg/mL)			
	IL-1β	IL-6	TNFα	IFNα
5000	810±75,36*	4910±503*	5140±466*	1060±799*
500	540±60,03*	4000±307*	3800±307*	780±180,3*
50	490±45,5*	3800±3183*	2600±183	460±39*
5.0	316±30,5*	2610±207*	1408±101*	100±17,7*
0.5	155±9,7*	10±110*	709±67,3*	107,6±8,13*
Control (RPMI + 0,1% cystamine)	60,8±6,55*	65,4±77,0*	377±28,9*	114±10,01*

(*) — differences are statistically significant ($p < 0.01$) as compared to the control.

Table 5. Effect of the test articles on IL-2 and GM-CSF production by splenocytes, bone marrow and blood cellular indices, and immune response to SRBC in cyclophosphamide treated mice. (M \pm m)

Parameter	n	Intact animals	Cyclophosphamide-treated animals			
		Normal saline	Normal saline	GSH	GSSG	GSSGO + H ₂ O ₂
IL-2 production by splenocytes, (U/mL)	10	39.7 \pm 5.4	11.1 \pm 3.0*	17.2 \pm 3.5*	28.1 \pm 3.9* [Ⓢ]	34.7 \pm 5.1* [Ⓢ]
GM-CSF production by splenocytes, (colonies /10 ⁵ cells)	10	180.0 \pm 14.2	34.3 \pm 9.1*	58.2 \pm 7.2*	129.1 \pm 13.4* [Ⓢ]	170.1 \pm 16.9* [Ⓢ]
Blood leukocyte count, 10 ⁹ /L	10	11.9 \pm 1.81	4.7 \pm 1.25*	5.2 \pm 1.36*	8.5 \pm 0.81* [Ⓢ]	9.4 \pm 1.40* [Ⓢ]
Blood lymphocyte count, 10 ⁹ /L	10	7.4 \pm 0.85	3.1 \pm 0.56*	4.3 \pm 1.13*	6.2 \pm 1.28* [Ⓢ]	6.8 \pm 1.04* [Ⓢ]
Bone marrow nucleated cell number, 10 ⁶ /L	10	53.7 \pm 8.7	23.8 \pm 5.0*	32.2 \pm 4.4*	45.4 \pm 3.9* [Ⓢ]	52.3 \pm 4.7* [Ⓢ]
SRBC agglutinin titer (log ₂)	5	5.33 \pm 0.74	1.47 \pm 0.35*	1.94 \pm 0.34*	3.68 \pm 0.59* [Ⓢ]	4.12 \pm 0.37* [Ⓢ]

Differences are statistically significant ($p < 0.05$) as compared:

(*) — to the group of intact animals; (*) — to the control group (CP + normal saline);
 (Ⓢ) — to the group of animals treated with GSH.

Table 6. Effect of GSSG in combination with 0.1% inosine on IL-2 and GM-CSF production by splenocytes, bone marrow and blood cellular indices, and immune response to SRBC in cyclophosphamide treated mice. (M±m)

Parameter	n	Intact animals	Cyclophosphamide-treated animals			
		Normal saline	Normal saline	GSH	GSSG	GSSG + 0,1% inosine
IL-2 production by splenocytes, (U/mL)	10	34,4±4,2	9,2±1,9*	15,3±2,7*	29,8±3,158 [Ⓜ]	39,7±4,8 ^{Ⓜ*}
GM-CSF production by splenocytes, (colonies /10 ⁵ cells)	10	168,0±14,9	25,5±4,2*	63,4±7,8*	143±15,06 [Ⓜ]	196,3±16,6 [Ⓜ]
Blood leukocyte count, 10 ⁹ /L	10	123±14	5,03±0,85*	6,3±0,05*	9,5±1,01 ^{Ⓜ*}	10,1±1,36 [Ⓜ]
Blood lymphocyte count, 10 ⁹ /L	10	8,2±0,09	2,8±0,67*	4,6±0,78*	6,7±0,81 [Ⓜ]	7,18±0,74 [Ⓜ]
Bone marrow nucleated cell number, 10 ⁶ /L	10	61,3±8,05	19,7±2,9*	36,4±4,5*	48,99±5,14 [Ⓜ]	69,4±17,7 [Ⓜ]
SRBC agglutinin titer (log ₂)	5	6,03±0,71	1,05±0,28*	1,62±0,27 [*]	4,08±0,58 ^{Ⓜ*}	5,13±0,53 ^{Ⓜ*}

Differences are statistically significant ($p < 0.05$) as compared:

(*) — to the group of intact animals; (Ⓜ) — to the control group (CP + normal saline);

(Ⓜ) — to the group of animals treated with GSH.

Table 7. Effect of GSSG in combination with 0.1% cystamine on IL-2 and GM-CSF production by splenocytes, bone marrow and blood cellular indices, and immune response to SRBC in cyclophosphamide treated mice. ($M \pm m$)

Parameter	n	Intact animals	Cyclophosphamide-treated animals			
		Normal saline	Normal saline	GSH	GSSG	GSSG +0.1% cystamine
IL-2 production by splenocytes, (U/mL)	10	43,5 \pm 4,01	14,0 \pm 2,7*	20,3 \pm 2,6*	30,9 \pm 3,03 ^{#@}	38,8 \pm 4,53 ^{#@}
GM-CSF production by splenocytes, (colonies /10 ⁵ cells)	10	190,5 \pm 18,4	42,0 \pm 5,7*	66,7 \pm 7,8*	137,0 \pm 13,09 ^{#@}	183,7 \pm 17,8 ^{#@}
Blood leukocyte count, 10 ⁹ /L	10	12,3 \pm 1,28	4,95 \pm 0,88*	6,2 \pm 1,06*	7,8 \pm 0,84 ^{#@}	10,5 \pm 1,56*
Blood lymphocyte count, 10 ⁹ /L	10	8,2 \pm 0,72	3,6 \pm 0,63*	5,31 \pm 0,77*	7,2 \pm 0,96 [#]	7,8 \pm 0,84 [#]
Bone marrow nucleated cell number, 10 ⁶ /L	10	61,3 \pm 5,9	28,5 \pm 4,2*	36,4 \pm 4,5*	48,9 \pm 5,14 ^{#@}	56,7 \pm 4,91 ^{#@}
SRBC agglutinin titer (log ₂)	5	6,03 \pm 0,60	1,78 \pm 0,36*	2,09 \pm 0,37*	4,08 \pm 0,57 ^{#*}	4,29 \pm 0,41 ^{#*}

Differences are statistically significant ($p < 0.05$) as compared:

(*) — to the group of intact animals; (*) — to the control group (CP + normal saline);

(@) — to the group of animals treated with GSH.

Table 8. Effect of the test articles on IL-2 and GM-CSF production by splenocytes, bone marrow, spleen and blood cellular indices, and bone marrow and spleen hematopoietic colony formation capability in irradiated mice. (M±m)

Parameter	n	Sham-irradiated animals	Irradiated animals			
		Normal saline	Normal saline	GSH	GSSG	GSSGO + H ₂ O ₂
IL-2 production by splenocytes, (U/mL)	12	41.2±4.4	5.0±0.5*	8.6±1.3*	25.1±4.9* [#] @	37.1±3.4* [#] @
GM-CSF production by splenocytes, (colonies /10 ⁵ cells)	12	120.2±12.4	20.7±8.6*	31.8±3.9*	93.1±11.5* [#] @	106.4±5.2* [#] @
Blood leukocyte count, 10 ⁹ /L	12	12.7±1.3	3.4±0.9*	4.8±0.8*	8.7±1.3* [#] @	10.7±2.0* [#] @
Blood lymphocyte count, 10 ⁹ /L	12	7.9±0.7	2.2±1.3*	3.4±0.6*	5.9±0.8* [#] @	6.9±0.8* [#] @
Spleen nucleated cell number, 10 ⁷ /L	12	9.8±1.5	4.8±1.3*	4.3±1.5*	7.7±1.2* [#] @	8.2±2.0* [#] @
Bone marrow nucleated cell number, 10 ⁶ /L	12	45.1±3.2	14.0±1.0*	17.2±3.5*	33.3±5.2* [#] @	37.0±4.0* [#] @
Bone marrow CFU	12	59.4±3.2	11.6±2.2*	22.1±3.6*	44.3±3.9* [#] @	49.3±3.9* [#] @
Spleen CFU	12	93.2±4.1	40.0±5.4*	56.3±6.8*	88.3±6.8* [#] @	87.6±4.7* [#] @

Differences are statistically significant ($p < 0.05$) as compared:

(*) — to the group of intact animals; (*) — to the control group (CP + normal saline);
 (@) — to the group of animals treated with GSH.

Table 9. Effect of GSSG in combination with 0.1% cystamine on IL-2 and GM-CSF production by splenocytes, bone marrow, spleen and blood cellular indices, and bone marrow and spleen hematopoietic colony formation capability in irradiated mice. ($M \pm m$)

Parameter	n	Sham-irradiated animals	Irradiated animals			
		Normal saline	Normal saline	GSH	GSSG	GSSG+0.1% cystamine
IL-2 production by splenocytes, (U/mL)	12	45,4 \pm 4,2	5,6 \pm 0,71*	9,3 \pm 1,44*	29,3 \pm 3,18**@	40,1 \pm 4,10**@
GM-CSF production by splenocytes, (colonies /10 ⁵ cells)	12	132 \pm 11,8	28,6 \pm 4,5*	34,3 \pm 3,99*	103 \pm 11,6**@	113 \pm 9,07*
Blood leukocyte count, 10 ⁹ /L	12	13,3 \pm 1,08	3,1 \pm 0,9*	5,7 \pm 0,9*	9,3 \pm 4,5**@	11,2 \pm 1,83*
Blood lymphocyte count, 10 ⁹ /L	12	8,6 \pm 0,74	3,38 \pm 0,61*	4,6 \pm 0,70*	6,79 \pm 0,82**@	7,12 \pm 0,899**@
Spleen nucleated cell number, 10 ⁷ /L	12	10,5 \pm 0,97	5,8 \pm 0,9*	6,93 \pm 0,85*	8,9 \pm 1,07**@	10,7 \pm 1,13*
Bone marrow nucleated cell number, 10 ⁶ /L	12	48,3 \pm 3,8	15,1 \pm 1,69*	24,7 \pm 3,0*	39,5 \pm 4,17**@	51,0 \pm 4,81*
Bone marrow CFU	12	61,3 \pm 5,2	16,0 \pm 2,5*	25,6 \pm 3,99*	50,3 \pm 5,14**@	55,7 \pm 5,31*
Spleen CFU	12	104 \pm 9,2	43,5 \pm 5,8*	66,3 \pm 7,07*	94,0 \pm 8,81**@	107 \pm 11,7**@

Differences are statistically significant ($p < 0.05$) as compared:

(*) — to the group of intact animals; (*) — to the control group (CP + normal saline);

@ — to the group of animals treated with GSH.

Table 10. Effect of GSSG in combination with 0.1% inosine on IL-2 and GM-CSF production by splenocytes, bone marrow, spleen and blood cellular indices, and bone marrow and spleen hematopoietic colony formation capability in irradiated mice. (M±m)

Parameter	n	Sham-irradiated animals	Irradiated animals			
		Normal saline	Normal saline	GSH	GSSG	GSSG+0.1% inosine
IL-2 production by splenocytes, (U/mL)	12	45,1±4,3	4,6±0,53*	9,9±1,08*	26,9±3,4**@	44,3±4,71**@
GM-CSF production by splenocytes, (colonies /10 ⁵ cells)	12	132±11,9	21,8±3,7*	35,9±4,15*	116±11,7**@	163±22,1**@
Blood leukocyte count, 10 ⁹ /L	12	12,0±1,4	3,04±0,81*	4,95±0,62*	7,93±0,96**@	10,9±2,04**@
Blood lymphocyte count, 10 ⁹ /L	12	8,15±0,76	1,94±0,51*	4,0±0,58*	6,7±0,83**@	7,8±0,86**@
Spleen nucleated cell number, 10 ⁷ /L	12	9,91±1,3	3,5±0,66*	5,5±0,70*	9,0±1,13**@	10,2±1,5**@
Bone marrow nucleated cell number, 10 ⁶ /L	12	47,3±3,18	13,0±1,8*	22,5±3,08*	39,9±4,5**@	51,7±4,98*
Bone marrow CFU	12	56,2±4,4	9,7±1,3*	25,3±3,7*	48,9±5,13**@	69,0±7,03*
Spleen CFU	12	154±9,45	35,0±5,14*	59,8±6,18*	99,3±10,11**@	167,0±17,3**@

Differences are statistically significant ($p < 0.05$) as compared:

(*) — to the group of intact animals; (*) — to the control group (CP + normal saline);
 (@) — to the group of animals treated with GSH.

□

Table 11. Effect of the test articles on number of normal lymphocytes per well ($\times 10^4$ cells) throughout the 96-hr incubation. ($M \pm m$)

Test articles (solutions)	24 hours	48 hours	72 hours	96 hours
GSSG in normal saline	27 ± 2	$98 \pm 6^*$	176 ± 12	$386 \pm 18^*$
GSSG + 0,003% H_2O_2	25 ± 4	$108 \pm 8^*$	$231 \pm 14^*$	$419 \pm 21^*$
GSSG + 0.1% inosine	28 ± 3	$107 \pm 5^*$	$212 \pm 16^*$	$306 \pm 12^*$
GSSG + 0.1% cystamine	26 ± 3	$93 \pm 5^*$	$186 \pm 10^*$	$263 \pm 14^*$
0,003 % H_2O_2	28 ± 2	73 ± 5	123 ± 8	206 ± 8
0.1% inosine	26 ± 4	78 ± 7	141 ± 12	216 ± 16
0.1% cystamine	30 ± 2	72 ± 4	122 ± 9	196 ± 11
10% fetal calf serum	29 ± 4	74 ± 7	133 ± 18	263 ± 13

* Differences are statistically significant ($p < 0.05$) as compared to 10% fetal calf serum.

Table 12. Effect of the test articles on number of HL-60 cells per well ($\times 10^4$ cells) throughout the 96-hr incubation. ($M \pm m$)

Test articles (solutions)	24 hours	48 hours	72 hours	96 hours
GSSG in normal saline	102 ± 4	$156 \pm 6^*$	$386 \pm 21^*$	$390 \pm 11^*$
GSSG + 0,003% H_2O_2	$96 \pm 6^*$	$132 \pm 4^*$	$286 \pm 18^*$	$306 \pm 18^*$
GSSG + 0.1% inosine	$49 \pm 3^*$	$76 \pm 6^*$	$138 \pm 11^*$	$165 \pm 9^*$
GSSG + 0.1% cystamine	$68 \pm 8^*$	$102 \pm 11^*$	$242 \pm 19^*$	$256 \pm 14^*$
0,003 % H_2O_2	122 ± 6	186 ± 12	488 ± 24	712 ± 22
0.1% inosine	$96 \pm 8^*$	$152 \pm 8^*$	$312 \pm 21^*$	$527 \pm 18^*$
0.1% cystamine	112 ± 10	182 ± 9	465 ± 11	618 ± 19
10% fetal calf serum	119 ± 7	181 ± 13	471 ± 7	752 ± 16

* Differences are statistically significant ($p < 0.05$) as compared to 10% fetal calf serum.

Table 13. Effect of the test articles on the cytokine serum levels, the accumulation of ascitic fluid and the mean survival time of mice inoculated with leukemia L1210 cells ($M \pm m$)

Group of animals	The number of injections	Concentration of factors in serum, (pg/mL);					Accumulation of ascitic fluid (weight gain, %)	Mean survival time
		IL-1	IL-2	IL-6	IFN α	TNF α		
1	2	3	4	5	6	7	8	9
Control animals	0	22.0 \pm 3.15	14.50 \pm 2.56	93.20 \pm 10.58	82.2 \pm 9.05	79.70 \pm 8.15	0.7 \pm 0.1	9.02 \pm 0.19
	3	28.5 \pm 4.01	23.18 \pm 3.11	108.0 \pm 14.12	100.55 \pm 11.34	80.3 \pm 8.81	7.14 \pm 0.9	
	7	13.4 \pm 2.68	17.8 \pm 2.51	136.70* \pm 15.2	140.3 \pm 16.25	196.90 \pm 21.30	25.4 \pm 2.62	
Intact animals	0	20.09 \pm 1.95	13.14 \pm 1.12	84.0 \pm 9.65	108.0 \pm 11.33	77.90 \pm 6.85	0.2 \pm 0.1	35 \pm 0
	3	25.10 \pm 2.31	21.75 \pm 1.44	85.60 \pm 9.01	101.0 \pm 8.72	89.0 \pm 7.13	1.12 \pm 0.3	
	7	21.30 \pm 2.98	21.15 \pm 1.86	84.9 \pm 7.16	90.0 \pm 10.11	116.1 \pm 10.83	4.6 \pm 1.23	
GSSG	0	27.5 \pm 3.60	14.7 \pm 3.13	124.40 \pm 13.7	144.80 \pm 15.34	98.10 \pm 11.54	0.77 \pm 0.16	10.74 \pm 0.51*
	3	57.6 \pm 7.14	57.7 \pm 6.80	301.0 \pm 32.2	508.0* \pm 54.3	397.0* \pm 44.50	4.02* \pm 0.53	
	7	167.5 \pm 18.30	144.5 \pm 17.03	678.1 \pm 74.5	1207.0* \pm 116.3	610.0* \pm 71.9	15.67* \pm 1.70	
GSSG +0.003% H ₂ O ₂	0	19.8 \pm 2.05	14.84 \pm 2.13	108.0 \pm 9.17	119.40 \pm 9.56	78.0 \pm 6.15	0.44 \pm 0.16	11.13 \pm 0.49*
	3	126.0 \pm 13.9	99.0 \pm 11.3	298.1 \pm 24.5	238.0 \pm 18.9	406.1 \pm 35.3	3.17* \pm 0.41	
	7	123.5 \pm 12.7	189.0 \pm 21.4	445.1 \pm 4.14	1413 \pm 129.	818* \pm 73.5	14.04* \pm 1.1	

Differences are statistically significant ($p < 0.05$) as compared to the control group

Table 13. (Continuation).

1	2	3	4	5	6	7	8	9
GSSG + 0.1% inosine	0	25.5±2.86	17.40±1.92	104.±8.15	122.4±10.43	121.9±10.33	0.63±0.16	12.01±0.49*
	3	83.10±9.15	40.8±5.0	512.±48.7	628.±56.4	565.±50.03	1.75±0.25	
	7	238.0±29.56	91.1±11.08	106.±9.14	1650.±148	1904.±186.0	5.69±0.74	
GSSC +0.1% cystamine	0	23.14±2.86	17.0±1.55	102.±8.04	129.0±9.80	101.5±8.16	0.76±0.19	11.96±0.59*
	3	118.0±13.42	59.16±7.55	145.±11.8	761±59.4	357.0±28.3	2.47±0.28	
	7	189.20±21.0	249.±22.7	400.0±32.5	1700.±163.	709.0±59.0	6.85±0.91	
0.003% H ₂ O ₂	0	17.07±1.65	16.18±1.68	120.9±10.7	133.7±10.45	110.±9.13	0.79±0.17	9.7±0.21
	3	38.15±4.11	23.5±3.3	140.±13.3	189.±15.45	158.0±11.97	6.12±0.73	
	7	23.6±3.05	45.5±5.8	103.±9.18	209.±18.30	220.0±24.5	21.61±2.55	
0.1% inosine	0	41.0±4.23	17.80±1.49	108.±9.03	117.3±10.81	104.3±9.17	0.61±0.14	9.61±0.18
	3	55.6±6.17	22.3±2.14	91.0±8.8	160.0±12.47	130.0±10.85	7.02±0.64	
	7	36.40±4.81	14.6±1.53	119.±10.5	205.±21.3	157.0±15.80	26.30±2.57	
0.1% cystamine	0	36.0±3.12	16.9±1.5	63.0±5.0	115.0±10.52	88.6±5.19	0.47±0.18	9.53±0.18
	3	47.50±5.17	17.30±1.46	70.0±12.6	200.±18.0	185.0±16.70	5.93±0.47	
	7	28.0±3.0	22.8±1.90	155.0±13.4	137.0±14.5	213.0±18.54	21.17±2.05	

Differences are statistically significant ($p < 0.05$) as compared to the control group

Table 14. Effect of the test articles on the cytokine serum levels, the accumulation of ascitic fluid and the mean survival time of mice inoculated with leukemia P388 cells ($M \pm m$)

Group of animals	The number of injections	Concentration of factors in serum, (pg/mL);					Accumulation of ascitic fluid (weight gain, %)	Mean survival time
		IL-1	IL-2	IL-6	IFN α	TNF α		
1	2	3	4	5	6	7	8	9
Control animals	0	19.6 \pm 3.85	10.5 \pm 1.59	86.18 \pm 7.13	90.5 \pm 7.76	85.0 \pm 6.15	0.5 \pm 0.07	9,6 \pm 0,22
	3	34.7 \pm 5.42	26.7 \pm 3.18	133.0 \pm 15.2	113.0 \pm 12.0	96.17 \pm 8.2	6.9* \pm 0.52	
	7	10.8 \pm 2.34	20.3 \pm 3.08	156.10* \pm 20,0	158 \pm 10.8	218* \pm 22.03	28.2* \pm 2.9	
Intact animals	0	25.12 \pm 1.76	17.70 \pm 1.84	104.50 \pm 9.94	90.50 \pm 7.19	88.64 \pm 7.14	0.3 \pm 0.2	35* \pm 0
	3	33.0 \pm 3.57	26.8 \pm 3.07	92.80 \pm 8.03	116.0 \pm 10.55	89.0 \pm 7.23	1.62 \pm 0.4	
	7	30.83 \pm 2.15	25.40 \pm 2.17	102.0 \pm 8.89	112.31 \pm 10.86	93.7 \pm 7.64	5.1 \pm 1.08	
GSSG	0	23.5 \pm 4.22	12.8 \pm 1.95	102.0 \pm 12.8	134.1 \pm 9.8	90.03 \pm 8.07	0.48 \pm 0.032	11.0 \pm 0.44*
	3	62.3 \pm 9.15	64.6 \pm 7.13	280.0* \pm 31.2	460.1 \pm 40.8	306.1 \pm 24.4	3.7* \pm 0.32	
	7	147.0 \pm 17.30	128.10 \pm 16.55	624.0* \pm 45.6	1024.1 \pm 97.0	560.1 \pm 48.8	15.2* \pm 0.16	
GSSG +0,003% H ₂ O ₂	0	17.4 \pm 2.4	9.41 \pm 2.02	90.8 \pm 10.10	101.0 \pm 9.88	73.5 \pm 5.17	0.39 \pm 0.11	11.6 \pm 0.53*
	3	109.6 \pm 14.4	104.8 \pm 15.30	314.0 \pm 37.2	255.0 \pm 22.3	355.1* \pm 36.2	2.93* \pm 0.33	
	7	142.6 \pm 16.3	174.0 \pm 20.9	501.0* \pm 48.3	1505 \pm 131.0	890.1* \pm 78.3	13.6* \pm 0.64	

Differences are statistically significant ($p < 0.05$) as compared to the control group

Table 14. (Continuation).

1	2	3	4	5	6	7	8	9
GSSG + 0.1% inosine	0	28.7±3.05	7.13±0.98	129.8±14.0	123.4±10.01	109.0±11.2	0.56±0.16	12.7±0.51*
	3	75.0±8.13	36.4±4.8	618.0*±52.3	693.0*±61.8	517.* ±44.5	1.64*±0.19	
	7	210.4±26.8	84.0±10.03	520.0*±51.0	1810.* ±129.	2120.* ±193.	5.15*±0.59	
GSSC +0.1% cystamine	0	20.8±2.91	16.7±1.88	118.9±12.3	114.6±9.87	95.6±9.1	0.61±0.15	12.5±0.56*
	3	109.2±10.45	37.03±4.15	156.6±11.8	708.0*±61.9	326*±28.7	2.26*±0.17	
	7	168.0±21.15	211.0±25.6	414.0*±18.4	1950*±180.0	785.*±69.0	6.08*±0.77	
0,003% H ₂ O ₂	0	15.5±2.04	14.95±2.16	134.0±15.6	129.±10.0	119.±9.13	0.63±0.15	9.9±0.24
	3	44.7±6.14	22.0±2.81	156.0±16.3	205.8±18.3	144.5±12.8	5.4±0.62	
	7	28.6±4.11	40.8±5.12	110.9±12.5	190.±16.7	248. ±20.7	20.3±2.28	
0.1% inosine	0	36.7±5.12	16.50±1.09	115.0±12.5	81.4±6.13	122.0±10.0	0.58±0.13	9.8±0.21
	3	48.2±7.13	20.19±1.54	90.0±7.11	105. ±11.3	96.5±8.7	6.8±0.8	
	7	31.0±5.12	13.40±1.68	129.0±10.4	184. ±16.1	144.8±12.9	25.0±2.22	
0.1% cystamine	0	30.0±4.02	14.9±2.05	72.7±9.10	107±8.06	80.5±7.14	0.67±0.22	9.93±0.27
	3	41.5±5.81	15.25±1.80	184.0±15.6	216. ±19.08	204. ±16.1	6.0 ±0.49	
	7	22.3±3.0	20.18±2.50	170.6±14.3	315. ±9.80	220. ±19.1	19.9±1.67	

Differences are statistically significant ($p < 0.05$) as compared to the control group

Table 15. Effect of the test articles on number of REF cells ($\times 10^3$ cells) throughout the 72-hr incubation ($M \pm m$).

Tests article (solution)	0 hours	24 hours	48 hours	72 hours
Li-GSSG in normal saline	860 \pm 25	1496 \pm 42	2606 \pm 46	5180 \pm 124
Li-GSSG + 0,003% H ₂ O ₂	830 \pm 17	1326 \pm 34	2695 \pm 72	5360 \pm 186
Li-GSSG + 0,1 % inosine	826 \pm 12	1340 \pm 64	2641 \pm 77	5063 \pm 134
Li-GSSG + 0,1% cystamine	831 \pm 24	1329 \pm 41	2831 \pm 53	5302 \pm 221
Li-GSSG+7%DMSO	800 \pm 22	1463 \pm 26	2820 \pm 48	5206 \pm 210
S-thioethylamine-GSSG in normal saline	789 \pm 21	1422 \pm 14	2602 \pm 43	5112 \pm 168
S-thioethylamine-GSSG + 0,003% H ₂ O ₂	782 \pm 14	1426 \pm 24	2645 \pm 32	5160 \pm 134
S-thioethylamine-GSSG + 0,1 % inosine	824 \pm 22	1398 \pm 17	2684 \pm 28	5210 \pm 156
S-thioethylamine-GSSG + 0,1% cystamine	841 \pm 18	1386 \pm 14	2478 \pm 31	5089 \pm 123
S-thioethylamine-GSSG + 7%DMSO	821 \pm 13	1462 \pm 15	2671 \pm 32	5121 \pm 68
0,003% H ₂ O ₂	822 \pm 11	1365 \pm 14	2598 \pm 63	5059 \pm 34
0,1 % inosine	811 \pm 10	1426 \pm 24	2642 \pm 25	5034 \pm 128
0,1% cystamine	822 \pm 14	1523 \pm 11	2486 \pm 34	5048 \pm 126
7% DMSO	801 \pm 12	1420 \pm 17	2651 \pm 36	5298 \pm 39
10% fetal calf serum	824 \pm 21	1486 \pm 46	2645 \pm 128	5125 \pm 246

Table 16. Effect of the test articles on number of clones of e-ras cells throughout the 72-hr incubation ($M \pm m$).

Tests article (solution)	0 hours	24 hours	48 hours	72 hours
Li-GSSG in normal saline	260 \pm 25	196 \pm 22	146 \pm 16	108 \pm 12
Li-GSSG + 0,003% H ₂ O ₂	250 \pm 17	186 \pm 14	125 \pm 12	106 \pm 16
Li-GSSG + 0,1 % inosine	248 \pm 11	201 \pm 11	134 \pm 12	98 \pm 14
Li-GSSG + 0,1% cystamine	254 \pm 15	182 \pm 10	121 \pm 14	102 \pm 11
Li-GSSG+7%DMSO	261 \pm 12	184 \pm 8	102 \pm 16	76 \pm 8
S-thioethylamine-GSSG in normal saline	286 \pm 14	202 \pm 14	156 \pm 10	112 \pm 12
S-thioethylamine-GSSG + 0,003% H ₂ O ₂	271 \pm 16	208 \pm 12	152 \pm 11	121 \pm 10
S-thioethylamine-GSSG + 0,1 % inosine	292 \pm 13	212 \pm 14	151 \pm 14	118 \pm 14
S-thioethylamine-GSSG + 0,1% cystamine	288 \pm 11	210 \pm 12	146 \pm 8	124 \pm 8
S-thioethylamine-GSSG + 7%DMSO	278 \pm 14	221 \pm 8	132 \pm 10	102 \pm 8
0,003% H ₂ O ₂	288 \pm 4	286 \pm 4	264 \pm 3	234 \pm 6
0,1 % inosine	292 \pm 11	290 \pm 8	269 \pm 8	243 \pm 8
0,1% cystamine	276 \pm 4	281 \pm 4	271 \pm 6	258 \pm 3
7% DMSO	268 \pm 11	271 \pm 2	268 \pm 8	243 \pm 6
10% fetal calf serum	272 \pm 8	275 \pm 3	258 \pm 4	232 \pm 4

Table 17. Effect of the test articles on number of REF c lls ($\times 10^3$ c lls) throughout the 72-hr incubation ($M \pm m$) after UV-irradiation.

Tests article (solution)	0 hours	24 hours	48 hours	72 hours
Li-GSSG in normal saline	860 \pm 25	496 \pm 42	260 \pm 46	190 \pm 24
Li-GSSG + 0,003% H2O2	830 \pm 17	326 \pm 34	269 \pm 22	193 \pm 18
Li-GSSG + 0,1 % inosine	826 \pm 12	340 \pm 64	241 \pm 17	163 \pm 13
Li-GSSG + 0,1% cystamine	831 \pm 24	329 \pm 41	281 \pm 33	192 \pm 21
Li-GSSG+7%DMSO	800 \pm 22	463 \pm 26	282 \pm 18	186 \pm 10
S-thioethylamine-GSSG in normal saline	789 \pm 21	422 \pm 14	260 \pm 23	212 \pm 16
S-thioethylamine-GSSG + 0,003% H2O2	782 \pm 14	426 \pm 24	245 \pm 22	2160 \pm 34
S-thioethylamine-GSSG + 0,1 % inosine	824 \pm 22	398 \pm 17	264 \pm 22	210 \pm 16
S-thioethylamine-GSSG + 0,1% cystamine	841 \pm 18	386 \pm 14	248 \pm 11	189 \pm 23
S-thioethylamine-GSSG +7%DMSO	821 \pm 13	462 \pm 15	271 \pm 22	212 \pm 16
0,003% H2O2	822 \pm 11	365 \pm 14	258 \pm 33	159 \pm 24
0,1 % inosine	811 \pm 10	426 \pm 24	262 \pm 22	234 \pm 28
0,1% cystamine	822 \pm 14	523 \pm 11	246 \pm 34	208 \pm 26
7% DMSO	801 \pm 12	420 \pm 17	251 \pm 36	208 \pm 39
10% fetal calf serum	824 \pm 21	486 \pm 46	265 \pm 28	195 \pm 46

Table 18. Effect of the test articles on number of clones of e-ras cells throughout the 72-hr incubation ($M \pm m$) after UV-irradiation.

Tests article (solution)	0 hours	24 hours	48 hours	72 hours
Li-GSSG in normal saline	261 \pm 20	166 \pm 12	116 \pm 6	78 \pm 4
Li-GSSG + 0,003% H2O2	250 \pm 12	146 \pm 14	115 \pm 5	76 \pm 6
Li-GSSG + 0,1 % inosine	248 \pm 11	141 \pm 11	124 \pm 8	68 \pm 4
Li-GSSG + 0,1% cystamine	254 \pm 15	142 \pm 10	101 \pm 4	70 \pm 11
Li-GSSG+7%DMSO	261 \pm 12	124 \pm 8	86 \pm 6	56 \pm 8
S-thioethylamine-GSSG in normal saline	286 \pm 14	182 \pm 14	116 \pm 8	82 \pm 4
S-thioethylamine-GSSG + 0,003% H2O2	271 \pm 16	168 \pm 12	102 \pm 7	71 \pm 10
S-thioethylamine-GSSG + 0,1 % inosine	292 \pm 13	162 \pm 7	111 \pm 4	76 \pm 4
S-thioethylamine-GSSG + 0,1% cystamine	288 \pm 11	152 \pm 8	116 \pm 8	72 \pm 8
S-thioethylamine-GSSG +7%DMSO	278 \pm 14	134 \pm 8	82 \pm 10	50 \pm 6
0,003% H2O2	288 \pm 4	186 \pm 4	124 \pm 3	84 \pm 6
0,1 % inosine	292 \pm 11	190 \pm 8	129 \pm 8	93 \pm 8
0,1% cystamine	276 \pm 4	181 \pm 4	111 \pm 6	108 \pm 3
7% DMSO	268 \pm 11	171 \pm 2	108 \pm 8	103 \pm 6
10% fetal calf serum	272 \pm 8	175 \pm 3	125 \pm 4	93 \pm 4

Table 19. Effect of the test articles on the accumulation of ascitic fluid and the mean survival time of mice inoculated with leukemia L1210 cells ($M \pm m$)

Group of animals	The number of injection	Accumulation of ascitic fluid (weight gain.%)	Mean survival time
Control animals	0	$0,7 \pm 0,1$	$9,02 \pm 0,19$
	3	$7,14 \pm 0,9$	
	7	$25,4 \pm 2,6$	
Intact animals	0	$0,2 \pm 0,1$	35 ± 0
	3	$1,12 \pm 0,3$	
	7	$4,6 \pm 1,2$	
S-thioethylamine-GSSG + normal saline	0	$0,77 \pm 0,2$	$19,2 \pm 0,8$
	3	$3,1 \pm 0,4$	
	7	$9,2 \pm 1,2$	
S-thioethylamine-GSSG + 0,003% H_2O_2	0	$0,56 \pm 0,2$	$19,8 \pm 0,6$
	3	$2,9 \pm 0,4$	
	7	$8,6 \pm 1,4$	
S-thioethylamine-GSSG + 0,1% inosine	0	$0,42 \pm 0,3$	$21,2 \pm 0,8$
	3	$2,2 \pm 0,6$	
	7	$7,8 \pm 1,4$	
S-thioethylamine-GSSG + 0,1% cystamine	0	$0,51 \pm 0,1$	$19,8 \pm 1,8$
	3	$3,4 \pm 0,4$	
	7	$8,6 \pm 2,1$	
S-thioethylamine-GSSG + 7% DMSO	0	$0,42 \pm 0,3$	$22,2 \pm 1,2$
	3	$2,8 \pm 1,0$	
	7	$6,6 \pm 2,1$	
Li salt of GSSG + normal saline	0	$1,27 \pm 0,2$	$12,2 \pm 0,1$
	3	$4,1 \pm 0,4$	
	7	$12,2 \pm 1,2$	
Li salt of GSSG + 0,003% H_2O_2	0	$1,56 \pm 0,2$	$14,8 \pm 0,6$
	3	$4,9 \pm 0,4$	
	7	$10,6 \pm 1,7$	
Li salt of GSSG + 0,1% inosine	0	$1,42 \pm 0,3$	$12,2 \pm 1,2$
	3	$4,2 \pm 0,6$	
	7	$9,8 \pm 1,0$	
Li salt of GSSG + 0,1% cystamine	0	$1,51 \pm 0,1$	$13,8 \pm 1,6$
	3	$3,4 \pm 0,4$	
	7	$10,6 \pm 1,7$	
Li salt of GSSG + 7% DMSO	0	$2,42 \pm 0,3$	$15,2 \pm 1,4$
	3	$5,8 \pm 1,0$	
	7	$12,6 \pm 1,7$	
0,003% H_2O_2	0	$0,77 \pm 0,2$	$9,2 \pm 0,8$
	3	$6,1 \pm 0,4$	
	7	$19,2 \pm 2,2$	
0,1% inosine	0	$0,56 \pm 0,2$	$9,8 \pm 0,6$
	3	$7,9 \pm 0,4$	

	7	26,6±2,4	
0,1% cystamine	0	0,42±0,3	10,2±0,8
	3	8,2±0,6	
	7	24,8±2,1	
7% DMSO	0	0,51±0,1	10,8±1,8
	3	6,4±1,4	
	7	23,6±2,6	

Table 20. Effect of the test articles on the accumulation of ascitic fluid and the mean survival time of mice inoculated with Erlich adenocarcinoma cells (M±m)

Group of animals	The number of injection	Accumulation of ascitic fluid (weight gain, %)	Mean survival time
Control animals	0	0,7 ± 0,1	9,6 ± 0,3
	3	9,2 ± 1,2	
	7	28,4 ± 1,6	
Intact animals	0	0,2 ± 0,1	35±0
	3	2,2±0,3	
	7	5,1 ± 1,2	
S-thioethylamine-GSSG + normal saline	0	0,8 ± 0,1	16,2±1,2
	3	3,2±0,6	
	7	10,2±2,2	
S-thioethylamine-GSSG + 0,003% H ₂ O ₂	0	0,6±0,1	15,2±1,1
	3	3,9±0,6	
	7	9,2±0,8	
S-thioethylamine-GSSG + 0,1% inosine	0	0,4±0,2	17,2±0,9
	3	3,2±0,5	
	7	8,8±1,1	
S-thioethylamine-GSSG + 0,1% cystamine	0	0,5±0,2	16,8±1,2
	3	3,7±0,3	
	7	9,6±1,7	
S-thioethylamine-GSSG + 7% DMSO	0	0,4±0,1	17,2±1,4
	3	4,8±1,1	
	7	8,6±1,4	
Li salt of GSSG + normal saline	0	1,2 ± 0,3	12,2±0,1
	3	8,1±0,4	
	7	17,2±1,4	
Li salt of GSSG + 0,003% H ₂ O ₂	0	1,5±0,2	14,8±0,6
	3	6,9±0,6	
	7	15,6±1,6	
Li salt of GSSG + 0,1% inosine	0	1,4±0,2	12,4±1,4
	3	9,1±0,5	
	7		

		15,2±1,3	
Li salt of GSSG + 0,1% cystamine	0	1,7±0,3	13,2±1,2
	3	9,4±0,2	
	7	16,6±1,4	
Li salt of GSSG +7% DMSO	0	2,4±0,2	13,2±1,6
	3	9,8±1,0	
	7	17,6±2,7	
0,003% H ₂ O ₂	0	0,9 ± 0,2	9,8±0,8
	3	14,1±0,6	
	7	27,2±1,2	
0,1% inosine	0	0,8±0,2	10,1±0,6
	3	11,9±0,2	
	7	26,8±2,1	
0,1% cystamine	0	0,6±0,2	10,2±0,8
	3	9,2±0,8	
	7	25,8±1,7	
7% DMSO	0	0,5±0,2	10,3±1,8
	3	11,4±1,1	
	7	24,6±2,2	

Table 21. Effect of the test articles on the accumulation of ascitic fluid and the mean survival time of mice inoculated with leukemia P388 cells (M±m)

Group of animals	The number of injection	Accumulation of ascitic fluid (weight gain,%)	Mean survival time
Control animals	0	0,7 ± 0,1	21,2 ± 0,3
	3	4,14 ± 0,9	
	7	18,2 ± 1,6	
Intact animals	0	0,2 ± 0,1	35±0
	3	1,2±0,3	
	7	4,8 ± 1,2	
S-thioethylamine-GSSG + normal saline	0	0,7 ± 0,2	28,2±0,8
	3	2,1±0,4	
	7	8,2±1,2	
S-thioethylamine-GSSG +0,003% H ₂ O ₂	0	0,6±0,2	29,8±0,6
	3	2,9±0,4	
	7	6,6±1,2	
S-thioethylamine-GSSG +0,1% inosine	0	0,4±0,3	31,2±0,8
	3	2,6±0,6	
	7	6,8±1,1	
S-thioethylamine-GSSG +0,1%	0	0,5±0,1	29,8±2,8
	3	2,4±0,4	
	7	6,6±2,0	

cystamine			
S-thioethylamine- GSSG +7% DMSO	0 3 7	0,4±0,1 2,6±1,0 6,2±1,4	22,2±1,2
Li salt of GSSG + normal saline	0 3 7	1,2 ± 0,2 4,1±0,4 11,2±1,2	32,2±0,1
Li salt of GSSG +0,003% H ₂ O ₂	0 3 7	1,5±0,2 4,9±0,4 11,6±1,7	24,6±0,6
Li salt of GSSG +0,1% inosine	0 3 7	1,4±0,3 4,2±0,6 8,8±1,0	28,2±1,2
Li salt of GSSG + 0,1% cystamine	0 3 7	1,5±0,1 3,4±0,4 10,6±1,7	26,8±1,6
Li salt of GSSG +7% DMSO	0 3 7	2,4±0,3 5,8±1,0 8,6±1,2	27,2±1,4
0,003% H ₂ O ₂	0 3 7	0,7 ± 0,2 4,1±0,4 19,0±2,1	21,2±0,8
0,1% inosine	0 3 7	0,5±0,2 3,9±0,4 16,6±2,6	21,8±0,6
0,1% cystamine	0 3 7	0,4±0,3 5,2±0,6 18,8±1,1	20,2±0,8
7% DMSO	0 3 7	0,5±0,1 5,4±1,4 19,6±1,6	20,6±1,8

Table 22. Animal mortality during the experiment

Animal groups	Total number of animals	Died before the first injection of the test articles	Died during the treatment with the test articles	Total number of animals died
¹ 1	20	-	-	-
¹ 2	20	4	7	11
¹ 3	20	5	-	5
¹ 4	20	3	1	4

Table 23. Extent of neurological symptoms (score)

Animal groups	Number	Before the treatment with the test articles	Number	During the treatment with the test articles
'1	20	-	20	-
'2	16	3.06	9	3.22
'3	15	3.00	15	2.06
'4	17	3.10	16	2.50

Table 24. Parameters of sensitization of blood lymphocytes of guinea-pigs with EAE to brain antigens in RILA (% , before/after the treatment with the test articles)

Antigen	Animal groups			
	'1	'2	'3	'4
Myelin Basic Protein	-	<u>64.20</u>	<u>68.40</u>	<u>70.22</u>
		78.08	34.86	42.12
Neuronal membrane antigen	-	<u>50.10</u>	<u>48.14</u>	<u>54.76</u>
		62.48	26.10	38.26

Table 25. Parameters of sensitization of blood lymphocytes of guinea-pigs with EAE to brain antigens in RILM (migration index, before/after the treatment with the test articles)

Antigen	Animal groups			
	'1	'2	'3	'4
Myelin Basic Protein	1.11 (± 0.08)	<u>0.52 (± 0.10)</u>	<u>0.46 (± 0.08)</u>	<u>0.54 (± 0.12)</u>
		0.38 (± 0.09)	0.88 (± 0.11)	0.74 (± 0.06)
Neuronal membrane antigen	1.20 (± 0.14)	<u>0.68 (± 0.06)</u>	<u>0.60 (± 0.04)</u>	<u>0.58 (± 0.06)</u>
		0.42 (± 0.12)	0.92 (± 0.06)	0.82 (± 0.10)

Table 26. Effect of GSSG administered intravenously on cytokine and erythropoietin serum levels in cancer patients

Patients	Number of injections	Serum level, pg/mL				
		IL-1 β	IL-6	TNF α	INF α	erythropoietin
Pulmonary adenocarcinoma with pleural metastases	0	18.3	138.0	57.2	83.3	143.0
	3	96.7	156.0	280.0	395.6	605.0
	7	104.6	150.0	315.0	378.0	548.0
Stomach adenocarcinoma with liver metastases	0	12.0	93.5	27.0	4.6	21.6
	3	28.1	228.0	215.0	33.6	53.5
	7	31.7	204.0	147.0	34.0	47.1
Suprarenal corticocytoma with liver, pulmonary and peritoneal metastases	0	8.4	61.9	39.8	41.3	8.3
	3	12.9	105.0	113.0	56.0	32.4
	7	17.3	167.0	103.9	61.5	28.6

Table 27. Effect of GSSG on blood indices, cytokine and erythropoietin serum levels, and immunological parameters in patient with colorectal cancer and chemotherapy induced hemodepression

Parameter	Prior to the treatment	After the treatment completion
Erythrocytes	$2.9 \times 10^{12}/L$	$4.1 \times 10^{12}/L$
Hemoglobin	79 g/L	108 g/L
Leukocytes	$3.6 \times 10^9/L$	$5.4 \times 10^9/L$
Lymphocytes	$0.67 \times 10^9/L$	$1.57 \times 10^9/L$
Platelets	$92 \times 10^9/L$	$208 \times 10^9/L$
ESR	44 mm/hr	19 mm/hr
CD4 ⁺	$204 \times 10^6/L$	$609 \times 10^6/L$
CD8 ⁺	$255 \times 10^6/L$	$661 \times 10^6/L$
NK-cells	$39 \times 10^6/L$	$109 \times 10^6/L$
IL-1 β	203 pg/mL	815 pg/mL
IL-6	318 pg/mL	1014 pg/mL
TNF α	117 pg/mL	937 pg/mL
IFN γ	84 pg/mL	506 pg/mL
Erythropoietin	162 pg/mL	618 pg/mL

Table 28. Effect of GSSG on blood indices, cytokine and erythropoietin serum levels, and immunological parameters in patient with AIDS and cryptococcal meningitis

Parameter	Pre-treatment	Post-treatment
Erythrocytes	$3.1 \times 10^{12}/L$;	$3.9 \times 10^{12}/L$;
Hemoglobin	84 g/L;	126 g/L;
Leukocytes	$6.3 \times 10^9/L$;	$5.1 \times 10^9/L$;
Lymphocytes	$0.8 \times 10^9/L$;	$1.45 \times 10^9/L$;
CD4 ⁺	$55 \times 10^6/L$;	$338.3 \times 10^6/L$;
CD8 ⁺	$135 \times 10^6/L$;	$883 \times 10^6/L$;
IL-1 β	18.9 pg/mL;	123.4 pg/mL;
IL-2	0.32 IU/mL	3.7 IU/mL
IL-6	16.0 pg/mL;	272.0 pg/mL;
IL-10	45.0 pg/mL;	608.0 pg/mL;
IFN α	27.0 pg/mL.	314.0 pg/mL.
IFN γ	15.7 pg/mL	349.8 pg/mL

Table 29. Effect of GSSG on blood indices, cytokine and erythropoietin serum levels, and immunological parameters in patient with AIDS and isosporiasis

Parameter	Pre-treatment	Post-treatment
Erythrocytes	$4.04 \times 10^{12}/L$	$4.75 \times 10^{12}/L$
Hemoglobin	108 g/L	129 g/L
Leukocytes	$5.4 \times 10^9/L$	$6.0 \times 10^9/L$
Lymphocytes	$0.9 \times 10^9/L$	$1.8 \times 10^9/L$
CD4 ⁺	$125 \times 10^6/L$	$436.5 \times 10^6/L$
CD8 ⁺	$270 \times 10^6/L$	$949.3 \times 10^6/L$
Total protein	46 g/L	78 g/L
IL-1 β	27.8 pg/mL	202.4 pg/mL
IL-2	0.51 IU/ml	12.9 IU/ml
IL-6	13.5 pg/mL	348.0 pg/mL
IL-10	62.0 pg/mL	956.0 pg/mL
IFN α	148.3 pg/mL	860.0 pg/mL
IFN γ	61.2 pg/mL	698.8 pg/mL

Table 30. Effect of GSSG on blood indices, erythropoietin serum level in patient with hypoplastic anemia and pancytopenia

Parameter	Pre-treatment	Post-treatment
Erythrocytes	$1.8 \times 10^{12}/L$	$4.3 \times 10^{12}/L$
Hemoglobin	43 g/L	119 g/L
Color index	0.72	0.83
Reticulocytes	0.22 %	2.85 %
Leukocytes	$4.2 \times 10^9/L$	$7.2 \times 10^9/L$
Lymphocytes	$1.6 \times 10^9/L$	$3.1 \times 10^9/L$
Platelets	$72 \times 10^9/L$	$219 \times 10^9/L$
ESR	46 mm/hr	15 mm/hr
Erythropoietin	9.2 pg/mL	201.7 pg/mL

Table 31. Effect of Glutamed MF-R-30 on blood and immunology indices and cytokine levels in patient with stomach cancer, peritoneal metastases, ascites and splenomegaly.

Parameter	Prior to the treatment	2 months after the treatment beginning	4 months after the treatment beginning
Erythrocytes, $10^{12}/L$	3,2	3,7	4,4
Hemoglobin, g/L	112	121	135
Platelets, $10^9/L$	205	195	275
Leukocytes, $10^9/L$	12,4	8,9	8,1
Neutrophils (stab), %	12	8	2
Neutrophils (segm.), %	54	44	47
Lymphocytes, %	21	36	41
Monocytes, %	8	7	9
Eosinophils, %	5	4	1
ESR, mm/hr	54	15	8
Total protein, g/L	62	76	82
Albumin, %	26	45	47
α 1-globulin, %	3,0	7	11
α 2- globulin, %	14,0	12	7

β - globulin, %	7	10	13
γ - globulin, %	50	26	22
A/G ratio	0.35	0.82	0,9
Urea, mmol/L	6.6	6.1	7.4
Creatinin, mmol/L	0,11	0,09	0,82
Bilirubin, mcmol/L	40,0	32,4	20,1
Bilirubin conjugated, mcmol/L	31,0	21,4	
Prothrombin index, %	75	79	95
Glucose, mmol/L	5,9	5,3	4,2
SGOT, mmol/hr/L	4,4	1,21	0,21
SGPT, mmol/hr/L	3,8	1,21	0,17
Lymphocytes, $10^6/L$	260,4	3204	3321
B-lymphocytes (CD20 ⁺) $10^6/L$	26	192	368
CD4 ⁺ -lymphocytes, $10^6/L$	132.8	574	1024
CD8 ⁺ -lymphocytes, $10^6/L$	13	374	908
CD4 ⁺ /CD8 ⁺	10.2	1.5	1.1
IL2-receptor bearing cells (CD25 ⁺), $10^6/L$	26.8	498	2009
HLA11-receptor bearing cells, $10^6/L$	13	258	754
NK-cells (CD16 ⁺), $10^6/L$	26	324	576
IgA, g/L	3.2	2.38	2.38
IgM, g/L	3.6	0.58	1.42
IgG, g/L	21.82	14.34	12.2
Immune Complexes, OD units	337	216	117
IL-1 β , pg./mL	92	727	813
IL-2, IU/mL	4.05	41.0	47.3
IL-6, pg./mL	118	806	551
IFN α , pg./mL	70.8	672	604
IFN γ ,pg./mL	105	624	519
TNF, pg./mL	183	707	980

Table 32. Effect of GSSG on blood and immunology indices and cytokine levels in patient with skin cancer (Merkel's cell carcinoma), local lymph nod metastases and chemotherapy-induced hemo- and immunodepression.

Parameter	Prior to the treatment	3 months after the treatment beginning
Erythrocytes, $10^{12}/L$	3,9	4,1
Hemoglobin, g/L	112	114
Platelets, $10^9/L$	210	262
Leukocytes, $10^9/L$	2.4	7.2
Neutrophils (stab), %	6	8
Neutrophils (segm.), %	79	60
Lymphocytes, %	8	24
Monocytes, %	4	7
Eosinophils, %	3	1
ESR, mm/hr	43	13
Total protein, g/L	61	78
α 1-globulin, %	9.20	2.3
α 2- globulin, %	12.32	8.2
β - globulin, %	13.08	14.0
γ - globulin, %	21.69	18.8
A/G ratio	0.78	0.94
Urea, mmol/L	8.54	4.3
Creatinin, mmol/L	0.123	0.095
Bilirubin, mmol/L	4.6	4.1
Prothrombin index, %	82	100
Glucose, mmol/L	5.5	4.3
SGOT, mmol/hr/L	0.48	0.32
SGPT, mmol/hr/L	0.43	0.21
Lymphocytes, $10^6/L$	192	1728
B-lymphocytes (CD20 ⁺) $10^6/L$	60	234
CD4 ⁺ -lymphocytes, $10^6/L$	84	604
CD8 ⁺ -lymphocytes, $10^6/L$	13	329
CD4 ⁺ /CD8 ⁺	6.5	1.8
IL2-receptor bearing cells (CD25 ⁺), $10^6/L$	64	881

HLA11-receptor bearing cells, $10^6/L$	36	498
NK-cells (CD16+), $10^6/L$	24	624
IgA, g/L	4.9	5.2
IgM, g/L	0.99	1.24
IgG, g/L	24.3	15.6
Immune Complexes, OD units	264	111
IL-1 β , pg./mL	156	637
IL-2, IU/mL	1.12	36.5
IL-6, pg./mL	244	1029
IFN α , pg./mL	79	513
IFN γ , pg./mL	58	234
TNF, pg./mL	202	855

Table 33. Changes in hematological, immunological, serological and biochemical parameters during 24 days after beginning the treatment with the use of GSSG series preparations

Parameter	Prior to the treatment	24 days after the treatment beginning
Hematology/Immunology		
Erythrocytes	$3.65 \times 10^{12}/L$	$\times 10^{12}/L$
Hemoglobin	96 g/L	128 g/L
Leukocytes	$12.6 \times 10^9/L$	$7.8 \times 10^9/L$
Lymphocytes	$1.1 \times 10^9/L$	$2.9 \times 10^9/L$
Platelets	$180 \times 10^9/L$	$240 \times 10^9/L$
ESR	28 mm/hour	12 mm/hour
CD3 $^+$	$711 \times 10^6/L$	$1319 \times 10^6/L$
CD4 $^+$	$410 \times 10^6/L$	$655 \times 10^6/L$
CD8 $^+$	$305 \times 10^6/L$	$662 \times 10^6/L$
Circulate Immune Complexes	142 units	108 units
IFN α	368.0 pg/mL	906.0 pg/mL
IFN γ	102.0 pg/mL	608.0 pg/mL
IL-6	245.9 pg/mL	653.0 pg/mL
Serology		
Hbs Ag	+	-
Hbe Ag	+	-
IgM Anti Hbs	+	+

Anti Hbe	-	+
Anti Hbs Ag	-	±
Blood Chemistry		
Bilirubin	-total	180 µmol/L
	-direct reacting	31 µmol/L
ALT	910 U/L	28.5 µmol/L
AST	31 µmol/L	6.1 µmol/L
Alkaline phosphatase	910 U/L	90.8 U/L
Serum cholinesterase	206 U/L	22 U/L
γ-Glutamyl transpeptidase	1316 U/L	206 U/L
Prothrombin Index of p	24 µmol/L	268 µmol/L
Acid-base balance	205 IE/L	39 IE/L
	38%	87%
	metabolic alkalosis	normal

Table 34. Changes in hematological, immunological, serological and biochemical parameters after the 1st and 2nd courses of the treatment with the use of GSSG series preparations

Parameter	Prior to the treatment	After the 1 st course of the treatment	After the 2 nd course of th treatment
Hematology			
Erythrocytes 10 ¹² /L	3,79	4,3	4,85
Hemoglobin g/L	128	126	133
Leukocytes 10 ⁹ /L	3,6	3,9	5,6
Lymphocytes 10 ⁹ /L	900	1600	2900
Platelets 10 ⁹ /L	140	156	220
ESR mm/hour	23	18	11
Immunology			
Α-lymphocytes (ND20*)10 ⁶ /L	270	302	389
ND4 ⁺ 10 ⁶ /L	374	407	936
ND8 ⁺ 10 ⁶ /L	204	612	727
CD25 ⁺ 10 ⁶ /L	228	246	680
Circulating Immune Complexes	190	170	106
IgA, g/L	5,6	5,2	1,2
IgM, g/L	6,9	6,0	4,8

IgG, g/L	29,0	18,9	3,4
IFN α pg/mL	304,6	200,8	128,6
IFN γ pg/mL	215,2	110,0	78,1
IL-1 β , pg/mL	405,5	198,0	158,9
IL-6, pg/mL	603,9	430,6	190,2
Serology			
HBs Ag	+	+	-
anti-HBs	-	+	+
anti-HBs-IgM	-	+	+
HBeAg	+	-	-
anti-I Δ e	-	+	+
Blood Chemistry			
Bilirubin			
-total μ mol/L	46,0	28,4	20,8
-direct reacting μ mol/L	27,0	15,7	6,2
ALT U/L	9,1	4,3	1,2
AST U/L	0,8	0,7	0,5
Alkaline phosphatase U/L	12,6	8,2	7,8
γ -Glutamyl transpeptidase IE/L	208	190	41
Total protein g/L	91	89	78
Albumin, %	40	44	60
α_1 - globulin, %	6,2	6,4	5,2
α_2 - globulin, %	7,4	7,5	9,0
β - globulin, %	16,82	16,2	12,6
γ - globulin, %	29,58	25,9	13,2

Table 35. Variations of hematology and blood chemistry indices

Parameter	Prior to the treatment	1 month after the treatment beginning	2 months after the treatment beginning
Erythrocytes, $10^{12}/L$	3,8	3,9	4,0
Hemoglobin, g/L	110	114	128
Leukocytes, $10^9/L$	7,9	5,4	5,0
Stab neutrophils, %	4	4	2
Segmented neutrophils, %	75	57	38
Lymphocytes, %	16	27	41
Monocytes, %	3	12	6
ESR, mm/hour	38	28	12
Platelets, $10^9/L$	168	225	244
ND3 ⁺ , %	32,6	44,8	72,2
ND4 ⁺ , %	16,1	22,8	50,2
ND8 ⁺ , %	11,0	15,4	16,9
"Active" T-lymphocytes (bearing receptors to IL-2, CD25 ⁺)	12,9	60,2	62,4
NE-cells (CD16 ⁺ /ND56 ⁺), μL^{-1}	64	292	404
A-lymphocytes (CD20 ⁺), %	6,4	10,2	15,4
Circulating Immune Complexes, units	385	212	102
Creatinine, mmol/L	0,06	0,08	0,07
Acid phosphatase, U/L	324	218	164
Alkaline phosphatase, U/L	10,4	8,3	6,8
Total bilirubin, mmol/L	17,8	8,5	9,0
Glucose, mmol/L	4,8	4,3	4,9

Tabl 36. Laboratory indices in patient with pancreas cancer throughout the observation period

Parameter	Before treatment	After one month of treatment	After 3 months of treatment	After 6 months of treatment	Normal limits
Hematology and blood chemistry					
Erythrocytes, $10^{12}/l$	3,8	4,0	4,1	4,6	4,0-5,0
Hemoglobin, g/l	128	130	134	141	130,0-160,0
Platelets, $10^9/l$	216	226	234	268	180,0-320,0
Leukocytes, $10^9/l$	9,6	8,8	8,3	6,8	4,0-9,0
Neutrophils and rods, %	10	4	3	3	1-6
Segmentonuclear neutrophils, %	70	59	50	54	47-72
Lymphocytes, %	15	27	39	34	19-37
Monocytes, %	4	6	6	7	3-11
Eosinophils, %	6	4	2	2	0-11
ESR, mm/h	64	30	19	15	2-10
Total protein, g/l	74	72	69	71	65-85
ALT/mmol/hL	0,8	0,4	0,33	0,3	0,1-0,7
AST/mmol/hL	0,5	0,4	0,21	0,2	0,1-0,5
α -amylase g/hL	46	30	21	18	12-32
LDH MU/l	1121	542	521	472	<450
Immunology					
Lymphocytes	1440	2376	3237	2312	1200-3000
B-lymphocytes (CD20+) $10^6/l$	272	348	554	392	200-400
T-helpers (CD4+), $10^6/l$	874	1114	1242	1092	700-1100
T-suppressors (CD8+) $10^6/l$	222	384	1082	721	500-900
CD4+/CD8+ ratio	3,94	1,63	1,15	1,51	1,0-1,5
Circulating immune complexes	362	194	136	108	50-100

Table 37. Hematology, blood chemistry and immunology parameters in patient with juvenile diabetes mellitus

Parameter	Before treatment	After one month of treatment	After 2 months of treatment
Erythrocytes, $10^{12}/l$	4,1	4,3	4,4
Hemoglobin, g/l	129	135	144
Platelets, $10^9/l$	205	222	278
Leukocytes, $10^9/l$	7,8	6,4	5,2
Neutrophils and rods, %	4	3	3
Segmentonuclear neutrophils, %	39	53	58
Lymphocytes, %	51	39	34
Monocytes, %	4	3	4
Eosinophils, %	2	2	1
ESR, mm/h	13	12	10
ALT/mmol/hL	0,44	0,38	0,22
AST/mmol/hL	0,3	0,3	0,3
Total protein, g/l	75	72	72
Bilirubin, total, mcmol/l	10,8	9,2	8,4
Cholesterol, total, mcmol/l	7,4	6,54	5,8
Triglycerides, mcmol/l	4,2	3,5	2,1
Urea, mmol/l	4,2	4,0	3,3
Creatinine, mmol/l	0,133	0,095	0,088
B-lymphocytes (CD20+) $10^6/l$	478	395	388
T-helpers (CD4+), $10^6/l$	1412	1014	874
T-suppressors (CD8+) $10^6/l$	1044	942	605
CD25 ⁺	422	512	495
Circulating immune complexes	214	123	95

Table 38. Laboratory parameters in patient with lung cancer throughout the observation period

Parameter	Before treatment	After two months of treatment	After 4 months of treatment	After one year	Normal limits
Erythrocytes, $10^{12}/l$	3,9	4,4	4,7	4,5	4,0-5,0
Hemoglobin, g/l	120	132	135	142	130,0-160,0
Platelets, $10^9/l$	396	235	282	270	180,0-320,0
Leukocytes, $10^9/l$	3,1	4,1	5,5	6,3	4,0-9,0
Neutrophils and rods, %	2	3	2,5	4	1-6
Segmentonuclear neutrophils, %	74	41	42	47	47-72
Lymphocytes, %	16	40	36	35	19-37
Monocytes, %	6	9	12	10	3-11
Eosinophils, %	1	5	5,5	4	0-11
ESR, mm/h	34	21	12	9	2-10
Total protein, g/l	61	78,4	80,6	78	65-85
Albumin, %	35,96	49,0	61,6	56	50-66
α 1-globulins, %	10,32	4,0	2,8	4,7	2,5-5,0
α 2-globulins, %	15,24	12,0	7,2	9,2	6,0-9,5
β -globulins, %	15,24	13,6	12,8	12,8	8,0-13,0
γ -globulins, %	23,33	21,4	15,6	17,3	13,0-17,0
A/G ratio	0,56	0,84	1,6	1,27	1,0-1,9
Urea, mmol/l	9,0	6,2	6,3	5,9	2,5-8,3
Creatinine, mmol/l	1,21	0,88	0,89	0,88	0,044-0,115
Bilirubin, total, $\mu\text{mol/l}$	19,5	13,0	14,0	5,1	3,5-20,5
Prothrombin index, %	88	90	104	100	80-105
Glucose, mmol/l	7,1	5,4	5,3	4,6	3,3-6,1
ALT/ $\mu\text{mol/hL}$	1,32	0,21	0,19	0,19	0,1-0,7
AST/ $\mu\text{mol/hL}$	1,22	0,36	0,15	0,17	0,1-0,5
Lymphocytes	496	1640	1980	2205	1200-1300
B-lymphocytes (CD20+), $10^6/l$	101	232	392	372	200-400
T-helpers (CD4+), $10^6/l$	321	824	1020	1064	700-

					1100
T-suppressors (CD8+)10 ⁶ /l	74	484	654	608	500-900
CD4+/CD8+ ratio	4,3	1,7	1,55	1,75	1,0-1,5
Cells with IL-2 receptors (CD25+)/10 ⁶ /l	202	472	682	605	208-576
HLA(11) receptor, 10 ⁶ /l	294	392	472	541	304-720
NK-cells (CD16+) 10 ⁶ /l	180	320	525	394	200-400
IgA, g/l	3,28	4,01	5,1	4,8	0,8-5,2
IgM, g/l	0,5	0,71	1,4	2,1	0,6-3,8
IgG, g/l	13,8	15,4	17,4	16,5	6,0-18,0
Circulating immune complexes	335	221	112	62	50-100
IL-1 β , pcg/ml	19,8	178,6	294,8	132	
TNF α , pcg/ml	34,1	121	149	98	

Table 39. Laboratory parameters in patient with sigmoid cancer throughout the observation period

Parameter	Before treatment	After one week of treatment	After two weeks of treatment	After one month
Erythrocytes, 10 ¹² /l	3,2	3,8	3,8	4,1
Hemoglobin, g/l	112	126	130	132
Platelets, 10 ⁹ /l	200	220	274	248
Leukocytes, 10 ⁹ /l	24,0	9,1	8,2	7,8
Neutrophils and rods, %	13	6	6	5
Segmentonuclear neutrophils, %	66	60	58	50
Lymphocytes, %	12	26	28	36
Monocytes, %	3	5	5	7
Eosinophils, %	6	2	2	2
ESR, mm/h	62	18	15	12
ALT/mmol/hL	0,8	0,5	0,3	0,22
AST/mmol/hL	0,5	0,4	0,4	0,18
IgA, g/l	3,8	3,6	3,5	3,2
IgM, g/l	2,8	2,5	3,0	2,8
IgG, g/l	19,8	16,3		17,4
Circulating immune complexes	162	134	94	96

Table 40. Laboratory parameters in patient with pancreas/duodenum cancer throughout the observation period

Parameter	Before treatment	After two weeks of treatment	After one months of treatment	After 3 months of treatment	After six months of treatment	Normal limits
Erythrocytes, $10^{12}/l$	2,9	4,0	4,3	4,1	4,4	4,0-5,0
Hemoglobin, g/l	118	129	134	130	132	130,0-160,0
Platelets, $10^9/l$	178	228	242	204	218	180,0-320,0
Leukocytes, $10^9/l$	12,4	8,2	5,4	5,6	4,8	4,0-9,0
Neutrophils and rods, %	10	5	4	4	3	1-6
Segmentonuclear neutrophils, %	72	54	47	40	51	47-72
Lymphocytes, %	8	32	39	45	36	19-37
Monocytes, %	3	5	6	8	6	3-11
Eosinophils, %	7	4	4	3	4	0-11
ESR, mm/h	48	18	13	14	15	2-10
Total protein, g/l	54	69	72	68	70	65-85
ALT/mmol/hL	0,8	0,3	0,22	0,28	0,3	0,1-0,7
AST/mmol/hL	0,4	0,3	0,2	0,22	0,2	0,1-0,5
α -amylase, g/hL	112	33	28	26	20	12-32
LDH MU/l	1082	454	352	178	212	< 450
Lymphocytes	992	2624	2106	2520	1728	1200-3000
B-lymphocytes (CD20+) $10^6/l$	174	384	304	388	241	200-400
T-helpers (CD4+), $10^6/l$	514	825	932	926	834	700-1100
T-suppressors (CD8+) $10^6/l$	102	584	784	732	701	500-900
CD4+/CD8+ ratio	5,0	1,41	1,19	1,27	1,19	1,0-1,5
CD25+	154	286	356	482	476	208-576
NK-cells (CD16/56+)	172	196	383	412	396	200-400
IgA, g/l	3,4	3,6	4,8	4,6	4,1	0,8-5,2
IgM, g/l	2,1	2,2	3,4	3,0	2,6	0,6-3,8
IgG, g/l	23,4	18,4	17,2	17,3	16,8	6,0-18,0
Circulating immune complexes	476	448	225	214	174	50-100

Table 41. Laboratory parameters in patient with severe postoperative complications

Parameter	Bef re treatment	After ne week of treatment	After one month of treatment
Erythrocytes, $10^{12}/l$	3,6	4,0	4,3
Hemoglobin, g/l	118	128	132
Platelets, $10^9/l$	200	212	248
Leukocytes, $10^9/l$	30,0	8,4	7,6
Neutrophils and rods, %	12	5	4
Segmentonuclear neutrophils, %	55	55	51
Lymphocytes, %	22	31	36
Monocytes, %	4	4	6
Eosinophils, %	7	5	2
ESR, mm/h	58	12	10
ALT/mmol/hL	1,1	0,42	0,32
AST/mmol/hL	0,6	0,32	0,28
Lymphocytes, $10^6/l$	6600	2604	2736
B-lymphocytes (CD20+) $10^6/l$	682	319	324
T-helpers (CD4+), $10^6/l$	2188	894	1112
T-suppressors (CD8+) $10^6/l$	2245	824	879
CD4+/CD8+ ratio	0,98	1,09	1,27
IgA, g/l	4,1	4,5	3,8
IgM, g/l	1,8	2,7	2,4
IgG, g/l	19,8	16,3	17,5
Circulating immune complexes	174	95	108

Table 42

The number of patients	Total	23-40 years	Over 40	Severe	Moderate	Mild
Male	4	2	2	4	-	-
Female	15	9	6	12	2	1

Table 43 Changes in mean values of T and B lymphocyte count in MS patients during the treatment with GSSG series preparations.

Parameter	Donors	Patients before treatment	After one month	After three months	After six months
CD3+ %	55,2±1,8	45,22±1,80	64,08±3,28	63,18±2,02	70,78±2,86
CD4+ %	36,0±2,0	28,64±1,22	33,18±2,86	43,64±1,18	55,78±2,12
CD8+ %	19,3±2,2	16,76±0,88	20,10±3,16	24,26±2,56	26,34±2,08
CD4/CD8	1,90±0,24	1,72±0,42	1,65±0,24	1,79±0,08	2,11±0,10
CD20+ %	12,8±1,8	18,78±0,44	15,26±0,64	15,32±1,44	14,44±1,20

Table 44. Parameters of sensitization of blood lymphocytes of MS patients to brain tissue antigens in Reaction of Suppression of Adhesion of Leukocytes (%)

Antigen	Patients before treatment	After one month	After three months	After six months
S-100	54,20	72,12	66,46	42,10
Neuronal membranes antigen	56,32	44,64	41,24	32,56
Myelin basic protein	68,34	77,30	54,323	42,20

Table 45. Changes in cytokine level (pcg/ml) after induction by GSSG medications in MS patients

	Patients before treatment	After one month	After three months	After six months
IFN- α , pcg/ml	0	202,26±4,38	312,14±6,28	406,18±4,66
IFN γ , pcg/ml	36,18±4,42	28,6±4,82	24,52±3,46	12,4±6,22
TNF, pcg/ml	64,38±8,64	52,42±7,62	51,86±4,32	51,46±3,80

Table 46. Changes in mean levels of immunoglobulins and circulating immune complexes in MS during the treatment course with GSSG medications.

Parameter	Donors	Patients before treatment	After one month	After three months	After six months
IgA, mE	3,2	1,3	1,4	1,6	1,4
IgM, mE	1,8	5,4	4,6	3,5	3,8
IgG, mE	8,4	4,2	8,4	13,4	12,3
Circulating immune complexes, units of optical density	52,1±6,8	142,2±8,1	124,4±4,4	107,4±4,0	68,2±5,4

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/RU 96/00340

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K38/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 92 21368 A (LIFE SCIENCES TECHNOLOGIES) 10 December 1992 cited in the application see the whole document ---	1-3, 17-27, 42,43
A	WO 94 00141 A (BOEHRINGER MANNHEIM ITALIA) 6 January 1994 cited in the application see the whole document ---	1-72
A	EP 0 616 803 A (HOLT J.) 28 September 1994 see the whole document ---	1-72
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

17 April 1997

Date of mailing of the international search report

27.05.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Moreau, J

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/RU 96/00340

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FASEB JOURNAL 8 (14). 1994. 1131-1138, XP002029618 DROEGE W ET AL: "Functions of glutathione and glutathione disulfide in immunology and immunopathology." see the whole document ---	1-3, 17-27, 42,43
A	BLOOD 86 (1). 1995. 258-267, XP000670315 AUKRUST P ET AL: "Increased Levels of Oxidized Glutathione in CD4+ Lymphocytes Associated With Disturbed Intracellular Redox Balance in Human Immunodeficiency Virus type 1 Infection." see the whole document -----	1-72

INTERNATIONAL SEARCH REPORT

International application No.

PCT/RU 96/00340

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-41, 67-72
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 1 to 41, and 67 to 72 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.☐ No protest accompanied the payment of additional search fees.